In vitro and computational modelling of drug delivery in the eye for the treatment of retinal pathologies by Davies, AE
  
 
IN VITRO AND COMPUTATIONAL MODELLING OF DRUG DELIVERY 
IN THE EYE FOR THE TREATMENT OF RETINAL PATHOLOGIES 
 
Thesis submitted in accordance with the requirements of the 
University of Liverpool for the degree of Doctor in Philosophy 
by 
Alys Elisabeth Davies 
 
January 2019 
  
   
Doctor of Philosophy Declaration 
 
I hereby declare that this dissertation is a record of work 
carried out at the Institute of Ageing and Chronic Disease 
at the University of Liverpool during the period of 
November 2014 to January 2019.This dissertation is 
original in content except where otherwise stated. 
 
January 2018 
Alys Elisabeth Davies  
   
i 
 
ABSTRACT 
Posterior segment diseases such as proliferative vitreoretinopathy and diabetic retinopathy 
have the potential to cause irreversible visual impairment. Delivery of therapeutic drugs to 
this region of the ocular globe poses many challenges owing to different anatomical and 
physiological constraints. There are some conditions that require drug treatment over 
prolonged periods of time and there is scope for the development of an extended drug 
delivery device to combat the burden of current treatment methods. Models can be a fast, 
inexpensive method of understanding the release profiles of therapeutics from such systems 
in an attempt to avoid toxic/ineffective treatment. Well designed, validated models could 
help speed the development of novel drug delivery systems and, if standardised, allow 
comparison between different technologies. Here the aim was to develop models of the drug 
clearance mechanisms in the posterior segment of the eye and test their ability to model 
drug transport behaviour from one potential drug delivery system. 
A static in vitro model of the outer blood retinal barrier (OBRB) was developed using a human 
retinal pigmented epithelium cell line, ARPE-19 cells, cultured on ammonium plasma treated 
expanded polytetrafluoroethylene (ePTFE) transwell membranes and used to evaluate the 
permeability of different molecular weight dextran molecules. Using COMSOL Multiphysics 
computational fluid dynamics (CFD) software, computational models of the transport of 
dextrans across this barrier within a dynamic microfluidic environment, the Kirkstall Ltd 
QV600 culture chamber, were developed and corresponding in vitro experiments were 
carried out in order to validate the simulations. This was then repeated for the release of 
ibuprofen (ibu) from a silicone oil (SiO) tamponade. Two other in vitro models; a spherical 
eye model and an eye-on-a-chip (EOC) device were also used to investigate different drug 
clearance mechanisms that are present in the eye in an attempt to gain a full understanding 
of the release dynamics of this potential delivery system.  
In order to build accurately described computer models, experimental data was obtained 
from simple experiments in each of the different in vitro models used to determine key input 
parameters. Within the Kirkstall QV600, transepithelial electrical resistance (TEER) and 
immunocytochemistry (ICC) showed increased barrier function of the ARPE-19 cells cultured 
under medium flow up to a flow rate of 200µL/min. At 400µL/min, there was decreased 
functionality and clusters of the epithelial mesenchymal transition marker, αSMA, appeared. 
Utilising permeability and diffusion coefficients derived from the static in vitro experiments, 
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transport of dextrans across unseeded ePTFE membranes were able to be simulated to 
within 15% error of the corresponding dynamic in vitro results. The introduction of cells 
increased this error to a maximum 30%. Simulating the release of ibu from SiO within the 
same dynamic environment produced results again, within a 15% error of the in vitro data. 
This was able to be repeated when investigating the other clearance mechanism in the 
spherical eye model. Within the EOC, the percentage release of ibu was equivalent after 7 
days, however the release profile over days 1, 2 and 3 was not comparable.  
The predicted results from the computational models showed good agreement with the 
results obtained from the benchtop experiments and the computer models showed that it is 
possible to investigate a vast range of parameters in a more time and cost efficient manner. 
Using a variety of models to investigate drug release from the ibu-SiO device provided a more 
comprehensive understanding of how both the anterior and posterior clearance mechanisms 
found within the posterior segment of the eye, affect the transport of the drug.  
Computational modelling can be a fast and cost-effective method to assist in the 
development of novel drug delivery devices. This study presents the design and development 
of three distinct yet complementary CFD models used to investigate the release of ibuprofen 
from silicone oil. The accuracy of these simulations was validated using data from 
corresponding in vitro experiments to produce models which can be used as valuable 
predictive tools. 
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1.1 THE EYE - STRUCTURE AND FUNCTION 
The eye (Figure 1-1) is a specialised structure in the body which is responsible for the 
conversion of light signals into neural signals, which can then be transformed into visual 
images. It can be divided into two segments, the anterior segment (the region from the front 
of the cornea to the lens containing the aqueous humour) and the posterior segment 
(extending from the lens to the optic nerve and containing the gel-like fluid called the 
vitreous humour). The supporting wall of the eye, the sclera, is an opaque, connective tissue 
layer which provides mechanical protection and maintains the shape of the eye.  Anteriorly, 
the sclera joins to the transparent cornea where light is able to enter the eye. Posteriorly it 
joins to the optic nerve. Beneath this outer layer (sclera and cornea) lies the uveal layer of 
the eye, comprised of the iris, ciliary body and choroid, each of which serve different 
functions. The iris forms a central circular opening, the pupil, which controls the amount of 
light that enters the eye. The ciliary body attaches to the lens and anchors it via the 
suspensory ligaments to focus light onto the retina via muscular adjustment in a process 
known as accommodation. The choroid is a vascularised layer that acts as the primary region 
of nutrient and gas exchange for the underlying retina. The innermost layer includes the 
neural sensory retina and the retinal pigment epithelium (RPE) and is the layer of the eye 
which is responsible for the conversion of light signals [1, 2]. The neural retina and RPE layer 
are further discussed in section 1.1.1. 
In order to produce an image, light follows a specific pathway through these many structures. 
Entering the eye initially through the cornea, light is partially refracted due to its convex 
shape. From there, the light passes through the aqueous humour and the pupil onto the lens 
where it is further refracted in order to focus the rays onto the macula region of the retina, 
containing the fovea – a region of densely packed neural cells. Here the light signal is 
processed and the neural signal is sent down the optic nerve to the visual cortex where it is 
further processed [1, 2]. 
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The Human Eye 
Figure 1-1. An illustration of the structure of the human eye. 
1.1.1 THE RETINA – STRUCTURE AND FUNCTION 
The retina is the neural layer of the eye which is responsible for transforming visual light 
stimuli into electrical signals which can be transmitted to, and interpreted by the brain. It is 
the innermost layer onto which the light received is focussed in order to produce an image. 
Extending round from the edge of the optic nerve head, it reaches to the ora serrata where 
it is joined to the ciliary body and the non-photosensitive region begins. On the sagittal plane 
it is bound by the vitreous and joined to the choroid via the Bruch’s membrane. One of the 
key features of the retina is the macula, an important structure for visual acuity and colour 
vision [3].  
Being the photosensitive region of the eye, the retina has a very complex structure and is 
made up of ten layers which can crudely be described as two distinct regions; the 
photosensitive region, comprised of an inner stratified layer of neural elements, and the 
retinal pigment epithelium layer. Moving from anterior to posterior the photosensitive 
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region is made up of the following layers: the inner limiting membrane (ILM), the nerve fibre 
layer, ganglion cell layer, the inner plexiform layer (IPL), the inner nuclear layer, the outer 
plexiform layer (OPL), the outer nuclear layer, the outer limiting layer (OLL) and the 
photoreceptor layer. This neurosensory layer terminates posteriorly with the photoreceptor 
cells, those cells which capture the light, beneath which lies the retinal pigment epithelium 
(RPE). The majority of these layers contain the cell bodies, processes and synapses of the 
neurosensory cells of the retina including the ganglion cells, bipolar cells, amacrine cells, 
horizontal cells and Müller cells which all have a role in the modification and integration of 
the electrical signal before it is sent down the optic nerve. It is the integrity and interaction 
of these layers which can determine the quality of our vision [3, 4]. 
The outermost layer of the neurosensory retina is the photoreceptor layer and in the human 
eye, two types of photoreceptor cell exist: rods and cones. The rods are responsible for vision 
in low light conditions and are used to detect brightness and contrast. These cells are 
distributed throughout the retina however they are predominantly found in the peripheral 
regions. Within the human eye, approximately 100 million rod cells exist and these slender 
cells have long outer segments, adjacent to the RPE, which house stacks of disc membranes 
containing the visual pigment rhodopsin. Rhodopsin is a sensory protein which is highly 
sensitive to light and it is this sensitivity which enables vision in dim conditions [5]. 
Cone cells are responsible for colour vision and high spatial resolution. Fewer numbers of 
these cells exist in the human eye in comparison to the rods, with approximately 6.5 million 
cells occurring predominantly within the macular region of the retina. As previously 
mentioned, the macula is a key region of the neurosensory retina located near the centre of 
the human retina and is responsible for central, high resolution vision. Within the macula sits 
the fovea and this region contains the highest density of cone cells within the retina with no 
rods residing in the fovea. Cone cells occur in three spectrally distinct types: red, green and 
blue sensitive cones, each containing different visual pigments.  These visual pigments 
absorb photons of light causing phototransduction of the light energy to electrical energy 
which can be transmitted to the brain. Red cones are responsible for the absorption of long 
wavelengths of light, green for medium and blue cones absorb short wavelengths [5].  
Once the photoreceptors absorb the light entering the eye, a biochemical change occurs 
which synaptically sends a signal to the bipolar cells within the neurosensory retina. The 
signal is modified by the horizontal and amacrine cells which surround the photoreceptors 
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before it is ultimately relayed to the ganglion cells and into the brain to form a representation 
of the environment. 
The photoreceptors are the outermost layer of the neurosensory retina, behind which lies a 
hexagonally packed, cuboidal, continuous monolayer of epithelial cells known as the retinal 
pigment epithelium (RPE). These cells exist between the photoreceptor cells and the Bruch’s 
membrane and are vital in maintaining homeostasis within the retina. The RPE is responsible 
for the supply of nutrients in, and the removal of waste products out of the inner retinal cells 
via the choroidal blood network, the choriocapillaris [4].  
Figure 1-2: Organisation of the retina. 
1.1.2 THE RETINAL PIGMENT EPITHELIUM 
The RPE is a highly specialised monolayer of pigmented cells located between the 
neurosensory retina and the vascular choroid. It has been reported that approximately 3.5 – 
6 million RPE cells exist within the human eye and, for the majority of adult life, this 
population remains stable in the absence of disease. The cells exhibit the cobblestone like 
appearance typical of epithelial cell layers and form a highly polarised monolayer, with 
microvilli on the apical side which interact with the photoreceptors of the neurosensory 
retina and the basal side forming firm attachment with the underlying Bruch’s membrane.  
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RPE cells carry out several major functions at the back of the eye which include: (1) transport 
of nutrients and ions, (2) absorption of scattered light entering the eye and protection 
against photo-oxidation, (3) isomerisation of key molecules involved in the visual cycle, (4) 
phagocytosis of membranes shed by photoreceptors and (5) secretion of factors which 
maintain the structural integrity of the retina [6, 7]. 
Transport occurs in two directions across the RPE, outward flux of electrolytes and water 
from the subretinal space into the choroid and inward flux of nutrients from the blood to the 
photoreceptors. Due to intense metabolic turnover that occurs in the photoreceptors and 
also the natural level of intraocular pressure, a large amount of water can reside in the 
subretinal space which must be constantly removed into the choriocapillaris. This water is 
eliminated by the RPE cells [8, 9]. In the other direction, the RPE takes up nutrients such as 
glucose and retinol, and delivers these to the photoreceptors to maintain their function [10]. 
Due to the frequent, direct light to which the retina is exposed, it is at high risk of photo-
oxidative stress. This stress leads to damage of the photoreceptor outer segments, whose 
membrane discs therefore require constant renewal. The role of the RPE in this renewal 
process is to phagocytose damaged photoreceptor outer segments which have been shed. 
This process, however, leads to the release of free radicals into an already highly photo-
oxidative environment. The RPE plays a vital role in counterbalancing the high oxidative 
stress by absorbing and filtering the light that enters the eye using their pigment, melanin, 
to protect other cells within the tissue [11]. 
RPE cells are essential in the visual cycle as they are responsible for the metabolism of 
retinoids. Light transduction begins when light is absorbed by chromophores in the 
photoreceptor cells. This absorption leads to a conformational change of the chromophore 
11-cis-retinal into all-transretinal. In order to be reactivated by another photon, there must 
be a reisomerisation back to 11-cis-retinal, however, photoreceptors lack the enzymes 
needed for this conversion therefore the metabolism takes place in the RPE after which 11-
cis-retinal is redelivered to the photoreceptors [12]. 
The RPE serves as the interface between the neural retina and the choriocapillaris. The cells 
of the epithelium are adjoined by tight junctions which form a partial seal that retards 
transepithelial diffusion. These cells in combination with their underlying basement 
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membrane, Bruch’s membrane (BM) form the outer blood retinal barrier (OBRB). This barrier 
disconnects the eye from the blood stream, establishing immune privilege [13]. 
1.1.3 THE BLOOD RETINAL BARRIER 
The blood retinal barrier is responsible for the maintenance of the neural retina environment 
through the regulation of nutrient delivery, ion concentrations and preventing access of 
circulatory factors such as immune cells and antibodies [14]. It consists of both an inner blood 
retinal barrier (IBRB) and an outer blood retinal barrier (OBRB). The IBRB is composed of the 
retinal endothelial cells which line the retinal microvasculature and regulates transport 
across the retinal capillaries. The OBRB comprises the RPE and Bruch’s membrane and 
regulates transport between the choriocapillaris and the neural retina (Figure 1-3)[15].  
Figure 1-3: Schematic of the outer blood retinal barrier. 
Bruch’s Membrane 
The Bruch’s membrane (BM) is an acellular structure which is comprised of five layers of 
extracellular matrix and lies between the RPE layer and the choroid. The layers include: the 
basement membrane of the RPE, an inner collagen fibre layer, an elastic fibre layer, an outer 
collagen fibre layer and the basement membrane of the choriocapillaris endothelium. As the 
layers suggest, the composition of the BM is predominantly collagen and elastin fibres. Other 
molecules that are present include fibronectin and laminin. The average thickness of the BM 
is between 2-5μm with the region in the macula being thinner and more porous than the 
surrounding areas. The primary function of the BM is structural, however, it also facilitates 
transport of nutrients and gases between the choroidal circulation and the RPE [16]. 
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Choroid 
The choroid is a tissue in the eye which predominantly serves as the vascular supply to the 
outer retina. It is composed of blood vessels, fibroblasts, melanocytes and supporting 
collagenous and elastic connective tissue. As well as supplying oxygen and nutrients to the 
outer retina, it is also believed to be involved in thermoregulation of the surrounding tissues. 
Within the choroid is a thin sheet formed by a network of capillaries. This sheet is known as 
the choriocapillaris. Due to the highly metabolic nature of the RPE and outer retinal layer, 
extensive molecular exchange occurs between these cells and the choriocapillaris. To aid in 
this demand, the walls of the choriocapillaris vessels are fenestrated to allow easier passage 
of molecules [17]. 
Both the IBRB and the OBRB are formed by the presence of zonulae occludens (tight 
junctions) between either the adjacent endothelial cells (IBRB), or the adjacent RPE cells 
(OBRB).  Tight junctions are multi-protein junctional complexes which are composed of a 
network of sealing strands that prevent paracellular transport [18]. Two major groups of 
proteins of tight junctions are claudins and occludins. Occludins are thought to have a pivotal 
role in maintaining the polarity of RPE cells by preventing the diffusion of integral membrane 
proteins from the apical to the basal surface. They interact with other proteins such as zonula 
occluden-1 (ZO-1) and -2 (ZO-2) to form complexes with the actin cytoskeleton which helps 
to regulate cell proliferation [19]. Claudins are thought to have a role in the selectivity of the 
tight junction and it has been shown that overexpression of Claudin-1 in kidney cells 
increases the transepithelial electrical resistance and reduces fluorescein isothiocynate 
conjugated dextran flux across the cell monolayer, suggesting it has a strong influence on the 
barrier function of epithelial cells [20, 21]. 
When trauma or disease occur within the RPE layer of the OBRB, a local breakdown in the 
barrier function of this structure occurs which can lead to circulatory factors entering the 
immune privileged  region of the eye. This can ultimately lead to further ophthalmic 
complications and disease.  
1.2 THE RETINAL PIGMENT EPITHELIUM IN DISEASE 
The dysfunction of RPE plays a central role in the pathogenesis of many retinal diseases which 
can ultimately lead to vision loss or impairment. Disorders which occur in the RPE can mostly 
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be categorised into three mechanistic actions: degenerative, dystrophic and proliferative. 
Degenerative and dystrophic diseases will briefly be discussed here, however the main 
emphasis will be on proliferative disease of the RPE with respect to migration and 
dedifferentiation.  
Degenerative and dystrophic diseases involving the RPE: The RPE is formed during early 
development and, in the absence of disease, remains as a stable population throughout 
normal life undergoing minimal proliferation. It is also a highly metabolic cell layer, 
continuously ingesting debris from the neural retina and expelling waste products. As we 
age, accumulation of debris can occur within the RPE making it less efficient and eventually 
leading to degeneration of the tissue. The most common degenerative disease that occurs 
which involves the RPE is age-related macular degeneration (AMD) [22]. As the name 
suggest, AMD is a disease that can develop as we age and is characterised by a breakdown 
of the macula (central portion of the retina). There are two types of AMD that occur: 
neovascular and geographic atrophy.  When geographic atrophy occurs, accumulated waste 
products aggregate on the Bruch’s membrane (BM) and form drusen, fatty deposits, which 
can impede the attachment of the RPE to the BM and deprive the RPE of oxygen and 
nutrients, causing degeneration of the RPE. In neovascular AMD, neovascularisation occurs 
in the choroid which produces fragile, leaky blood vessels that can haemorrhage into the 
subretinal space, again impeding attachment of the RPE. This degeneration then leads to lack 
of functionality and prevents the RPE from performing its role in homeostasis of the neural 
retina, leading to degeneration of the photoreceptors within the macula and eventually loss 
of central vision [23-25]. AMD is a leading cause of visual impairment in the developed world 
and approximately 35,000 people develop neovascular AMD each year in the UK alone. The 
most common treatment is intravitreal injection of either aflibercept or ranibizumab. In 
2015/16 the cost associated with the use of these drugs in the NHS was estimated to be 
approximately £450 million [26]. 
An example of a dystrophic disease is retinitis pigmentosa, a rare, inherited condition which 
arises from genetic abnormalities within the RPE cells causing altered cellular morphology 
and function. This disease can present itself in the early stages of life and progressively 
narrows a person’s field of view over the course of their lifetime. [27]. 
Proliferative diseases involving the RPE: As previously mentioned, the monolayer of RPE 
cells reside in a highly differentiated, mitotically inactive state in healthy eyes. However, 
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these cells will dedifferentiate and become mobile, proliferative cells in response to trauma 
or inflammation [28]. Robust proliferation of RPE cells in humans is relatively uncommon but 
when it does occur it can result in pathologic epithelial-mesenchymal transition (EMT), 
whereby the epithelial cells lose their differentiated phenotypes and convert to more mobile, 
mesenchymal-like cells. Dedifferentiation and proliferation of RPE cells can depend on 
several factors including: condition of the underlying BM, size of injury, and interaction with 
cytokines and growth factors. It is possible for a fibrotic wound healing response to be 
triggered following retinal trauma; in this case, RPE cells will proliferate and migrate into the 
vitreous and form epiretinal membranes which contract and distort the natural architecture 
of the retina. This is seen in pathologies such as proliferative vitreoretinopathy (PVR), a 
complication of retinal detachment, which will be discussed further in section 1.2.2. 
1.2.1 RETINAL DETACHMENT 
Retinal detachment (RD) is a potentially blinding condition whereby the neural retina 
becomes detached from the underlying RPE. By definition, there are three types of RD: 
rhegmatogenous RD (RRD), exudative RD (ERD) and tractional RD (TRD) (Figure 1-4). Of these 
three, RRD is the most common and occurs where there is a tear in the retina. There are 
approximately 12 cases of retinal detachment per 100,000 people each year in the UK and it 
is classified as one of only a few ophthalmic emergencies [29] [30]. 
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Figure 1-4: Diagram of retinal detachment. (A) Retinal tear, (B) rhegmatogenous retinal 
detachment, (C) exudative and tractional retinal detachment. 
Breaks in the retina can occur for a number of reasons such as trauma, complications of 
diabetes, inflammatory eye diseases or myopia [31, 32]. Ageing can also increase the risk of 
RRD due to thinning of the retina and breakdown of the collagen network of the vitreous. 
The vitreous is the transparent gel-like structure which occupies the posterior segment of 
the eye. Over 97% of the vitreous is water with the remaining composition consisting of a 
network of collagen and glycoproteins such as hyaluronic acid. In non-diseased eyes it 
attaches to the optic nerve, retina and back of the lens. Predominantly, it acts as a shock 
absorber from mechanical trauma, as well as allowing circulation of metabolites through the 
eye and maintaining the positioning of the retina and lens [33]. With age, the consistency of 
the vitreous becomes more fluid-like and it begins to shrink due to collapsing of the collagen 
network. The average age of presentation is 60 years of age [30]. In severe cases, the vitreous 
can become detached from the retina resulting in posterior vitreous detachment (PVD). 
When this happens, movement of the eye can result in the vitreous and retina moving 
relative to one another, leading to tractional forces between the two that can cause tears in 
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the retina. Vitreous humour is then able to penetrate the subretinal space and accumulate 
underneath the retina which can lead to further separation from the RPE [34].  
In the case of ERD and TRD, retinal detachment happens without the occurrence of a tear in 
the retina. ERD is usually a result of a breakdown within the blood retinal barrier, when fluid 
leaks into the subretinal space from retinal vessels. The accumulation of this fluid forces the 
retina away from the RPE. In TRD, contractile membranes form on the neural retina which 
pull the retina away from the RPE by traction forces. TRD usually occurs as a complication of 
other conditions such as diabetic retinopathy or proliferative vitreoretinopathy [35, 36]. 
1.2.2 PROLIFERATIVE VITREORETINOPATHY 
Proliferative vitreoretinopathy (PVR) is a condition that can happen following a break in the 
retina. It is a modified form of a wound healing response with respect to inflammation, 
proliferation and formation of scar tissue and results in epi- and subretinal membranes on 
the surface of the neural retina [37]. 
Figure 1-5: Diagram of the proliferative vitreoretinopathy cycle following a retinal tear. 
Adapted from [38]. 
PVR can manifest itself in two ways: traumatic PVR and idiopathic PVR. Traumatic PVR occurs 
in patients with perforating ocular injuries which involve the posterior segment or following 
ocular surgery [39]. Idiopathic PVR is a complication observed in approximately 5-10% of 
severe cases of RRD and is the leading cause of failure in RRD surgery [40] . 
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RRD causes a breakdown in the blood retinal barrier. Loss of contact, and therefore loss of 
signalling, between adjacent RPE cells triggers their proliferation and dedifferentiation in an 
attempt to repair the defect [41]. The tear also exposes the RPE to cytokines and 
inflammatory factors which are normally excluded from these cells due to the immune 
privilege in the eye. As the cells dedifferentiate, they undergo a process called epithelial-
mesenchymal transition (EMT) in which they adopt a more fibroblastic phenotype and 
become more migratory and proliferative [42]. The abnormal wound healing response and 
continual inflammation contributes to the formation of epiretinal membranes (ERM). These 
ERM have been shown to consist of a number of different cell types, predominantly RPE cells, 
however there are also fibroblasts, myofibroblasts and immune cells present. The fibroblasts 
and myofibroblasts are thought to play a key role in the contractile phase of PVR which 
occurs once the membranes have invaded the vitreo-retinal surface of the retina. These 
membranes contract and distort the retina which ultimately leads to TRD [43]. 
1.3 CURRENT TREATMENTS 
1.3.1 RETINAL DETACHMENT TREATMENTS 
Numerous treatment options exist to combat RD, all of which aim to reattach the neural 
retina to the RPE and repair any tears that are present.  RD is described as an ophthalmic 
emergency and so it is crucial that treatment is urgent in order to achieve a successful 
outcome. The type of procedure is dependent on a number of factors including severity, 
location and type of RD [44]. 
1.3.1.1 PNEUMATIC RETINOPEXY 
Pneumatic retinopexy (PR) is a procedure to treat RRD which uses laser photocoagulation or 
cryotherapy in addition to injection of a gas bubble to seal small tears in the retina and 
prevent progression of the RD [45]. The gas bubble is injected into the vitreous cavity and 
serves to force the retina back against the RPE layer. The RPE will then remove any subretinal 
fluid which may have accumulated [46]. The choice of gas used is either air or a 
perfluorocarbon gas such as sulphur hexafluoride, perfluoropropane or perfluoroethane. Air 
is more rapidly absorbed by the surrounding tissues in comparison with the other available 
gases and is therefore not suitable for long term support of retinal reattachment. PR is 
usually reserved for patients with RD in the superior segment of the retina as the head must 
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maintain a set position over a period of approximately 2 weeks. For this reason, PR is not an 
appropriate treatment method for all patients due to the restriction of head movement 
which is required to achieve successful reattachment of the retina [47, 48]. 
1.3.1.2 SCLERAL BUCKLE SURGERY 
Scleral buckle surgery involves suturing a piece of silicone, natural rubber or hard plastic onto 
the sclera in an attempt to push, or ‘buckle’, the sclera inwards, towards the middle of the 
eye. This buckling effect relieves tractional forces on the retina and allows it to settle back 
against the RPE. The buckle may be applied to just the area behind the detachment or a 
circumferential band can be placed to encircle the eye, depending on the size of the break. 
As with PR, laser photocoagulation or cryotherapy can be used in conjugation with a scleral 
buckle to seal the tear. This treatment method is more invasive than PR, but has higher 
success rates (approximately 85% anatomic success versus 65% in PR) [49, 50]. 
1.3.1.3 VITRECTOMY/ TAMPONADE PLACEMENT 
The most common course of treatment for severe or complicated cases of retinal 
detachment is a vitrectomy followed by the insertion of a tamponade agent in to the vitreous 
cavity. During surgery, the vitreous humour is removed whilst the eye is simultaneously filled 
with saline to maintain the pressure. After this, a silicone oil or gas tamponade is inserted to 
fill replace the saline. The tamponade prevents the migration of any aqueous within the 
vitreous cavity to the wound site, excluding inflammatory factors and cytokines and initiating 
retinal reattachment.  
The effectiveness of a tamponade is dictated by its ability to maintain contact with the retina 
and displace any aqueous away from the retinal surface [51]. There are a number of 
properties which influence this, such as specific gravity, interfacial tension and viscosity [52]. 
Hydrophobic materials are used as they form a bubble within the aqueous in order to 
minimise surface contact with the aqueous. This also prevents any of the tamponade 
material migrating through the wound, instead providing a plug effect. There are a number 
of materials that are available as tamponade agents which are currently used clinically, and 
they are either gas or oil based.  
Gas tamponades include materials such as air or perfluorocarbon gases. The major 
disadvantage of some gas tamponades is they have a short residency time due to diffusion 
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of the gas into surrounding tissues, leading to a reduced tamponade effect. This residency 
time can be increased depending on which gas is used however, this can also affect the 
expansion of the gas within the vitreous cavity following insertion. Perfluoropropane, for 
example, has a residency time of approximately 7 weeks, however can expand by as much 
as 100% following insertion. This expansion can cause increased pressure on structures such 
as the optic nerve and ultimately cause more damage [53]. As with pneumatic retinopexy, 
there is also a requirement for patients to maintain a constant head position for the majority 
of time over approximately 2-3 weeks. This can contribute to the lack of success of gas 
tamponades due to poor patient compliance [54]. 
Unlike gas tamponades, silicone oil (SiO) tamponades are permanent and do not dissipate 
over time. This does however require further follow-up surgery to remove the tamponade 
once treatment has concluded. SiO is transparent, chemically inert within the vitreous cavity 
and has a high interfacial surface energy. These properties, in combination with its low 
toxicity and highly hydrophobic nature, make it a useful material as a tamponade agent. 
Silicone oils are often used in cases where RD or tears are very complicated or when PVR is 
present (see section 1.2.2) [55]. 
Both silicone oils and tamponade gases have very low specific gravities and therefore float 
on the aqueous within the eye. This can lead to less successful treatment of inferior retinal 
detachments, although SiO has still been shown to be effective. Heavy-than-water 
tamponades, such as heavy silicone oils (Densiron®) and perfluorocarbon liquids, have now 
been developed and provide a more successful treatment option in these cases [56, 57]. 
A disadvantage of SiO is that forces at the interface between the oil and aqueous, which are 
often caused by movements of the eye, can cause break-up of the SiO into droplets. In the 
presence of surfactants or cellular debris, these droplets can stabilise and form emulsions. 
Emulsions pose two threats in that they can reduce the effectiveness of the tamponade and 
also initiate an inflammatory response, if the droplets are small enough to be engulfed by 
macrophages [58, 59]. Additionally, it is possible for the SiO to migrate into the anterior 
chamber which has been shown to lead to glaucoma [60]. The tendency for SiO to emulsify 
is a product of its rheological properties. The lower the shear viscosity of the oil, the lower 
the shear force required to disperse the bulk oil into droplets. Silicone oils which are 
currently used clinically have viscosities ranging from 1000 centistokes (c.st) to 5000 c.st and 
the choice is often down to preference of the surgeon, although there are distinct 
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advantages and disadvantages of both high and low viscosity oils. High viscosity oils, such as 
5000c.st, are very stable and reduce the risk of emulsification, however, 1000 c.st oils are 
often used as they offer ease of manual injection and removal. The difference in anatomical 
success and visual acuity following either 1000 c.st or 5000 c.st oil placement was 
investigated by Scott et al. who showed no significant difference between the two oils [61].  
Although there are disadvantages associated with using SiO as a tamponade agent, they are 
greatly outweighed by the advantages in terms of patient comfort and conformity. It 
removes the need for restricted head movement and allows recovery during normal day-to-
day activity over the long term. Also, modified silicone oils (such as Siluron XTRA, Fluoron) 
have been developed incorporating physical properties such as shear thinning, making them 
easy to inject manually but providing resistance against emulsification in situ [62].  
1.3.2 PROLIFERATIVE VITREORETINOPATHY TREATMENT 
Surgical methods are often applied in the treatment of proliferative vitreoretinopathy (PVR), 
this is due to the limitations involved in the use of pharmacological agents. The aim of PVR 
surgery is to reduce the tractional forces of the epi- and subretinal membranes and repair 
the break in the retina. This is often achieved using a combination of the surgical procedures 
described above (section 1.3.1). Given the complexity of PVR, the risk of retinal 
redetachment is high following surgery. There are currently some pharmacological 
approaches to managing PVR, however an understanding of how different pharmacological 
agents could potentially target different phases of the disease could provide a more 
successful approach.  
1.3.2.1 DRUG TREATMENTS IN PVR 
A variety of drugs have been investigated in the prevention/reduction of PVR. Mostly they 
can be grouped into either anti-proliferative or anti-inflammatory drugs, however, some 
studies have investigated the use of anti-growth factors and anti-oxidants also.  
Anti-proliferative drugs: Following a break in the BRB and the subsequent inflammation, 
proliferation ensues, therefore drugs which inhibit the cell cycle and suppress cell 
proliferation have been investigated to target this initial phase of PVR. Those which have 
been extensively include: 5-fluorouracil (5-FU), daunorubicin, α-tocopherol and retinoic acid 
(RA). 5-FU is one of the most thoroughly investigated dugs for use in PVR [63, 64]. It was 
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originally developed as an anti-cancer drug but has been shown to reduce fibroblastic 
proliferation. One disadvantage of 5-FU is that it has a very short half-life and is rapidly 
eliminated from the vitreous (t1/2 = 3.5 hours for 1 mg), therefore multiple doses are required. 
This can lead to complications from increased risk of infection and danger of administering 
toxic levels. Borhani et al. developed a sustained release device which administered 5-FU in 
a rabbit model of PVR which showed a 100% efficiency in preventing tractional RD [65].  
Anti-inflammatory drugs: Some of the first agents tested in the treatment of PVR were 
corticosteroids. Corticosteroids are anti-inflammatory drugs which are used in a vast range 
of medical conditions and act to suppress inflammation at the early stages of its initiation 
[66]. Triamcinolone acetonide (TAA) showed success in early animal experiments with an 
approximately 64% reduction in recurring RD following intravitreal injection of the drug [67]. 
However in humans, although it has been shown to potentially reduce breakdown within 
RPE, the success of the animal experiments has not been observed. A human study 
conducted by Chen et al. assessed the role of low-dose triamcinolone as an adjunctive 
therapy with a vitrectomy and silicone oil tamponade which appeared to be safe and 
effective [68]. Other corticosteroids that have been investigated in animal models include: 
methylprednisolone, and methotrexate. Methylprednisolone reduced the incidence of RD 
following PVR and minimised infiltration of cells into the vitreous whereas methotrexate had 
no beneficial effect [69, 70].  
1.3.2.2 IBUPROFEN 
2-(4-Isobutylphenyl)propionic acid, also known as ibuprofen (ibu), is a non-steroidal anti-
inflammatory drug (NSAID) often used to treat pain, fever and inflammation. In the context 
of PVR, it is yet to be studied, however, its characteristic action of reducing inflammation 
could make it a suitable candidate to be investigated further. A paper published by Cauldbeck 
et al. proposes its use in the treatment of the disease but it is yet to be investigated in a PVR 
model [71]. The mechanism of action of ibuprofen is not greatly understood, however it has 
been shown to be a non-selective inhibitor of the enzyme, cyclooxygenase (COX), which is 
required for the synthesis of prostaglandins, active lipid compounds which promote 
inflammation [72]. Ibuprofen was chosen to be investigated in this study due to its potential 
applications as a PVR treatment but also because it is soluble in silicone oil and the 
concentration is easily detectable in relevant media using established techniques. 
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1.4 OCULAR DRUG DELIVERY 
Due to the unique anatomical and physiological structure of the eye, delivery of drugs to the 
posterior segment poses a major challenge. There are a number of both static and dynamic 
barriers which must be overcome in order to achieve a therapeutic dose at the target 
location. Here, the major routes of ocular drug administration will be discussed. 
1.4.1 TOPICAL  
Topical administration of drugs in the eye involves application of eye drops to the surface of 
the eye at the cornea. The usefulness of topical administration in the treatment of posterior 
segment diseases such as PVR is limited due to poor bioavailability. It has been estimated 
that only 5% of topically applied drugs penetrate the cornea and reach intraocular tissues 
and this approach typically does not yield a therapeutic dose in posterior tissues [73]. Much 
of the loss of drug occurs rapidly following application as a result of tear fluid turnover and 
subsequent drainage, furthermore, the corneal epithelium presents a significant barrier to 
solute flux in to the cornea. Additionally, the use of many topical drugs requires strong 
patient compliance which can often be a cause of failure in such treatments. Despite the 
shortcomings of this technique, topical eye drops are still widely prescribed due to their non-
invasive nature but predominantly for anterior segment conditions [74]. 
1.4.2 SYSTEMIC 
It is possible for drugs to reach the retinal/choroidal tissue via the blood circulation through 
systemic administration either orally or intravenously. The availability of drugs in tissues of 
the posterior segment is limited due to the presence of tight junctions in the BRB which 
control the movement of large molecules from the blood into the retina, as previously 
discussed (section 1.1.3). This can lead to a need to administer high doses of the drug which 
can have negative side effects on non-target tissues [75]. This is not a conventional 
administration route for PVR drug treatment but there has been a trial which studied oral 
administration of 13-cis retinoic acid for PVR. They suggest that at their stated dose and 
duration of treatment, orally administered 13-cis retinoic acid could reduce the risk of PVR 
following RD surgery [76]. 
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1.4.3 INTRAVITREAL INJECTION 
The quickest and most direct route to administering drug solution to the posterior segment 
is via intravitreal injection. This is currently the most common approach used for drug 
therapies in posterior diseases. The benefit of this method is that it bypasses the BRB and 
directs the drug to the site of action. However, the majority of intravitreal drugs that are 
used have a short half-life in the vitreous, and require frequent repeat injection to maintain 
a therapeutic level. This requirement increases the risk of complication due to the invasive 
nature of the technique and can lead to injuries such as lens damage or endopthalmitis 
(inflammation of intraocular tissues) [77]. 
1.4.4 OCULAR IMPLANTS 
In recent times there has been a surge in research looking to develop implantable sustained-
delivery drug devices to overcome the problems associated with the traditional 
administration techniques described above. There have been a number of diverse 
approaches utilised in the development of such devices, ranging from biodegradable and 
non-biodegradable drug-loaded biomaterials, to scleral plugs, to polymeric drug matrices, 
each of which can provide unique mechanisms of drug release depending on requirement 
[78]. Implantable drug delivery devices are thought to present a number of advantages over 
current techniques, these are outlined in Table 1-1 [79, 80]. These devices are not without 
risk however, and can also lead to complications associated with invasive surgeries. It has 
also been reported that implantable ocular drug delivery devices can caused increased 
intraocular pressure which cause damage to tissues such as the optic nerve [81].  
Advantages of Implantable Drug Delivery Devices 
Delivery close to target site, minimising off target effects 
Direct delivery allows for less total drug to be delivered, reducing the risk of possible 
side-effects 
Sustained release removes risk of lack of patient compliance 
Bypasses BRB allowing use of macromolecules  
Can offer molecular protection for drugs which are unstable in vivo 
Table 1-1: Advantages of ocular drug delivery devices [79, 80]. 
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1.4.5 CURRENT RESEARCH IN PVR DRUG DELIVERY DEVICES 
Ideally, pharmacological intervention for PVR would occur over a course of 6-8 weeks as this 
is the time over which the disease process occurs, therefore a sustained-release drug delivery 
device would be valuable tool for use in this disease. Some of the technologies that are 
suitable for use following a vitrectomy which have been investigated include injectable 
liposome and microsphere suspensions. Liposomes are membrane-like vesicles which are 
composed of concentric phospholipid bilayers containing aqueous compartments. These 
vesicles can either encapsulate hydrophilic drugs within the aqueous or combine 
hydrophobic drugs in to the membrane and act as a reservoir [82]. Drugs that have been 
investigated as liposomal formulations in rabbit PVR models include: 5-FU [83], cytarabine 
[84] and daunomycin [85], and in each case the half-life of the drug within the vitreous was 
significantly increased when the liposomal formulation was used in comparison with 
administration of free drug. Microspheres are micron-sized, drug containing polymer 
matrices which are suspended in a liquid medium. Drug dissolves through the matrix and out 
of the polymer which may or may not simultaneously degrade. Microspheres loaded with 5-
FU [86] and retinoic acid [87] have been studied both in vitro and in vivo in PVR models and 
shown gradual release of drug over time periods up to 30 days, for the case of RA. 
It seems as though there is an opportunity to exploit the tamponade agents used in the 
treatment of RD and PVR to administer an adjunctive therapy as a drug delivery device whilst 
simultaneously repairing retinal wounds. Silicone oil (SiO) is most commonly used as a 
vitreous replacement in PVR surgery and its lipophilic nature means there are a number of 
lipophilic compounds which are readily dissolved in it and can utilise the material as a 
reservoir. Chung et al. were the first to investigate the drugs dissolved in SiO as a treatment 
in PVR. They evaluated lipophilic 1,3-bis(2-chloroethyl)-nitrosourea (BCNU) in terms of its 
solubility and stability in SiO, its release into aqueous and antiproliferative properties in vitro 
as well as in a rabbit PVR model [88, 89]. BCNU is not a suitable drug for the treatment of 
PVR and is normally reserved for cancer treatment, however this work has led to further 
drugs such as RA [90] and 5-FU [91] being investigate as possible candidates for this delivery 
method. Ibuprofen is a lipophilic drug by nature, but it is able to be dissolved in SiO, a non-
lipid based oil. Given this and its anti-inflammatory effects, it is possible that is has 
applications in this drug delivery system to treat PVR. This study will investigate ibuprofen 
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release from silicone oil, with a focus on its transport and clearance away from the oil 
reservoir.  
1.5 OCULAR DRUG ELIMINATION PATHWAYS 
With respect to ocular drug delivery and clearance, the eye can be visualised as four 
compartments: the anterior chamber, vitreous cavity, tear film cul-de-sac and periocular 
space. The route of both administration and elimination alters moving through these 
compartments [92]. 
Following topical administration of drugs, the majority of the dose is washed out 
immediately via the blinking mechanism. Upon installation, drug compounds combine with 
the lacrimal fluid present on the ocular surface. Normally, lacrimal fluid turnover occurs at 
just 1µL/min, however, the excess fluid is rapidly removed through the nasolacrimal duct 
[93]. Once in the nasal cavity, drugs and metabolites are able to be removed via systemic 
absorption. Systemic absorption also occurs in the conjunctival sac, the narrow pocket where 
the conjunctiva meets the eyelid. This sac is able to hold approximately 30µL of the typical 
70µL volume of eye drop normally administered but has a rich capillary bed which is able to 
absorb drugs and metabolites and remove them systemically [94]. The dose that remains in 
the lacrimal fluid following this early elimination permeates across the cornea into the 
anterior chamber. 
Once in the humour of the anterior chamber, drugs can be easily transported to structures 
such as the iris and ciliary body. Drug elimination in the anterior chamber primarily occurs 
via two mechanisms: aqueous humour outflow through the Schlemm’s canal and through 
the blood flow in the anterior uvea [95]. Aqueous humour is produced by the ciliary body 
and travels from the posterior chamber in to the anterior chamber through the pupil. In the 
anterior chamber, it flows out in to the Schlemm’s canal through the trabecular meshwork 
and is subsequently absorbed by the episcleral vasculature. Flow of aqueous humour is 
thought to occur at a rate of 3-5µL/min [96]. Elimination of drugs via the uveal blood flow is 
dependent on the ability of the drug to penetrate the endothelium of the blood vessels. This 
causes lipophilic drugs to be cleared more readily by this mechanism than hydrophilic drugs 
as they move more freely across the endothelial cell membranes. Once in the blood flow, 
elimination is estimated to occur at approximately 20µL/min [97]. 
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Drugs administered intravitreally, whether via injection or implant, are cleared via two 
routes, either anteriorly or posteriorly. Nearly all compounds can be eliminated via the 
anterior route (described above). Once the drug has diffused across the vitreous, it enters 
the aqueous of the posterior chamber, where it is transported in to the anterior chamber 
and cleared either out through the Schlemm’s canal or in to the uveal blood flow [98]. 
Alternatively, posterior elimination occurs through permeation across the posterior blood-
ocular barriers such as the outer and inner BRB. This route requires either adequate passive 
permeability of agents, generally very low molecular weight or lipophilic substances, or 
active transport of molecules by the cells present in the barrier. This is the reason for larger 
or hydrophilic molecules generally exhibiting longer half-lives in the vitreous [99].  
This study will investigate in vitro models of drug transport and clearance through the 
aqueous outflow and posterior drug elimination pathways used to remove drugs that are 
administered intravitreally.  
1.6 IN VITRO MODELS OF OCULAR DRUG TRANSPORT 
In vitro models have been used for many years to establish a basic mechanistic 
understanding of a system in a relatively simple, quick and reproducible manner. 
Additionally, in vitro models allow more combinations of parameters to be tested which can 
be unachievable in in vivo models. Models have applications in basic science, toxicological 
and pharmaceutical studies and are often heavily involved in the early discovery phases of 
drug development. Frequently these cells are based around either primary or immortalised 
cell lines, and in the context of ocular models, both have been heavily used [100]. In recent 
times there has been a focus on developing more biologically representative in vitro models 
by building them up in a 3-dimensional (3D) environment, incorporating more the one cell 
type as well as biomaterials to establish more realistic cell signalling environments [101]. In 
vitro models of both healthy and diseased ocular tissues have been reported for the cornea 
[102], conjunctiva [103], inner and outer BRB [104, 105] and vitreous body [106]. 
Vitreoretinal and BRB models will be discussed here. 
1.6.1 MODELS OF THE BLOOD RETINAL BARRIER 
In section 1.1.3, the structure of both the inner and outer BRB was discussed. The inner BRB 
contains the complex tight junctions of the retinal vasculature endothelial cells and is 
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designed to limit non-specific transport from the microvasculature to the cells of the retina. 
It is thought the main contributing components to this barrier are the retinal endothelial 
cells, the pericytes which reside around the outside of the blood vessels, and the extracelluar 
matrix surrounding both, however, other cell types such as retinal astrocytes may also be 
involved [107]. Breakdown of this barrier is common in pathologies such as diabetic 
retinopathy, therefore extensive research has been done to model the breakdown of this 
barrier and understand the factors that influence conditions such as the permeability of the 
retinal endothelium in the hope of discovering new treatment strategies [108].  
Beharry et al. developed a 3-dimensional (3D) co-culture model of the inner blood retinal 
barrier to investigate ocular drug delivery development. In this model, primary human retinal 
endothelial cells (HREC) were cultured together with primary human retinal astrocytes (HRA) 
on hydrogel scaffolds in an attempt to create a more representative biomimetic model of 
the dynamic inner BRB in comparison to a traditional 2-dimensional culture [109]. They then 
used this model to assess the response of the HRECs to drugs for use in the treatment of 
retinopathy and reported that the HRECs response to the drugs showed less variability when 
cultured in their in vitro model in comparison with a single cell type 2D culture [109].  
In vitro study of the outer blood retinal barrier is well reported. As with the inner BRB, these 
models have often been used to investigate the permeability of drugs and compounds across 
the RPE or look to model disease of the OBRB. In order to obtain a true model of the OBRB, 
the main structures need to be incorporated. These being the RPE, BM and choroidal 
endothelium. Hamilton et al. developed a trilayer in vitro model of the OBRB using an 
immortalised human RPE cell, ARPE-19, and human umbilical vein endothelial cells (HUVEC) 
cultured either side of amniotic membrane. This model was able to maintain the polarisation 
of the ARPE-19s whilst simultaneously forming a fenestrated endothelial phenotype in the 
HUVECs and was planned to be used to study age-related macular degeneration [104]. Other 
models of the OBRB have used alternative cell sources and BM materials, such as primary 
human RPE cells and. Skottman et al. describe an OBRB model which used human embryonic 
stem cell derived retinal pigment epithelium cells and human retinal microvasculature 
endothelial cells either side of polyethylene terephthalate (PET) membrane. They suggest 
that co-culture of the two cell types together drastically improves the barrier functionality of 
the RPE cells and that this model would be useful in investigating OBRB drug transport [110]. 
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Although many of the in vitro models of the OBRB that have been reported include the main 
structures within the tissue, few include a flow mechanism to model the blood flow within 
the choroid. This flow mechanism is particularly important when investigating the clearance 
of drugs across the BRB as it causes systemic removal of permeated drugs. Yeste et al. 
describe a system which comprises the co-culture of human retinal endothelial cells and 
ARPE-19s in a microfluidic culture system. This system compartmentalises the cells and they 
therefore do not create a single construct and the transepithelial electrical resistance of each 
of the cells was measured independently and no drug permeability studies were conducted 
[111]. Another microfluidic chip device was reported by Chen et al. who investigated the co-
culture of ARPE-19s and HUVECs in a microfluidic model of choroidal angiogenesis. Within 
this model, glucose was transported to the cells within the flow of the media but the actual 
transport mechanisms were not the parameter of interest [112].  
The lack of studies regarding in vitro modelling of the effects of posterior systemic clearance 
of drugs in the eye leaves scope for this mechanism to be investigated further. This study will 
look to produce a relevant in vitro model of this clearance pathway using ARPE-19 cells, 
synthetic BM and a blood flow system. 
1.6.2 MODELS OF AQUEOUS OUTFLOW CLEARANCE 
There have been few studies that have looked to develop an in vitro model of aqueous 
outflow to investigate the transport of molecules which follow this anterior clearance 
pathway [113]. One model, the PK-Eye model, was developed by Awaad et al. and was 
designed as a flow model for use in preclinical drug development. The model uses a Perspex 
eye model with both an anterior and posterior chamber which are separated by a dialysis 
membrane. The model was used to estimate the intraocular residency time of the drugs, 
ranibizumab, bevacizumab and triamcinolone acetonide. The drugs were administered to 
the posterior chamber of the model and the flow was introduced through the front of the 
posterior chamber with the outlet positioned at the front of the anterior chamber. With this 
model they were able to produce results for the clearance of drugs which showed good 
agreement with similar studies which used animal trials to investigate the mechanism [114].  
To the best of my knowledge there are no other in vitro models of aqueous outflow drug 
clearance. As with dynamic OBRB models, there is scope for this to be investigated further 
as this mechanism is of equal importance in terms of intravitreal drug clearance. In this study, 
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an in vitro model of aqueous outflow will be investigated using a spherical eye model which 
was originally designed to study the emulsification of silicone oils as discussed in section 
1.3.1.3. 
1.7 COMPUTER MODELLING IN DRUG DELIVERY 
Over the past two decades, significant advances in information technology and computer 
systems have made complex mathematical modelling of processes, such as drug delivery, 
more available. Novel drug delivery systems can now be optimised in silico with great 
accuracy and the ease of application has only increased. Computer science and simulation of 
pharmacokinetic behaviour is becoming an integral part of pharmaceutical research and 
development due to the significant reduction in cost and time they can offer. Professor 
Takeru Higuchi was the first describe drug release from an ointment based matrix using a 
mathematical equation [115] and this study began the trend of using mathematical 
equations to explain drug release and pharmaceutical dosing. Models used to describe such 
processes can be divided into two categories: empirical/semiempirical or mechanistic. 
Empirical models are purely descriptive mathematical equations based on no real physical, 
chemical or biological phenomena. This kind of description can for example be used to 
compare the release profiles of drugs in respect to a specific parameter such as apparent 
release rate constant [116]. Mechanistic modelling is based around real phenomena, such as 
diffusion or degradation. These models can be used to determine system specific parameters 
and provide an understanding of the underlying mechanisms of drug delivery within the 
system. Mechanistic approaches allow for quantitative analysis and prediction of the effects 
of the specified input parameters which makes unknown, desired properties theoretically 
predictable [117]. 
1.7.1 THE FINITE ELEMENT METHOD 
Finite element analysis (FEA) is a computational tool used to simulate and analyse physical 
problems. The laws of physics and the characterisation of phenomena such as diffusion, as 
described in time and space, are often solved using partial differential equations (PDE). These 
complex PDEs are often not solvable analytically and approximations of the equations have 
to be built based on discretisations. Discretisation involves approximating the PDEs with 
numerically solvable equations, which in turn, produces solutions which are an 
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approximation of the PDE. Finite element analysis is used to compute these approximations 
[118]. 
When a model body is discretised, it is divided into an equivalent system made up of many 
smaller units, elements. These elements are interconnected at points which are common to 
two or more other elements (nodes) and/or boundary lines.  
Figure 1-6: Discretisation in finite element analysis. 
The assembly of the complete set of elements that divide the object is known as the mesh. 
Rather than solve the PDEs which describe the object as a whole, it is assumed that the field 
variable in question, for example concentration of drug, acts through each element in a 
predefined manner which could be a linear, quadratic or high order function. The number of 
elements must adequately approximate the variable distribution across the body as a whole 
[119]. If the mesh is too coarse, the resolution of the distribution becomes insufficient. If the 
mesh is too fine, it becomes computationally intensive and requires much more time to 
solve. The ordinary differential equations are solved for each individual element based on 
their location within the mesh. These elemental solutions are then assembled into a solution 
for the variable field across the entire body of the object [120]. 
The advantages of FEA is that it provides a comprehensive description of the variable field 
and can be used to predict behaviours of systems to minimise experimental burden. It also 
allows accurate analysis of critical design parameters and can increase the rate of the 
developmental process whilst minimising failures. FEA has applications across many 
engineering disciplines including electrical, mechanical, fluid and chemical engineering and 
has been used previously in studies investigating the design of drug delivery devices. There 
are a number of software packages that are commercially available such as ANSYS, SimScale 
and COMSOL Multiphysics, each of which have different benefits in terms of user friendliness 
and analytical power [121]. 
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COMSOL Multiphysics is a FEA solver and simulation software package used in solving various 
physical and engineering problems. It was initially developed for use in structural mechanics 
but now provides a number of application-specific sub modules such as: acoustics, chemical 
engineering, microfluidics and heat transfer. The major benefit of using COMSOL over other 
FEA software is that it has a user-friendly interface and allows the problems with multiple 
physics interfaces to be solved. It provides professionally predefined modelling interfaces as 
well as allowing to user to define their own PDEs, it also has the capability to be integrated 
with other computer software such as computer aided design software which can be used 
to import problem specific geometries [122].  
1.7.2 THE EQUATIONS OF FLUID DYNAMICS 
This study aimed to produce computer simulations of drug clearance in in vitro models of the 
eye. The two clearance mechanisms of interest are those which are experienced by 
intravitreally administered drugs, so anterior clearance via aqueous outflow and posterior 
clearance by transport through the BRB and away via the systemic circulation. Both of these 
pathways involve convective fluid flow to influence the distribution of drug. For this reason, 
the models were built using computational fluid dynamics descriptions.  
Computational fluid dynamics (CFD) is a branch of fluid dynamics which uses methods such 
as FEA described above, to solve problems that involve fluid flow. COMSOL Multiphysics 
provides a physics module to solve for the equations of fluid dynamics and has been used in 
many studies where fluid flow is present in the model, such as flow through pipes and design 
of microfluidic devices. 
The fundamental basis of almost every CFD problem are the Navier-Stokes equations [123]. 
These equations govern the motion of fluids and are the fluid equivalent of Newton’s second 
law of motion: 
 
𝐹 = 𝑚𝑎 
Equation 1-1: Newton's second law of motion. 
which shows Force, F, is a product of the mass, m, of an object and its acceleration, a. In the 
case of fluids though there are additional forces present between the layers of the fluids and 
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fluids also transfer energy differently to solids all of which is taken into account with the 
Navier-Stokes equations, which can be written as: 
𝜌 (
𝜕𝒖
𝜕𝑡
+ 𝒗. ∇𝒗) =  −∇p + ∇. 𝐓 + 𝐟 
Equation 1-2: Navier Stokes equation. 
The left-hand side of the equation describes the product of the density of the fluid and the 
acceleration that is experienced by the particles within the fluid. This side of the equation is 
analogous to the ma side of Newton’s second law of motion, where u is the velocity vector. 
The right-hand side of the equation incorporates the forces which are responsible for the 
particle acceleration: the pressure gradient p, the viscous shear stresses, T and volume 
forces, f, which for the purposes of the models in this study are due to gravity, which makes 
f equal to the product of the gravity constant, g, and the density of the fluid. 
The continuity equation is the law that describes how mass cannot be created nor destroyed 
and represents the mass conservation of the system. In the case of fluid dynamics it states 
that the rate at which mass enters a system is equal to the rate at which mass leaves a system 
plus the accumulation of mass within the system. In the case of incompressible fluids, such 
as the culture medium used in these models which will maintain a constant density, this mass 
continuity equation simplifies to a volume continuity equation: 
∇. 𝒖 = 0 
Equation 1-3: Volume continuity equation 
This equation states that the volume dilation rate of the fluid is zero, therefore the fluid will 
alter its velocity based on the geometry of the pipe [124]. 
The models in this study need to provide solutions not only for the velocity of the fluid field 
within the system but also the concentration field of drug ibuprofen both in the silicone oil 
and once it is released. To do this a diffusion equation will be implemented: 
𝜕𝑐𝑖
𝜕𝑡
+  ∇. (−𝐷∇𝑐𝑖) + 𝒖 . ∇𝑐𝑖 =  𝑅𝑖 
Equation 1-4: Diffusion equation for transport of diluted species. 
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This equation models diffusion and convection and solves the mass conservation equation 
for one or more chemical species ci. D is the diffusion coefficient which is based on the 
molecular size of the chemical species and can be calculated theoretically, u is the velocity 
vector and Ri is the reaction rate expression. 
The first term on the left side of equation 1-4 corresponds to the accumulation of the species. 
The second term accounts for the diffusive transport, accounting for the interaction between 
the dilute species and the solvent. The third term on the left side of describes the convective 
transport due to a velocity field u. This field can be expressed analytically or obtained from 
coupling this physics interface to one that computes fluid flow, such as Laminar Flow. For the 
case of these models, the solutions from the laminar flow study can be used as the velocity 
field in this mass balance equation [125]. 
1.7.3 FINITE ELEMENT ANALYSIS OF DRUG DELIVERY WITHIN THE EYE 
Finite element analysis has be used to produce a number of simulations which look to predict 
the behaviour of novel drug delivery devices. The studies that have been conducted 
investigated devices such as transdermal patches [126], microneedles [127], hydrogel 
matrices [128] and nanoparticles [129], all of which aimed to understand the release and 
transport profiles of the loaded drug through the system. 
There have been several studies carried out that specifically model drug delivery and kinetics 
in the posterior segment of the eye, including systemic delivery methods, intravitreal 
injection and ocular implants. The diffusion and convection of drugs across ocular tissues has 
been investigated by Balachandran and Barocas who designed a model to identify the 
barriers to the diffusion of drugs following transcleral administration [130]. Similarly, Jooybar 
et al. developed a computer simulation using COMSOL Multiphysics which investigated the 
transport of drugs through the eye following intravitreal injection. This study examined the 
effects that needle gauge had on the injected drug bolus and how that subsequently affected 
the drug distribution through the eye [131].  Other studies have looked to simulate drug 
distribution following implantation of a drug delivery device, including polymer gel implants, 
scleral patches and controlled release implants [132-134]. These models all simulate drug 
delivery within computer built geometries of the eye and although they can provide useful 
information regarding the drug kinetics in the eye, experimentally these results cannot be 
validated in vivo due to the invasive nature of the techniques that would be required to do 
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so. Much of the work carried out is based on experimental work conducted by Palestine and 
Brubaker who investigated the kinetics of fluorescein in the human eye [135]. In order for 
the sophistication of these models of drug delivery in the eye to be improved, more 
experimental data is required to provide a greater database for FEA validation. For this 
reason it could be useful to build predictive models of in vitro devices used in the 
development of novel drug delivery devices as they are able to be validated using data from 
benchtop experiments. Although these models will not provide an approximation of what 
will occur once the device is administered in the eye, it may make the discovery phase 
development process more efficient. This is the rationale behind the use of computational 
models in this study. They may be able to reduce the number of time intensive and costly 
experiments that would be required in the development of an ibu-SiO drug delivery system 
by predicted the behaviour of the device under a range of experimental parameters. There 
are obvious limititaions to computational models, namely the solution will always be an 
approximation and the accuracy of the results produced is a relfection of the quality and 
accuracy of the user implemented parameters and boundary conditions. However, they still 
have the power to be a useful predictive tool.  
 
1.8 HYPOTHESIS, AIMS AND OBJECTIVES 
Hypothesis 
Computer models built using experimentally derived parameters from simple in vitro 
experiments would be able to accurately predict the release behaviour of ibuprofen from 
silicone oil in more complex in vitro experiments across a number of model designs 
Aims and Objectives: 
Aim 1: To develop an experimentally validated in silico model which can be used to predict 
the release and transport profiles of compounds across an equivalent in vitro model of the 
outer blood retinal barrier. 
Objective 1: To develop a simple, yet relevant in vitro model of the OBRB and use 
this model to define key parameters needed for the in silico model. 
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Objective 2: To build an in silico model of an equivalent in vitro model of posterior 
drug clearance across the OBRB. 
Objective 3: To validate the in silico model using data from in vitro experiments and 
use the in silico model to predict ibuprofen release from silicone oil within the in 
vitro model. 
Aim 2: To develop experimentally validated in silico models which can be used to predict the 
release and transport of ibuprofen from a silicone oil reservoir within equivalent in vitro 
models of both the aqueous outflow pathway and an eye-on-a-chip microfluidic device. 
Objective 1: To build in silico models of equivalent in vitro models of aqueous outflow 
drug clearance of ibuprofen from silicone oil within a spherical eye model and 
release of ibuprofen from silicone oil in an eye-on-a-chip device. 
Objective 2: To validate the in silico models using data from in vitro experiments and 
use the in silico models to predict ibuprofen release from silicone oil within the in 
vitro models. 
Objective 3: To determine the effects that exposure to simulated saccadic 
movements has on the release profiles of ibuprofen within these in vitro models. 
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 CHAPTER 2 
MODELLING THE OUTER 
BLOOD RETINAL BARRIER 
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2.1 AIM AND OBJECTIVES 
AIM 
To design complimentary in vitro models and computer simulations for use in the study of 
molecule permeation across the outer blood-retinal barrier. 
OBJECTIVES 
 Develop and optimise a relevant in vitro model of the RPE – Bruch’s Membrane – 
Choroidal blood flow complex. 
 Study the permeability of this barrier model in vitro and investigate the diffusion of 
different size molecules across it.  
 Develop, optimise and validate a complimentary CFD model of the in vitro model. 
 Determine whether the CFD model can be used to predict molecule concentrations 
across the in vitro model.  
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2.2 IN VITRO MODEL OF THE OUTER BLOOD RETINAL BARRIER 
In vitro models can be a valuable tool in understanding biological systems particularly in drug 
development and toxicology. Knowledge of parameters such as barrier permeability and 
diffusion coefficients, is of crucial importance when studying the movement of potential 
therapeutic treatments across epithelial tissues. Many existing in vitro models do not 
sufficiently mimic the many different environmental and dynamic factors associated with 
these physiological barriers. However, with the rapid rise in microfluidic technologies for cell 
culture which has occurred over recent years, the creation of dynamic in vitro models has 
become more accessible. 
2.2.1 THE KIRKSTALL QV600 CELL CULTURE SYSTEM 
The Kirkstall QV600 cell culture chamber (Figure 2-1) is a novel system which has been 
designed to allow surface cultures of cells which are found in an air-liquid interface 
environment in vivo, for example skin, respiratory epithelium or corneal cells.  
The media flow culture platform perfuses volumes of media in the range of millilitres, 
potentially allowing a more physically relevant perfusion model to be designed for this study 
in comparison with traditional microfluidic devices. The external dimensions of the chamber 
are 40mm in height and 30mm in diameter meaning it can be used with transwell inserts 
already commercially available. The chamber and the tubing are made from PDMS and a 
pump is required to generate the fluid flow. It was initially designed as an air-liquid interface 
culture system whereby a hanging transwell insert hangs in the top half of the chamber and 
medium is perfused through the bottom half. This split chamber design (Figure 2-2) allows 
for independent control of fluid flow across either side of the transwell membrane and the 
placement of the inlet and outlet ports mean that the media flow is maintained at a 
consistent level. Moving the height of the media reservoir in relation to the chamber can 
manipulate the pressure gradient across the system, altering the level of media flow based 
on whether the cells require an air-liquid interface or complete submersion in media. 
Being a new technology, previous studies using this system are limited. However, there are 
examples where the QV600 has been used to study permeability across epithelial models 
[136] and to build dynamic 3D models to study disease [137]. For the purposes of 
investigating the outer blood retinal barrier, this system provides many of the necessary 
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properties for a representative model as outlined in section 1.6. Kirkstall Ltd also 
manufacture two other cell culture chambers which are not air-liquid interface chambers but 
are designed for fully submerged cultures which expose the apical surface of the cells to fluid 
flow. These chambers, the QV500 and QV900, have been used in studies using cardiac cells 
[138], liver hepatocytes [139] and fibroblasts [140] however these are not relevant in this 
study.  
The main aim of this study was to investigate the movement of molecules and drugs across 
an RPE-Bruch’s Membrane model from an implantable drug reservoir within the vitreous 
cavity, and their subsequent clearance via a flow system. Simple modification of the QV600 
chamber provides these features in an in vitro model that can be used to study this drug 
clearance pathway (Figure 2-3, Figure 2-4). 
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The Kirkstall QV600 Cell Culture Chamber 
 
 
 
Figure 2-1: Kirkstall QV600 cell culture chamber. 
 
 
 
 
 
 
 
 
 
Figure 2-2: Kirkstall QV600 cell culture chamber, side view.  
Inlet ports Outlet ports 
Transwell Membrane 
Fluid Flow 
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Comparison of In Vivo Structure vs In Vitro Model 
 
Figure 2-3: Schematic of the outer blood retinal barrier in vivo showing the structures drugs 
must travel through to reach the bloodstream from the vitreous cavity. 
 
Figure 2-4: Schematic of the Kirkstall QV600 cell culture chamber showing analogous 
structures to those shown in Figure 2-3. Red arrows indicate culture media flow. 
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2.2.2 MATERIALS AND METHODS 
2.2.2.1 MODIFICATION OF THE KIRKSTALL QV600 CHAMBER FOR OUTER BRB STUDIES 
The Kirkstall QV600 culture system with its novel split chamber design, could be modified to 
allow a static fluid reservoir on the apical side of the cells with dynamic media flow on the 
basal side. This media flow was used as an analogy to choroidal blood flow, one of the 
clearance mechanisms in the posterior segment of the eye. Choroidal blood flow rates in vivo 
have been reported to peak up to approximately 10µL/min during systole with the maximum 
blood velocity reaching 45mm/s [3]. However, given the dimensional differences between 
choroidal arteries and the QV600 chamber, the flow velocities will be significantly different 
for equal flow rates. For this reason a range of flow rates was investigated in these studies. 
The flow was generated via a peristaltic pump connected to a reservoir of fresh perfusion 
medium. To create a drug implant reservoir on the apical side of the membrane, the inlet 
and outlet ports to the top half of the chamber were sealed. 
The Bruch’s Membrane was modelled using commercially available transwells as a 
substitute. These transwell inserts are provided as 12mm diameter membranes set in a 
standing transwell mould, they are further described in section 2.2.2.4. For use in the QV600 
system, a silicone O-ring was placed around the outer wall of the transwell prior to the 
sterilisation step described in section 2.2.2.4. This O-ring was used to create a seal within the 
chamber between the apical and basal sides of the transwell membrane and allowed the 
insert to sit a specified level within the chamber. However, the pressure generated by the 
force of closing the lid of the chamber following the insertion of the transwell caused the 
transwell to become dislodged and produced variability in the position of the membrane 
across the different experiments. To overcome this problem, a transwell mount design was 
developed to ensure each transwell would sit at the same level in each experiment. The 
mounts were produced from acrylonitrile butadiene styrene (ABS) via additive manufacture 
and were designed to have no impact on the flow of the medium (Figure 2-5).  
To complete the model, a retinal pigment epithelium cell line, ARPE-19, was seeded onto the 
apical side of the transwell membranes and the cells were allowed to develop into a 
confluent monolayer prior to insertion into the QV600 chamber. 
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Figure 2-5: ABS mount design and position within chamber. 
2.2.2.2 CULTURE OF HUMAN RETINAL PIGMENT EPITHELIAL CELL LINE (ARPE-19 CELLS) 
The ARPE-19 cell line (ATCC® Number: CRL-2302™) is a well-established, spontaneously 
arisen adult retinal pigment epithelium cell line from the normal eyes of a 19 year old male 
donor who died in a motor vehicle accident. In culture, these cells are able to form stable 
monolayers with a distinctive cobblestone morphology and functional polarity. They display 
the normal phenotype of RPE cells found in vivo and express RPE-specific markers hence 
making them a useful model in assessing RPE permeability and drug interaction [141, 142]. 
A recent study has also shown that they are able to become repigmented in long term 
cultures [143]. 
The ARPE-19 cells were maintained in complete culture medium, a 1:1 (vol/vol) mixture of 
DMEM/F-12 containing cell culture supplements (Table 2-1), in a humidifying incubator at 
37⁰C with 5% carbon dioxide (CO2) as recommended by ATCC. The cells were grown in 75cm2 
flasks (Greiner 658175) and the media was replenished three times a week. Once the cells 
had reached approximately 80% confluency in the flask, the culture medium was removed 
and the cells were washed in 10ml of phosphate buffered saline solution (PBS) (Thermo 
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Scientific Oxoid BR0014G; 1 tablet per 100ml distilled water (dH2O)). After adding 5mL of 1x 
Trypsin-ethylenediaminetetraacetic acid (EDTA) solution (Sigma T4171; 2mL of stock solution 
(as provided) mixed with 18mL sterile PBS) and incubating the cells for five minutes at 37⁰C, 
they rounded and detached from the flask. To prevent protein digestion, 5mL of complete 
culture medium was added to the Trypsin-EDTA and the solution was transferred to a 30mL 
universal tube. The mixture was then centrifuged (Thermo Scientific Heraeus Multifuge x1) 
at 1500 x g for five minutes. The supernatant in the tube was removed and the cell pellet 
was resuspended in 1mL of complete culture medium. A sample of this suspension was taken 
and further diluted 1:10 in complete culture medium in a micro-centrifuge tube before being 
counted with haemocytometer. The cells were then seeded into culture containers at cell 
densities and medium volumes appropriate for the subsequent experimental needs. All cells 
used in experiment were between passage 22 and passage 30. 
2.2.2.3 CRYOPRESERVATION AND RETRIEVAL OF CELLS 
Spare flasks of ARPE-19 cells were frozen down and stored in liquid nitrogen until needed. 
Cells were trypsinised and centrifuged as above and the pellet was resuspended in freezing 
media (Table 2-2) at room temperature. This cell suspension was transferred into cryogenic 
vials (flask/vial ratio 1:3) and slowly frozen in a Mr Frosty™ Cryo 1⁰C freezing container 
(Thermo Scientific, 5100-0001) containing isopropanol (Sigma I9516) which has a cooling rate 
of approximately 2⁰C/min. The container was stored in a -80⁰C freezer overnight. The 
cryogenic vials were then transferred into liquid nitrogen for long term storage.  The 
presence of dimethyl sulfoxide in the freezing media prevents its rapid cooling as it is a 
cryoprotective agent which reduces the freezing point. This is necessary to reduce the risk of 
ice crystal formation which can cause cell death [144]. 
When required, the cells were retrieved from the liquid nitrogen and thawed via immersion 
in a 37⁰C for one to two minutes.  The cell suspension was transferred to a 30ml universal 
tube, 9ml of culture media was added and the solution was thoroughly mixed. The cell 
solution was then centrifuged at 1500 x g for five minutes, resuspended in 1ml of culture 
media and transferred into a 75cm2 flask. A further 9ml of culture media was added to the 
flask which was then maintained inside a humidifying incubator (37⁰C, 5% CO2). The media 
was replenished after 24hrs and then three times a week thereafter.  
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2.2.2.4 CULTURE SUBSTRATE AND PLASMA TREATMENT 
As mentioned in section 1.1, the Bruch’s membrane (BM) is an integral structure in 
maintaining the outer BRB. To develop a relevant in vitro model of the outer BRB, a suitable 
replacement for the BM must be used to support the growth of an ARPE-19 cell monolayer. 
A number of studies have looked to identify suitable synthetic materials for use in the 
replacement of BM with some of the necessary physical properties being porosity, bio-
stability and mechanical strength [145, 146]. 
Polytetrafluoroethylene (PTFE), also known as Teflon®, is a synthetic fluoropolymer which 
was discovered in 1938 and was widely used in wiring as insulation. In 1969, it was found 
that by heating and stretching PTFE, a porous membrane could be formed, known as 
expanded PTFE (ePTFE). The unique physical and chemical properties of ePTFE have made it 
a leading biomaterial used in many medical applications such as synthetic vascular grafts, 
sutures and ligaments [147-149]. ePTFE has many properties which make it appropriate as a 
BM replacement. It has well-established biocompatibility, porosity, flexibility and bio-
stability, however, ‘as-received’ ePTFE is hydrophobic in nature and therefore does not 
promote the adhesion and formation of cell layers [146, 150]. 
Commercially available expanded modified polytetrafluoroethylene (ePTFE) culture inserts 
(Merck Millipore, PICM01250) were used for all permeability and cell culture experiments. 
The inserts are provided as 12mm diameter standing well inserts with a pore size of 0.4µm 
and a membrane thickness of approximately 50µm, making them suitable for use in 24 well 
plates and the Kirkstall QV600 system. These membranes are subjected to proprietary 
treatment by the manufacturer to increase the hydrophilicity, however they still recommend 
coating with protein prior to seeding attachment dependent cells such as ARPE-19 cells.  It is 
believed that the long term behaviour of RPE cells grown on synthetic substrates will be 
affected by the stability of their surrounding basement membrane. Deposition of ECM by 
cells has been shown to be affected by surface topography therefore coating the membranes 
with synthetic proteins prior to seeding could promote abnormal deposition of matrix by the 
cells thus affecting the ability to form a polarised monolayer [146, 151]. 
Previous studies have shown that the use of plasma technology allows modification of the 
surface of ePTFE to achieve greater hydrophilicity. This technique allows the fibrous, porous 
architecture of the material akin to the natural BM to be maintain whilst enhancing cell 
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attachment without requiring any additional ECM coating [146, 152]. Gas plasma treatment 
works by using an electrical charge to ionise gas within a vacuum chamber which creates 
plasma ions. These plasma ions react with molecular groups on the surface of the treatment 
sample and alter the surface chemistry of the material [153]. 
All the inserts used in the experiments were surface modified by ammonia gas (100% purity; 
BOC Ltd) plasma treatment using a helical resonator plasma system. The system was built in 
house and is formed from a 100-turn copper wire wound outside of a glass tube. The 
resonant frequency was <1W and the treatment time was 2 minutes at a gas pressure of 
1.2x10-1mbar and flow rate of 85sccm as described previously [154, 155]. Immediately 
following treatment, the inserts were placed into distilled water to maintain the stability of 
the modification [156] and stored at room temperature until required for experiments. All 
inserts were U.V. sterilised (CL-1000 U.V. Crosslinker; UVP) for 5 minutes on either side 
immediately before use in cell culture. 
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Components of Complete Culture Medium 
Name Concentration Source 
Dulbecco’s Modified Eagle 
Medium/Ham’s Nutrient Mixture F-12 
Formulation (1:1 mix) with L-Glutamine, 
15mM HEPES and sodium bicarbonate 
 Sigma (D8437) 
Penicillin/Streptomycin 10mg/ml 
streptomycin in 0.9% NaCl 
1% Sigma (P0781) 
Foetal Calf Serum (FCS) 10% BioSera (S1900) 
Table 2-1: Components of complete culture media used to culture ARPE-19 cells. 
Components of Freezing Medium 
Name Concentration Source 
Dulbecco’s Modified Eagle 
Medium/Ham’s Nutrient Mixture F-12 
Formulation (1:1 mix) with L-Glutamine, 
15mM HEPES and sodium bicarbonate 
 Sigma (D8437) 
Dimethyl Sulfoxide Hybri-max 10% Sigma (D2650) 
Foetal Calf Serum (FCS) 10% BioSera (S1900) 
Table 2-2: Components of freezing media used in the cryopreservation of ARPE-19 cells. 
Components of Reduced Serum Culture Medium 
Name Concentration Source 
Dulbecco’s Modified Eagle 
Medium/Ham’s Nutrient Mixture F-12 
Formulation (1:1 mix) with L-Glutamine, 
15mM HEPES and sodium bicarbonate 
 Sigma (D8437) 
Penicillin/Streptomycin 10mg/ml 
streptomycin in 0.9% NaCl 
1% Sigma (P0781) 
Foetal Calf Serum (FCS) 2% BioSera (S1900) 
Table 2-3: Components of reduced serum culture medium used in experimental cultures of 
ARPE-19 cells. 
  Chapter 2 
44 
 
2.2.2.5 CELL SEEDING ONTO SUBSTRATES 
Throughout these studies ARPE-19 cells were cultured on NH3 treated ePTFE transwell insert 
membranes with tissue culture polystyrene (TCP) used as a control substrate. All 
experiments were conducted with a cell density of 2.6x104cells/cm2.  
Cells were seeded onto TCP coverslips (ThermoFisher 174950) in a 24 well plate (Greiner 
662160) and allowed to settle for one hour before an additional 1mL of complete culture 
media was added to maintain the cultures. The cells cultured on NH3 treated ePTFE transwell 
were seeded on to the apical side of the membrane and the inserts were maintained in 24 
well plates with 400µL of complete culture media on the apical side and 600µL of complete 
culture media on the basal side.  Previous studies have shown that reducing the 
concentration of serum in culture media can prevent over-proliferation of the cells and 
maintain the polarised monolayer morphology which is vital to the barrier functionality [157, 
158] Therefore, 24hr post-seeding, the serum content in the media was reduced to 2% FCS. 
All cultures were incubated at 37⁰C with 5% CO2 and cells were fed with fresh reduced serum 
culture medium (RSC) (Table 2-3) three times a week for all experiments. 
2.2.2.6 EPITHELIAL BARRIER FORMATION AND FUNCTION 
At days 2, 7, 10 and 14 post seeding the cell tight junction formation was assessed to 
determine the optimal time to allow for cell barrier formation. At each time interval, the 
media was removed from the cells and each sample was washed three times with PBS. The 
cells were then fixed in 10% neutral buffered formalin (NBF) (Sigma HT501128) for 10 
minutes at room temperature. NBF is a fixative agent which cross-links proteins to preserve 
the natural architecture of the cellular components. Immunocytochemistry was used to 
visualise the presence of tight junctions within the samples, this method is further described 
in section 2.2.3.10. 
In addition to immunocytochemical assessment, those cells cultured on ePTFE membranes 
were subjected to transepithelial electrical resistance (TEER) measurements to study the 
extent and integrity of the tight junction formation in the cell monolayer. This is a widely 
accepted quantitative method which has been used to determine barrier integrity in many 
epithelial and endothelial models. TEER uses Ohm’s Law to determine the electrical 
resistance between the two sides of a cell monolayer grown on a semipermeable membrane, 
in this case the electrical resistance of the ARPE-19 monolayer on the ePTFE membrane. By 
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placing an electrode on either side of the membrane and applying an alternating current, the 
electrical resistance between the two electrodes can be measured. 
The commercially available Epithelial Voltohmeter (EVOM) system with STX-2 electrodes 
(World Precision Instruments) was used for all TEER measurements. The electrodes were 
sterilised in 70% ethanol for 15 minutes, then washed in fresh sterile RSC media. Control 
background readings were taken from a transwell without cells on to determine the 
resistance of the membrane, the mean of these values was then subtracted from the values 
obtained from the samples with cells grown on. These values were then normalised per unit 
area (cm2) of the membrane and the mean ± 1 standard deviation TEER values (Ω/cm2) are 
presented. 
2.2.2.7 CELL CULTURE IN THE PRESENCE OF FLOW 
The bioreactor system was set up in a recirculating fluid series circuit (Figure 2-6). A reservoir 
bottle was connected to a single QV600 chamber, which was connected to the peristaltic 
pump (Parker, PF22X0103) and then reconnected to the initial reservoir bottle. This 
recirculating system allows continuous perfusion of media without the need to monitor and 
refresh the media supply. The chambers and tubing are made from poly(dimethylsiloxane) 
(PDMS) and the reservoir bottles and Luer connectors from polypropylene which allows 
them all to be sterilised via autoclaving prior to cell culture experiments.  
Cells were cultured statically on the transwell membranes for 10 days prior to insertion into 
the perfusion system. This was to allow the monolayer to develop fully and form tight 
junctions before the cells were exposed to fluid flow. Cell morphology, viability and 
transepithelial electrical resistance (TEER) were also studied prior to their exposure to the 
fluid flow to provide comparison post-flow. 
All parts of the system were assembled in a sterile, class II biosafety cabinet and the sterile 
ABS transwell mounts were inserted to the bottom of the chamber. The system was rinsed 
through with 30ml of sterile PBS for 20 minutes after which the system was primed with 
30ml of fresh RSC medium and incubated at 37⁰C with 5% CO2 for 10 minutes. The system 
was returned to the class II cabinet, the inlet and outlets were clamped shut and the 
transwell membrane with the ARPE-19 cells were inserted into the chamber. The chamber 
was closed, the ports unclamped and the system was connected to the peristaltic pump at a 
predetermined flow rate and incubated at 37⁰C, 5% CO2 for 24 hours.  
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Control samples were also incubated at 37⁰C, 5% CO2 for 24 hours and maintained statically 
on the membranes within a 24 well plate (Greiner 662160). The RSC media in the control 
plates was replenished at the same time as the bioreactor system was filled and cell 
morphology, viability and TEER were assessed alongside the flow samples. 
After 24 hours, the transwell membranes were removed from the system and TEER 
measurements were taken from all of the samples. The media was then removed and the 
samples were washed 3 times in PBS. Samples were fixed in either 100% ice-cold methanol 
(Fisher Scientific, 11976961) or 10% neutral buffered formalin (NBF) (Sigma HT501128) to 
assess cell morphology and characteristic cell markers. 
2.2.2.8 CALIBRATION OF THE PERISTALTIC PUMP 
The Parker PF22X0103 peristaltic pumps used in these studies have two independent pump 
heads which are controlled via Vernier dials. In order to assign flow rates to the numbers on 
the dials, the pumps had to be calibrated to the specific configuration of the system. The 
bioreactor system was set up in a single pass fluid series circuit (Figure 2-7). A reservoir of 
fresh distilled water connected to a single QV600 chamber then connected to the peristaltic 
pump which circulated the water into a waste collection reservoir. The QV600 chamber was 
set up as per the cell culture experiment, with a transwell membrane without cells seeded, 
inserted atop an ABS mount. The system was primed with distilled water to expel all the air 
between the starting reservoir and the outlet into the waste reservoir. The pump was run 
for 5 minutes after which the water output was collected and the volume measured. For 
each speed, this was repeated 3 times and the mean was taken to calculate a flow rate in 
mL/min. To ensure reproducibility in flow rates across each experiment, the exact lengths of 
PDMS tubing was measured for each experimental circuit. 
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Experimental Setup for Flow Culture and Peristaltic Pump Calibration 
 
 
 
 
Figure 2-6: Flow culture experiment recirculating setup. Dotted line represents dynamic 
flow. (a) Media reservoir (b) QV600 chamber (c) peristaltic pump. 
 
 
 
Figure 2-7: Flow culture experimental single pass setup. Dotted line represents dynamic 
flow. (a) Fresh media reservoir (b) QV600 chamber (c) peristaltic pump (d) waste collection 
reservoir. 
Figure 2-8: Schematic of experimental assembly process. 
  
(a) (b) (c) (d) 
(a) (b) (c) 
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2.2.2.9 CELL METABOLIC ACTIVITY 
Throughout these studies, cell metabolic activity was measured using a resazurin reduction 
assay which determines the mitochondrial activity of the cells. The cell permeable redox 
indicator begins as a deep blue coloured solution and in the presence of cells with active 
mitochondrial metabolism, is reduced to fluorescently active resorufin, which is pink in 
colour but fluoresces when exposed to green light. This can be quantified using a fluorescent 
plate reader with a λexcitation = 530nm, λemission = 590nm filter set [159]. 
Resazurin assays were performed on cells prior to and post exposure to basal RSC media flow 
to assess the cell metabolic activity alongside the barrier formation studies as described 
previously. Again, this was to determine whether their exposure to flow had any effect on 
the metabolic activity of the cells. Resazurin salt (ThermoFisher, R12204) was dissolved in 
sterile PBS to a stock concentration of 0.1mg/mL, filtered to sterilise and stored at 4°C in the 
dark. At the point of assay, the stock solution was further diluted 1:10 in RSC media to a final 
concentration of 0.01mg/mL. At day 10 post seeding, a resazurin assay was performed on 
transwell inserts prior to insertion in the Kirkstall QV600 chamber. The RSC media was 
removed and 400µL of resazurin solution was added inside the transwell, with 600µL of RSC 
media added outside the transwell. The background fluorescence was measured using 
transwells containing no cells with 400µL of resazurin added inside and 600µL RSC media 
added outside of the transwell. The plates were then incubated for 2 hours at 37°C, 5% CO2 
in dark conditions. Post-incubation, 3x 100µL samples were taken from each well and 
transferred to a black 96-well plate (Corning, CC780). Resorfurin fluorescence was read using 
BMG Labtech FLUOROstar Optima plate reader (λexcitation = 530nm, λemission = 590nm). The 
background fluorescence was deducted from all values and they were then normalised to 
the pre-flow controls and the values are reported as the mean ± 1 SD. 
2.2.2.10 CELL NUMBER 
At culture days 2, 7, 10 and 14 (n=9 for each treatment) the media was removed from the 
cells and they were washed three times in PBS. The cells were then fixed in 100% ice cold 
methanol (Fisher Scientific 11976961) for 5 minutes and washed again 3 times in PBS. 
Methanol is a fixative agent which also permeabilises the cells. The nuclei of the cells were 
stained using 4’,6-Diamidino-2-Phenylindole, Dilactate (DAPI; Life Technologies D35741, 
5mg/mL), diluted in 1:30,000 in PBS for 5 minutes at 37⁰C. DAPI forms a fluorescent complex 
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by attaching to adenine/tyrosine rich regions of DNA which can be visualised using a 
fluorescent microscope [160]. The samples were then washed again 3 times in PBS and then 
stored under 500µL of fresh PBS.  
All samples were visualised using a Nikon Eclipse Ti-E microscope (Japan). To determine the 
cell number for each sample, five images from five different fields of view were taken from 
each well/substrate using a 10X objective and the number of nuclei per field of view were 
counted using the image analysis software ImageJ. The mean number of nuclei per view was 
used to calculate the mean number of cells/cm2 for each sample. These values are presented 
as the mean ± SD, n=9. 
2.2.2.11 IMMUNOCYTOCHEMISTRY FOR CELL-CELL JUNCTIONS AND DIFFERENTIATION MARKERS 
To evaluate cell-cell contact, a protein component of tight junctions, Zonula Occluden-1 (ZO-
1) was stained and visualised using immunocytochemistry. At culture days 2, 7, 10 and 14, 
cells seeded on TCP coverslips in 24-well plates and in transwells were fixed in 10% NBF as 
described previously. The cells were then permeabilised with 0.1% Triton-X100 for 5 minutes 
at 4°C following three PBS washes. The samples were blocked in 10% goat serum (Sigma 
G9023) (diluted in PBS) for 30 minutes at 37°C. Blocking with a solution such as serum, which 
contains an abundance of charged proteins, reduces the non-specific binding of antibodies 
which give rise to background staining. The samples were then incubated with a primary 
rabbit anti-ZO-1 antibody (details in Table 2-4A) diluted with 1% BSA solution, at 4°C 
overnight. Following three washes in wash buffer (0.1% PBS Tween 20) (Sigma P1379) the 
samples were incubated with an anti-rabbit secondary antibody (details in Table 2-4B) for an 
hour at 37°C and then counterstained with DAPI. The transwell membranes were removed 
from the transwells by cutting around the edge of the membrane with a scalpel, in order to 
mount them onto microscope slides. All microscope slides were mounted using 
VECTASHIELD antifade mounting media (VECTOR Laboratories, H-1000) which prevents rapid 
photobleaching and preserves fluorescence in samples. Images were taken using a Zeiss LSM 
800 laser confocal microscope.  
The expression of alpha-smooth muscle actin (αSMA) was also evaluated. αSMA is 
biochemical marker and its expression in RPE cells is an indication of epithelial-mesenchymal 
transition. In stable, differentiated monolayer cultures, RPE cells will not express αSMA 
[161]. At each time point, the samples were washed three times in PBS and fixed in ice cold 
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methanol for 5 minutes at room temperature. Following three further washes in PBS, the 
samples were blocked in 10% goat serum (diluted in PBS) for 30 minutes at 37°C after which 
they were incubated with a mouse anti-αSMA antibody (details in table) diluted in 1% BSA, 
overnight at 4°C. The samples were washed three times with wash buffer and incubated for 
a further hour with an anti-mouse secondary antibody (details in table) at 37°C and 
counterstained with DAPI. Images were taken using a Zeiss LSM 800 laser confocal 
microscope. To ensure the specificity of the antibodies used, rabbit or mouse 
immunoglobulins (IgG) were used as an isotype control (details in table). 
ZO-1 and αSMA expression were also evaluated in the experiments where the samples were 
exposed to flow. Cells were fixed and stained for each of the antibodies described above 
after their exposure to flow for each flow rate as well as the static controls.   
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Antibodies used to detect Cell-Cell Junctions and Differentiation Markers in ARPE-19 
Cells 
Table 2-4: Primary (A) and secondary (B) antibodies used to detect cell-cell junctions and 
differentiation markers in ARPE-19 cells. 
 
Fluorescein Isothiocynate Conjugated Dextrans used in Permeability Studies 
FITC Dextran Molecular Weight (kDa) Source 
FD4 4 Sigma (FD4-100MG) 
FD40 40 Sigma (FD40-100MG) 
FD70 70 Sigma (FD70-100MG) 
Table 2-5: Different molecular weights of fluorescein isothiacynate conjugated dextrans 
used in the in vitro permeability studies.  
A   
Primary Antibodies Dilution Source 
Rabbit polyclonal anti-ZO-1 1:100 Invitrogen (40-2200) 
Mouse monoclonal anti-alpha 
smooth muscle Actin 
1:200 abcam (ab7817) 
B   
Secondary Antibodies Dilution Source 
Goat anti-rabbit, Alexa Fluor 488 1:500 Life Technologies (A-11034) 
Goat anti-mouse, Alexa Fluor 594 1:500 Life Technologies (A-11032) 
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2.2.2.12 STATIC TRANSPORT STUDIES TO DETERMINE BARRIER PERMEABILITY 
A classic two compartment, zero flow model system was used to study the permeability of 
different sized molecules across the NH3 treated, ePTFE membrane. Following plasma 
treatment, transwell inserts with ePTFE membranes were sterilised via UV treatment (5 
minutes UV exposure on both sides) and inserted into a 24-well plate. The transwells were 
then either seeded with ARPE-19 cells or left unseeded. For seeded experiments, ARPE-19 
cells were seeded on to transwell membranes at 2.6x10-4cells/cm2 in complete culture 
medium as per previous experimental conditions. Day 1 post seeding, the medium was 
changed to reduced serum culture medium and the cells were allowed to grow for 10 days 
to ensure tight junction formation, this was also confirmed with TEER measurements. 
Transwells without cells were used immediately after sterilisation and soaked in RSC medium 
prior to the experimentation. Transport studies were done using fluorescently labelled 
dextrans with different molecular weights to obtain apparent permeability coefficients over 
a range of particle sizes.  
Fluorescein isothiocynate (FITC) conjugated dextrans of different molecular weights (Table 
2-5) were each diluted in PBS to yield stock solutions with a concentration of 1mg/mL. At the 
point of experimentation, the stock solutions were further diluted in RSC medium to create 
a tracer solution with a final concentration of 50µg/mL and filtered to sterilise. The media in 
the transwells was discarded and the inside and outside of each was washed with PBS. The 
apical compartment of the transwells was filled with 400µL of tracer solution, with 600µL of 
RSC medium added to the basal compartment and the plates were incubated at 37°C with 
5% CO2 in the dark. At time intervals of 1, 3, 8 and 24 hours, the unidirectional flux (apical to 
basal) of FITC-dextran was measured by taking three, 50µL samples from the basal 
compartment. An equal volume of fresh RSC medium was added to the basal compartment 
after sampling to replace the lost volume. The samples were kept at 4°C in the dark until all 
samples had been collected. The samples were transferred to a black 96-well plate and the 
fluorescence of each sample was measured using a fluorescence spectrophotometer 
(FluorSTAR Optima, BMG Labtech) with λexcitation = 492nm, λemission = 520nm filter set. For each 
molecular weight of dextran a standard curve was generated by measuring the fluorescence 
of a serial dilution. The tracer solution was diluted 1:4 in RSC medium for 5 dilutions and 
triplicate 50µL samples were taken for each dilution and the fluorescence was measured as 
described previously. Experimental and standard curve samples were performed in triplicate 
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for each molecular weight. The time-dependent increase in FITC-dextran in the basal 
compartment is presented. Results are shown as the mean concentration at each time point 
± 1 SD. 
Under static conditions, the transmembrane flux of the dextran particles (JD) is 
predominantly determined by diffusive forces and can be calculated using the quantity of 
dextran traversing the membrane in time t (dQ/dt) and the exposed area of the membrane 
(A): 
𝐽𝐷 =
𝑑𝑄
𝑑𝑡
𝐴 
Equation 2-1: Transmembrane Flux. 
Flux can also be defined by the change in concentration through the thickness of the 
membrane (dC/dx) multiplied by the diffusion coefficient (D) of the membrane: 
𝐽𝐷 = −𝐷
𝑑𝐶
𝑑𝑥
 
Equation 2-2: Relationship between flux and diffusion coefficient. 
If we assume steady state flux through the membrane and that the concentration at the 
apical side of the membrane is equal to the donor concentration, CA, and the concentration 
at the basal side of the membrane is equal to the receptor concentration, CB, then equation 
2-1 can be written as: 
𝐽𝐷 = 𝐷
𝐶𝐴 − 𝐶𝐵
ℎ
 
Equation 2-3: Intergrated equation for transmembrane flux. 
where h is the thickness of the barrier. Using the concentration curves obtained from the 
two-compartment static transport studies, the transmembrane flux was calculated using 
equation 2-1. The calculated flux was then used to determine the diffusion coefficients for 
each molecular weight of dextran across both the seeded and unseeded NH3 treated ePTFE 
membranes. The values obtained for the diffusion coefficients were then used as initial 
parameters in the computational models described in section 2.3. 
  Chapter 2 
54 
 
The other input parameter required by the computational models is the permeability 
coefficient (KP) of the membrane. This was also calculated from the data obtained from the 
two-compartment static transport studies. 
If the amount of dextran traversing the membrane were an infinite dose, then the 
permeability coefficient (KP) can be defined by the relationship:  
𝐾𝑃 =
𝑄
𝐴𝑡(𝐶𝐴 − 𝐶𝐵)
 
Equation 2-4: Apparent permeability coefficient from time-dependent FITC-dextran 
concentration. 
where CA is the concentration of the dextran in the apical compartment and CB is the 
concentration of dextran in the receptor compartment on the basal side of the membrane. 
Normally CA can be simplified as the donor concentration and CB can be simplified to 0. For 
each different molecular weight dextran used, the apparent permeability coefficient was 
calculated for both the ePTFE membrane with ARPE-19 cells and without ARPE-19 cells.  
2.2.2.13 DYNAMIC TRANSPORT STUDIES 
The experimental set-up was designed to emulate mass transport and drug clearance at the 
interface between the vitreous cavity and the outer blood retinal barrier therefore the 
system was arranged in a single pass series fluid circuit as described in section 2.2.2.7. This 
set up allowed the study of the movement of the dextran particles from a static reservoir, 
through the ePTFE membrane into a dynamic flow environment representative of the 
movement from the vitreous cavity, through the Bruch’s membrane into the choroidal 
capillary network. 
Initial experiments were conducted in the absence of ARPE-19 cells. The Kirkstall QV600 
system was assembled as previously described in 2.2.2.7 but for a single pass, non-
recirculating circuit. The system was rinsed with 30mL of sterile PBS for 20 minutes prior to 
being primed with 30mL of RSC media. Once the system was filled with media, the inlet and 
outlet tubes of the Kirkstall QV600 chamber were clamped shut and the ABS transwell mount 
was inserted after which the plasma treated ePTFE membrane transwell with the silicone O-
ring was inserted. The apical compartment of the transwell was filled with 400µL of tracer 
solution, the chamber was sealed and the inlet and outlet were unclamped. The media was 
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then perfused through the system. At defined time points, samples were taken from the 
chamber on the basolateral side of the membrane. The inlet and outlet tubes were clamped 
shut and the transwell containing the tracer solution was removed. The remaining volume 
of media (2.5mL) in the Kirkstall QV600 chamber was removed using a syringe and the 
solution was homogenised. Three 100µL samples were taken from this solution and 
transferred to a black 96-well plate. The chamber was then refilled with 2.5mL of fresh RSC 
media, the transwell reinserted and resealed after which the tubes were unclamped and the 
flow was allowed to perfuse once more. This was repeated for each time point up to 24 
hours. Once all the samples had been collected, the fluorescence of each was measured 
using a spectrophotometer (FluorSTAR Optima, BMG Labtech) with λexcitation = 492nm, λemission 
= 520nm filter set. The concentration of FITC-dextran in each of the samples was determined 
by comparison with the standard curve for each molecular weight of FITC-dextran. Data are 
presented as the average concentration profile for the basolateral side of the membrane 
within the chamber. This procedure was repeated for each molecular weight of FITC-dextran 
at flow rates of 20uL/min, 200uL/min, 400µL/min and 2mL/min. Each experiment was 
repeated in triplicate and the results are shown as mean concentration ± 1 SD. For the 
2mL/min experiment the systems were unable to be left overnight due to the risk of 
exhausting the media supply within the reservoir, therefore these experiments were 
conducted over 8 hours. 
2.2.2.14 STATIC RELEASE OF IBUPROFEN FROM SILICONE OIL 
The release of ibuprofen (ibu) from silicone oil (SiO) was measured over time to determine a 
static release profile. Ibu is a lipophilic drug and is also soluble in SiO, one of the reasons it 
was selected for use in these studies. An experimental concentration of 1mg of ibu (Tokyo 
Chemical Industry UK, I0415) was added to 1mL of 1000c.st Silicone oil (Fluoron GmbH) and 
the mixture was stirred for a minimum of 72 hours in a sealed flask. Following stirring, the 
ibu-SiO was filtered in a Class II biological safety hood to sterilise and remove any undissolved 
material before being stored at RT. The initial experimental set-up was designed to measure 
the release of ibu from SiO directly into RSC culture media at 37⁰C with 1mL of the ibu-SiO 
on top of 500µl of RSC media in the well of a 24-well plate. At defined time points, three 
100µl samples were taken from the RSC media, transferred to UV transparent cuvettes 
(UVette, Eppendorf) and the time-dependent increase in ibu concentration was measured 
using a UV spectrophotometer (SPECTROstar Nano, BMG Labtech) λabsorption = 264nm. Due to 
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the abundance of proteins and other molecules present in the RSC media, the absorption 
spectra of the ibuprofen in the samples produced undetectable results due to interference, 
therefore the experimental set up was altered to measure the release of ibu into PBS. As 
culture media was unable to be used, the release experiments could not be conducted in the 
presence of cells therefore it should be noted that all results presented for the release of 
ibuprofen are without the passage of the drug across an ARPE-19 monolayer. Similarly, initial 
experiments were designed to measure the release of ibuprofen from the SiO across the NH3 
treated EPTFE membrane, however a fluid-fluid interface was needed to allow movement of 
the drug from the oil phase to the aqueous phase. To overcome this, a small volume (100µL) 
of PBS was added to the donor compartment on the apical side of the transwell membrane 
with 300µL of SiO and 600µL of PBS added to the receptor compartment on the basal side of 
the membrane. Due to the transwell design and the differences in density between the PBS 
and the SiO, hydrostatic forces caused the level of the PBS phase on the apical side to alter 
during the timeframe of the experiment leading to inconsistences across replicates. The final 
experimental design therefore involved direct release of ibuprofen from the SiO into the PBS 
without crossing a membrane. In a well plate, 500µL of PBS was added with 1mL of ibu-SiO 
added on top. This was repeated in 12-well plates, 24-well plates and 48-well plates to 
investigate the effect of interfacial surface area on the release profile. 
The concentration of ibuprofen present in each of the samples was determined by 
comparison with the standard curve. Concentration gradient effects were investigated with 
experiments being carried out with the PBS completely replaced following sample removal, 
or just the 150µl sample volume replaced with fresh PBS. Experiments were carried out in 
triplicate and results are presented as the mean cumulative release ± 1 SD. 
2.2.2.15 DYNAMIC RELEASE OF IBUPROFEN FROM SILICONE OIL 
The Kirkstall QV600 chamber was used to investigate the effects of dynamic flow on the 
release of ibu from SiO. Utilising the single pass, non-recirculating set up described in 
2.2.2.13, the concentration of ibu in the bottom of the QV600 chamber was measured at 
defined time points, as previously described. As with the static experiments, release of ibu 
was measured into PBS. The Kirkstall QV600 chamber, tubing and peristaltic pump were 
assembled as previously described. The system was rinsed and primed with 30mL of fresh 
sterile PBS. The inlet and outlet ports were clamped shut and 2mL of 1mg/mL ibu-SiO was 
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added directly on top of the PBS. The clamps were removed and the flow was allowed to 
perfuse.  
At set time intervals, the ports were clamped shut and the volume of PBS beneath the ibu-
SiO in the QV600 chamber (2.5mL) was removed using a 25 gauge (25G) needle and syringe. 
Using a 25G needle allows the PBS to be removed from the chamber without removing any 
silicone oil as 1000 c.st SiO is too viscous to be drawn into the needle. The PBS removed was 
homogenised and three 50µL samples were added to individual UV-clear cuvettes and the 
UV light absorption of the samples was measured using a UV spectrophotometer 
(SPECTROstar, BMG Labtech) λabsorption = 264nm. The absorption of each of the samples was 
compared to a standard curve and the concentration of the ibu present in each sample was 
determined. Results are presented as mean concentration at each time point ± 1 SD. 
2.2.2.16 STATISTICS 
GraphPad Prism statistical analysis software was used to analyse all data.  
Unpaired student t-test 
 Concentration curve statistics of transport through NH3 treated ePTFE and NH3 
treated ePTFE seeded with ARPE-19 cells. 
A significance level of p < 0.05 was set for these experiments. 
One-way Analysis of Variance (ANOVA) 
 Effects of dynamic flow on cell number. 
 Effects of dynamic flow on cell viability. 
 Effects of dynamic flow on TEER. 
Dunnet’s post hoc test was used. A minimum significance level of P < 0.05 was set for each 
experiment. D’Agostino & Pearson normality tests were used to confirm the normal 
distribution of the data. 
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2.2.3 RESULTS 
2.2.3.1 CELL MORPHOLOGY AND EPITHELIAL BARRIER FORMATION 
ARPE-19 cells seeded on both TCP coverslips and NH3 treated ePTFE transwell membranes 
were investigated to determine the optimal culture time for the cells to develop tight 
junctions and exhibit the barrier properties necessary to study the transmembrane transport 
of molecules. Previous models of the outer BRB which used ARPE-19 cells report epithelial 
barrier functionality at time points ranging from 7 days to 4 weeks [104, 162, 163]. Cell 
number, immunocytochemistry and transepithelial electrical resistance were all used to 
evaluate the monolayer and epithelial barrier integrity. 
Cell Number and Growth 
The cell populations showed an increasing trend in cell number up until day 7 after which 
the number appeared to begin to plateau up to day 14 where the cells had reached 
confluence; this is a typical growth pattern for cells in culture [164]. Although both materials 
were initially seeded with a density of 2.6x104 cells/cm2, the increase in cell number was 
more rapid for those cells grown on TCP controls compared with the NH3 treated ePTFE 
membranes however both surfaces displayed similar shaped curves but with the nuclei count 
on the ePTFE being lower at each time point (Figure 2-9). These differences however, were 
not statistically significant (Two-way ANOVA, Sidak post-hoc. F (3, 24)= 0.556, p= 0.65). The 
growth of the cells on TCP was also confirmed with phase contrast microscope images which 
appear to show approximately 80% confluency by day 7 and a confluent monolayer, with a 
cobblestone appearance typical of that seen in epithelial cell morphology, by day 10 (Figure 
2-9). Due to the opacity of the NH3 treated ePTFE membrane, images were not able to be 
obtained with a standard light microscope therefore the presence of an intact monolayer 
was confirmed via immunocytochemistry. 
Expression of the Tight Junction Marker Zonula Occluden-1 
The formation of junctional complexes which are typically found in epithelial cell types 
provides the necessary intercellular adhesion needed for the RPE cells to form a functional 
polarised monolayer.  The monolayer formation was therefore verified by fluorescent 
staining of the tight junctional protein Zonula Occluden-1 (ZO-1). The use of ZO-1 in the 
identification of the presence of tight junctions within a culture is common and established 
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method [112, 162, 165, 166], however other tight junction protein components, such as 
occludin, can also be used.  
The presence of ZO-1 was demonstrated from culture day 7 on both the NH3 treated ePTFE 
and the TCP controls (Figure 2-11, Figure 2-12). For both surfaces, the ZO-1 staining was 
localised at the cell-cell borders as expected, with the majority of the cell monolayer 
expressing the protein. Qualitatively, this expression was maintained across the monolayer 
at both the 10 day and 14 day time point on both surfaces suggesting that an intact, polarised 
monolayer had been formed. 
Transepithelial Electrical Resistance 
Transepithelial electrical resistance (TEER) was used to study the integrity of the tight 
junction formation within the monolayer, as described in section 2.2.2.6. Briefly, ARPE-19 
cells were cultured on NH3 treated ePTFE membranes and TEER measurements were 
conducted at each time interval: day 2, day 7, day 10 and day 14. Additionally, control 
membranes (NH3 treated ePTFE membranes without cells) were used to determine the 
background resistance of the membranes which was then subtracted from the experimental 
group membranes containing cells. According to the suppliers (ATCC), ARPE-19 cells are able 
to reach a maximum TEER measurements of 50-100 Ω.cm2 in culture, however within the 
literature, measurements have been reported to be between 40 and 120 Ω.cm2 for intact 
monolayers depending on the culture surface [163, 167].  
There was a sharp increase in the TEER of the ARPE-19 cells cultured on the NH3 treated 
ePTFE membranes between day 2 and day 7. Following the increase, the TEER did continue 
to rise to a maximum of 59.4 ± 6.7 Ω.cm2 at day 10 however at a lower rate of increase. This 
is to be expected as the monolayer stabilises and the tight junctions mature. This value was 
maintained at day 14, when the TEER had appeared to plateau (Figure 2-13). These TEER 
values are consistent with the qualitative assessment of the presence of tight junctions 
within the cultures as shown by the cobblestone appearance of the cells and the positive 
staining indicating the expression of the protein ZO-1. Based on these results, it was decided 
that the cells would be cultured on the NH3 treated ePTFE membranes for 10 days before 
conducting the transport studies in order to ensure the presence of an intact epithelial 
monolayer barrier. 
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Growth Curve of ARPE-19 Cells 
Figure 2-9: Growth curve of ARPE-19 cells on NH3 treated ePTFE membranes vs TCP controls 
over 14 days in culture. Data are presented as mean cells/cm2(x103) ± 1 SD, n=9. 
Phase Contrast Images of ARPE-19 Cells 
Figure 2-10: Phase contrast images of ARPE-19 cells cultured on TCP over 14 days. By day 7 
in culture, cells had reached 80% confluency and by day 10 the cells had formed a complete 
monolayer. Scale bar = 50µm. 
2 4 6 8 10 12 14
0
50
100
150
200
250
Time (Days)
C
e
ll
s
/c
m
2
 (
x
1
0
3
)
TCP
NH3 treated ePTFE
DAY 2 DAY 7 
DAY 10 DAY 14 
  Chapter 2 
61 
 
Expression of the Tight Junction Marker ZO-1 on TCP over 14 Days 
Figure 2-11: Expression of the tight junction protein, ZO-1, by ARPE-19 cells cultured on TCP 
over 14 days. Presence of ZO-1 was demonstrated using anti-ZO-1 staining with Alexa Fluor 
488 conjugated secondary antibodies. From day 7, there is positive expression of ZO-1 at 
the cell borders. Scale bar = 50µm. 
 
 
 
 
 
  Chapter 2 
62 
 
Expression of the Tight Junction Protein ZO-1 on NH3 treated ePTFE over 14 Days 
Figure 2-12: Expression of ZO-1 by ARPE-19 cells cultured on NH3 treated ePTFE over 14 
days. The presence of ZO-1 was demonstrated at the cell borders from day 7 onwards. Scale 
bar = 50µm. 
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Transepithelial Electrical Resistance of ARPE-19 Cells cultured on NH3 treated ePTFE 
over 14 Days 
Figure 2-13: Transepithelial electrical resistance of ARPE-19 cells cultured on NH3 treated 
ePTFE normalised to culture area. Ω.cm2 calculated as Ω.cm2 = (Ωcell - Ωcontrol) x 0.6membrane 
area cm2. Data presented as mean TEER (Ω.cm2) ± 1 SD, n=9. 
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2.2.3.2 EFFECTS OF DYNAMIC FLOW ON ARPE-19 MORPHOLOGY AND FUNCTION 
Studies of ARPE-19 cells cultured in a dynamic flow environment are limited [168] and 
although the cells in the following experiments were not directly exposed to the fluid flow, 
it was necessary to determine their viability within this culture system prior to conducting 
any transport studies. Cells cultured in flow environments are exposed to shear stresses 
which are not observed in static cultures, therefore as the culture of ARPE-19 cells under 
flow is not well documented, their survival in this system is unknown. ARPE-19 cells were 
cultured on NH3 treated ePTFE transwells for 10 days before being inserted into the Kirkstall 
QV600 cell culture chamber and set up in a recirculating perfusion system as described in 
section 2.2.2.7. The basolateral side of the transwells were then exposed to perfusion flow 
of RSC media at flow rates ranging from 20µL/min to 400µL/min for 24 hours.  
As with the static cultures in the previous section, cell number, TEER and expression of the 
tight junction protein ZO-1 were used to assess the barrier integrity of the ARPE-19 
monolayer before and after exposure to flow. Additionally, cell viability and expression of 
alpha-smooth muscle actin (αSMA) were evaluated to determine any detrimental effects on 
the monolayer caused by the presence of the flow. 
Cell Number and Viability 
Compared with the mean cell number obtained from the pre-flow cultures, there was no 
significant difference observed in either the static cultures or those cultured under flow for 
any flow rate. There was also no significant differences in mean cell number between those 
cells cultured statically for 24 hours and those exposed to flow at any of the flow rates used 
(F (5, 48)=0.3877, p=0.85) (Figure 2-14). The metabolic activity of the cells also appeared to 
be unaffected by their exposure to flow up to a flow rate of 200µL/min compared with their 
metabolic activity measured prior to the exposure. There was also no differences in 
metabolic activity shown between those cells cultured statically and those exposed to flow 
for 24 hours up to a flow rate of 200µL/min. However, the metabolic activity of the cells 
cultured under a flow rate of 400µL/min showed a significant decrease compared with both 
the static controls and the pre-flow values (F (5, 138)=6.114, p<0.001) (Figure 2-15). Given 
that there was no difference in cell number between the pre-flow and static controls and 
those cells exposed to 400µL/min flow, this suggests that the highest flow rate used had a 
negative effect on the metabolic activity of the cells.  
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Effect of Media Flow Rate on ARPE-19 Cell Number 
Figure 2-14: Mean cell number per cm2 for ARPE-19 cells cultured on NH3 treated ePTFE 
membranes prior to exposure to flow and following 24 hour exposure to different flow 
rates. There were no significant differences shown between any of the groups. Data 
presented as mean cell number/cm2 ± 1 SD, n=9. 
Effect of Media Flow Rate on ARPE-19 Cell Metabolic Activity 
Figure 2-15: Normalised resorufin fluorescence of ARPE-19 cells cultured under different 
flow conditions. Values for each group are normalised to pre-flow control. Resorufin 
fluorescence was significantly decreased in cells cultured under 400µL/min compared with 
both the pre-flow fluorescence (p<0.001) and the cells grown in static conditions (p<0.001) 
suggesting a decrease in the metabolic activity of the cells. Data presented as mean 
resorufin fluorescence ± 1 SD, n=9; *** p < 0.001 (One-way ANOVA; Dunnett’s post hoc 
test). 
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Expression of Tight Junction Protein ZO-1 and Mesenchymal Cell Marker αSMA 
The ARPE-19 cells cultured for 10 days in RSC medium all stained positive for the tight 
junctional protein complex, ZO-1, at the cell-cell borders prior to their basal exposure to 
media flow. Following a further 24 hours in static culture, the expression of ZO-1 was 
maintained at the cell-cell contact points across the monolayer. This was also evident in the 
ARPE-19 cells which had been cultured in the Kirkstall QV600 chamber, exposed to media 
flow rates of 20, 100 and 200µL/min for 24 hours (Figure 2-16). Qualitatively, the basolateral 
exposure of the cells to media flow at lower flow rates has no effect on the expression of ZO-
1 shown by a network of ZO-1 staining which can be seen across the whole surface area of 
the substrate, as was the case prior to any exposure to flow. Additionally, for the pre-flow, 
static, 20µL/min, 100µL/min and 200µL/min cultures, no positive staining was observed for 
the mesenchymal cell marker alpha-smooth muscle actin (αSMA). αSMA is widely recognised 
of an indication of fibrosis in ARPE-19 cells and its positive expression is used as indicator of 
epithelial-mesenchymal transition [169, 170]. In contrast, the ARPE-19 cells exposed to the 
highest flow rate of 400µL/min showed a more granulated appearance of ZO-1 expression, 
without clearly defined staining around the cell borders as seen in cells cultured under the 
other conditions. There were also clusters of cells across the monolayer which exhibited 
positive staining for αSMA (Figure 2-16). 
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Expression of ZO-1 and αSMA under different Flow Conditions 
 
Figure 2-16: Expression of ZO-1 and αSMA in ARPE-19 cells exposed to different flow 
conditions for 24hrs. All cells were cultured for 10 days prior to exposure. Positive staining 
for ZO-1 was seen in all conditions, whereas the only positive staining for αSMA was seen 
in small clusters of cells exposed to 400µL/min flow. Scale bar = 20µm. 
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Transepithelial Electrical Resistance 
Prior to the exposure of cells to flow, the mean TEER across ARPE-19 cells on all membranes 
was 60.3 ± 8.5 Ω.cm2, as expected following 10 days in culture. A one-way ANOVA indicated 
a significant difference between the mean TEER values for different flow rates (F (5, 54) = 
23.12, p <0.001). Dunnett’s post hoc test was used to analyse significance between flow 
rates. No significant change in TEER was observed in the cells cultured statically for a further 
24 hours, in keeping with the result shown in section 2.2.4.1 which showed a plateau in TEER 
after day 10 in culture (p = 0.93). The results show that the cells exposed to static media for 
24 hours had a mean TEER of 66.3 ± 8.4 Ω.cm2. Compared with the static conditions, cells 
exposed to 20µl/min flow for 24 hours also showed no significant change in TEER (p = 0.98). 
For each flow rate higher than 20µL/min, there were statistically significant changes in the 
TEER values of the cell monolayers compared with the static controls (Figure 2-17) 
Dunnett’s post-hoc test revealed at flow rates 100µL/min and 200µL/min, results show a 
significant increase in TEER measurements in comparison with the static controls following 
24 hour exposure (both p <0.001). The cells exposed to 200µL/min flow showed the greatest 
increase in TEER, reaching a mean TEER of 93.0 ± 12.9 Ω.cm2. The trend appears to be an 
increase in TEER with increasing flow rate, however, Dunnett’s post hoc test also revealed 
the cells exposed to the highest flow rate of 400µl/min, showed a significant decrease 
(p=0.0119) in TEER compared with the static controls with the mean TEER value = 46.3 ± 9.5 
Ω.cm2 (Figure 2-17). 
Comparing the TEER values for each group to their own pre-flow value, the greatest change 
was observed in the 200µL/min group where there was a 61.46% increase in TEER following 
exposure to flow. In comparison, the cells exposed to 400µL/min flow showed a 23.47% 
decrease in TEER compared to their pre-flow measurements. These results corroborate the 
qualitative observation from the immunocytochemistry images which showed less distinct 
positive staining for ZO-1 in the 400µL/min group, suggesting a breakdown in the 
intercellular junctional complexes. 
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Effect of Media Flow on TEER of ARPE-19 Cells cultured on NH3 treated ePTFE 
Membranes 
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Figure 2-17: TEER values for ARPE-19 cells cultured under flow for 24hrs. All cells were 
cultured for 10 days prior to exposure. The 20µL/min showed no difference compared with 
the static control, however there was a significant increase (p<0.001) in both the 
100µL/min and 200µL/min groups. The 400µL/min group showed significant decrease in 
TEER (p=0.0119) compared with static controls. Data presented as mean TEER Ω.cm2 ± 1 
SD, n=9; * p =0.0119, *** p < 0.001 (One-way ANOVA; Dunnett’s post hoc test). 
Changes in TEER of ARPE-19 Cells cultured under different Flow Conditions 
Transepithelial Electrical Resistance Ω.cm2 
Flow Rate Pre-flow Post-flow % Change 
Static 58.4 ± 7.2 63.3 ± 8.4 + 8.39 
20µL/min 61.7 ± 1.9 66.3 ± 13.4 + 7.46 
100µL/min 63.5 ± 3.0 86.3 ± 5.2 + 35.90 
200µL/min 57.6 ± 4.5 93.0 ± 12.9 + 61.46 
400µL/min 60.5 ± 2.9 46.3 ± 9.5 - 23.47 
Table 2-6: Changes in TEER of ARPE-19 cells following culture under different flow 
conditions. Values reported as mean TEER Ω.cm2 ± 1 SD, n=9.  
*** 
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2.2.3.3 STATIC TRANSPORT OF DEXTRAN TO DETERMINE PERMEABILITY AND DIFFUSION COEFFICIENTS 
NH3 treated ePTFE membranes either seeded with ARPE-19 cells or left unseeded were used 
to study the transport of FITC-conjugated dextrans across the membranes. The unseeded 
membranes were used immediately following the sterilisation step, as described in section 
2.2.2.12. The membranes seeded with ARPE-19 cells were cultured for 10 days when the 
monolayers were exhibiting maximum TEER values, after which the transport studies were 
conducted. FITC-conjugated dextran (FD) of different molecular weights were used to 
ascertain the diffusion and permeability coefficients of each size molecule across the 
membranes. 
The initial concentration of FD in the donor solution on the apical side of the membrane was 
50µg/mL in a volume of 400µL. Therefore the equilibrium concentration in the receptor 
compartment on the basal side of the membrane (volume: 600µL) was 20µg/mL. In the 
absence of cells, FD4 (4kDa dextran) had reached a concentration of 18.4±2.83µg/mL, 92% 
of the equilibrium concentration, in the receptor compartment by 8hrs and by the 24hr time 
point the concentration had reached 20±1.69µg/mL. FD40 also reached the equilibrium 
concentration by 24hrs in the absence of cells but the rate of passage was lower with the 
concentration in the receptor compartment only reaching 12.6±2.06µg/mL after 8hrs (fig 2-
15). Similarly, FD4 and FD40 had both reached 20µg/mL at 24hrs in the presence of ARPE-19 
cells, however the rate of passage was lower for both as expected (Figure 2-18). 
Increasing the molecular weight to 70kDa, the amount of dextran transported through either 
the membrane or monolayer-membrane complex was decreased. In the absence of the cell 
monolayer, the concentration of FD70 in the receptor compartment reached a maximum of 
14.98±2.6µg/mL at 24hrs, only 75% of the equilibrium concentration (Figure 2-18). The 
transport was further decreased in the presence of ARPE-19 cells with a maximum 
concentration of 12.12±2.58µg/mL reached at 24hrs (Figure 2-18). 
Using the data from the curves and the equations described in section 2.2.2.12, diffusion and 
permeability coefficients for each molecular weight of dextran were calculated for both the 
unseeded and seeded membranes (Table 2-7, Table 2-8).The highest permeability and 
diffusion coefficient was observed in the experiments using FD4 across the unseeded 
membranes with values of 1.34x10-5 cm/s and 1.23x10-6 cm2/s. As expected, the value of both 
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coefficients decreases with increasing molecular weight of dextran. There is also a decrease 
in permeability and diffusion in the presence of the ARPE-19 monolayer.   
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Static Transport of Dextrans across NH3 treated ePTFE Membranes 
Figure 2-18: Passage of fluorescently labelled dextrans (FD) through NH3 treated ePTFE 
membranes over time. Graph indicates concentration of different molecular weight FDs on 
basolateral side of the membrane at each time point (FD4, 4kDa, black) (FD40, 40kDa, red) 
(FD70, 70kDa, blue). Equilibrium limit shows maximum possible concentration of FD in 
basolateral compartment. n= 9. 
Figure 2-19: Passage of fluorescently labelled dextrans (FD) through NH3 treated ePTFE 
membranes, seeded with ARPE-19 cells, over time. Cells were cultured for 10 days prior to 
experimental use. Graph indicates concentration of different molecular weight FDs on 
basolateral side of the membrane at each time point (FD4, 4kDa, black) (FD40, 40kDa, red) 
(FD70, 70kDa, blue). Equilibrium limit shows maximum possible concentration of FD in 
basolateral compartment. n= 9. 
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Diffusion and Permeability Coefficients of Dextrans across NH3 treated ePTFE 
Membranes  
Molecular Weight 
Diffusivity in RSC 
Medium 
(m2/s) 
Diffusion 
Coefficient across 
Barrier 
(m2/s) 
Permeability 
Coefficient of 
Barrier 
(m2) 
4kDa 2.4x10-11 1.22x10-11 1.35x10-9 
40kDa 7.4x10-12 8.90x10-12 7.97x10-10 
70kDa 5.6x10-12 4.89x10-12 4.28x10-10 
Table 2-7: Diffusion and permeability coefficients of different molecular weight dextrans 
across NH3 treated ePTFE membranes. Coefficients calculated using data from static 
transport studies and the equations described in section 2.2.2.12. 
 
Diffusion and Permeability Coefficients of Dextrans across NH3 treated ePTFE 
Membranes seeded with ARPE-19 cells 
Molecular Weight 
Diffusivity in RSC 
Medium 
(m2/s) 
Diffusion 
Coefficient across 
Barrier 
(m2/s) 
Permeability 
Coefficient of 
Barrier 
(m2) 
4kDa 2.4x10-11 1.07x10-11 8.80x10-10 
40kDa 7.4x10-12 5.18x10-12 5.90x10-10 
70kDa 5.6x10-12 1.82x10-12 2.23x10-10 
Table 2-8: Diffusion and permeability coefficients of different molecular weight dextrans 
across NH3 treated ePTFE membranes seeded with ARPE-19 cells. Coefficients calculated 
using data from static transport studies and the equations described in section 2.2.2.12. 
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2.2.3.4 DYNAMIC TRANSPORT AND CLEARANCE OF DEXTRAN WITHIN THE KIRKSTALL QV600 SYSTEM 
Each experiment was performed using two transwells in separate perfusion systems, and this 
was repeated three times for each flow rate. The membranes seeded with ARPE-19 cells 
were exposed to basolateral flow rates of 20µL/min, 200µL/min and 400µL/min for 24 hours. 
The membranes without cells were exposed to the same flow rates and an additional flow 
rate of 2mL/min (8 hours for 2mL/min).  
The initial donor concentration was equal to that of the static experiments (50µg/mL) and 
the measured concentration in the receptor compartment shows the mean concentration ± 
1 SD in the receptor compartment at that instance in time, as the dextran is continuously 
cleared from the chamber by the flow. 
20µL/min 
For each molecular weight of dextran and irrespective of the presence of ARPE-19 cells, the 
concentration profiles for each condition exposed to 20µL/min appear to follow that of a 
typical single dose response (Figure 2-20). This is defined by a rise in concentration up to a 
maximum peak after which the concentration decreases with time as it is cleared away. As 
expected, given the diffusion and permeability coefficients, the concentration in the receptor 
compartment of chambers with ARPE-19 cells was lower compared with chambers absent of 
cells. This is reflected in the area under the curve values (AUC). The AUC value for a 
concentration vs time graph is an indication of the total amount of drug which has moved 
into the receptor compartment over the measured time. In the presence of ARPE-19 cells, 
the AUC was lower and the AUC decreased with increasing molecular weight of FD. The 
highest value for the AUC was seen with FD4 used across unseeded NH3 treated ePTFE 
membranes (table 2-8), AUC = 16.63µg.hr/mL. In comparison, FD4 across NH3 treated ePTFE 
membranes seeded with ARPE-19 cells 10 days prior to experimental use had an AUC 30% 
lower, AUC = 11.57µg.hr/mL.  
The diffusion and permeability coefficients established in section 2.2.3.3 showed that as the 
molecular weight of FD increased, a greater difference in permeability and diffusion occurred 
between seeded and unseeded membranes. This was reflected in the percentage decrease 
in AUC. For FD40, the AUC for unseeded membranes = 15.89µg.hr/mL and for seeded 
membranes = 9.05µg.hr/mL, a 43% decrease (Table 2-9). The decrease between unseeded 
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and seeded membranes was greatest for FD70. The AUC for the unseeded membranes was 
14.76µg.hr/mL and for the seeded membranes 6.04.µg.hr/mL, a reduction of 59%. 
Peak concentration (Cmax) was also significantly decreased in the presence of ARPE-19 cells 
for each molecular weight of FD (p<0.001 FD4, FD40) (p=0.0013 FD70). The fall in peak 
concentration was consistent across the different molecular weights, with the reduction 
being 32%, 33% and 35% for FD4, FD40 and FD70 respectively. As expected, the conditions 
which contributed to the highest Cmax were FD4 through unseeded membranes, where the 
maximum concentration in the receptor compartment reached 1.72±0.15µg/mL. By 
comparison, FD70 through cell seeded membranes only reached a peak concentration of 
0.87±0.22µg/mL. 
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Concentration Profiles of Fluorescently labelled Dextrans in Receptor Compartment of 
Kirkstall QV600 exposed to a Flow Rate of 20µL/min 
Figure 2-20: Concentration profiles of different molecular weight fluorescently labelled 
dextrans a) 4kDA, b) 40kDa and c) 70kDa in receptor compartment of Kirkstall QV600 
chamber. Studies carried out on unseeded and seeded NH3 treated ePTFE membranes.  
Experimental flow rate = 20µL/min. Data presented as mean ± 1 SD, n=6. 
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 Concentration Curve Statistics for Dynamic Transport Studies at 20µL/min 
Table 2-9: Concentration curve statistics for 4kDa fluorescently labelled dextran exposed 
to a flow rate of 20µL/min. 
 Table 2-10: Concentration curve statistics for 40kDa fluorescently labelled dextran exposed 
to a flow rate of 20µL/min. 
Table 2-11: Concentration curve statistics for 70kDa fluorescently labelled dextran exposed 
to a flow rate of 20µL/min. 
  
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
NH3 ePTFE 16.63 1.72±0.15 4 0.81 
NH3 ePTFE + 
ARPE-19 cells 
11.57 1.17±0.22 3 0.50 
 
Area under 
Curve 
(AUC,  
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
NH3 ePTFE 15.89 1.59±0.11 3 0.69 
NH3 ePTFE + 
ARPE-19 cells 
9.05 1.07±0.17 3 0.42 
 
Area under 
Curve 
(AUC,  
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
NH3 ePTFE 14.76 1.34±0.12 3 0.81 
NH3 ePTFE + 
ARPE-19 cells 
6.04 0.87±0.25 3 0.28 
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200µL/min 
Unlike at 20µL/min, the concentration profiles of the dextran at 200µL/min show a burst 
release response with an exponential decay in concentration in the receptor compartment 
over time (Figure 2-21). As expected, in the presence of cells, the AUC values were much 
lower compared with those experiments absent of cells. The percentage decrease in AUC 
between the seeded and unseeded membranes followed the same trend as seen at 
20µL/min, with a 28%, 48% and 52% decrease seen in FD4, FD40 and FD70 experiments 
respectively.  
Statistically significant decreases in peak concentration (Cmax) were seen between the seeded 
and unseeded membranes at 200µL/min for each molecular weight of dextran (p=0.004 FD4) 
(p<0.001 FD40, FD70). For FD4, Cmax= 1.60±0.30µg/mL in the absence of cells. Comparatively, 
in the presence of cells Cmax = 0.96±0.29µg/mL, a 40% decrease in peak concentration (Table 
2-12). For the larger molecular weight dextrans, FD40 and FD70, the percentage decrease 
was much larger. FD40 showed a decrease of 75% from 0.81±0.12µg/mL to 0.20±0.09µg/mL 
and FD70 dropped from 0.13±0.02µg/mL to 0.05±0.01µg/mL, 62% (Table 2-13, Table 2-14). 
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Concentration Profiles of Fluorescently labelled Dextrans in Receptor Compartment of 
Kirkstall QV600 exposed to a Flow Rate of 200µL/min 
Figure 2-21: Concentration profiles of different molecular weight fluorescently labelled 
dextrans a) 4kDA, b) 40kDa and c) 70kDa in receptor compartment of Kirkstall QV600 
chamber. Studies carried out on unseeded and seeded NH3 treated ePTFE membranes. 
Experimental flow rate = 200µL/min. Data presented as mean ± 1 SD, n=6. 
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Concentration Curve Statistics for Dynamic Transport Studies at 200µL/min 
Table 2-12:  Concentration curve statistics for 4kDa fluorescently labelled dextran exposed 
to a flow rate of 200µL/min. 
Table 2-13:  Concentration curve statistics for 40kDa fluorescently labelled dextran exposed 
to a flow rate of 200µL/min. 
Table 2-14:  Concentration curve statistics for 70kDa fluorescently labelled dextran exposed 
to a flow rate of 200µL/min. 
 
  
 
Area under 
Curve 
(AUC,  
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
NH3 ePTFE 13.70 1.60±0.30 1 0.76 
NH3 ePTFE + 
ARPE-19 cells 
9.91 0.96±0.29 1 0.43 
 
Area under 
Curve 
(AUC,  
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
NH3 ePTFE 3.03 0.81±0.12 1 0.20 
NH3 ePTFE + 
ARPE-19 cells 
1.58 0.20±0.08 1 0.07 
 
Area under 
Curve 
(AUC,  
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
NH3 ePTFE 1.00 0.13±0.02 1 0.05 
NH3 ePTFE + 
ARPE-19 cells 
0.48 0.05±0.01 1 0.02 
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400µL/min 
Qualitatively, the shapes of the concentration curves at 400µL/min showed little difference 
to those at 200µL/min, however, the differences between the seeded and unseeded 
membranes were not as distinct (Figure 2-22). FD4 was the only molecular weight to 
decrease in AUC for both the seeded and unseeded membranes compared to 200µL/min, 
with FD40 and FD70 both displaying an increase in comparison to the lower flow rate. FD40 
and FD70 also showed instances where the curves for the seeded and unseeded membranes 
cross, indicating time points at which the passage of dextran was greater in the seeded 
experiments compared with the unseeded. 
FD4 had shown a percentage decrease in AUC of 30% and 28% for 20µL/min and 200µL/min 
respectively, however, at 400µL/min the AUC for the unseeded membranes was 
11.27µg.hr/mL and for the seeded membranes AUC = 11.32µg.hr/mL, an increase of 0.4% 
(Table 2-15). Similarly, there was little percentage difference between the AUC using FD40. 
For the unseeded membranes AUC = 6.80µg.hr/mL and for the seeded membranes AUC = 
6.78µg.hr/mL, a decrease of 0.29% (Table 2-16). Only FD70 showed a percentage decrease 
comparable to the lower flow rates with the AUC dropping 54% from 2.42µg.hr/mL unseeded 
to 1.11µg.hr/mL seeded. 
FD4 also showed an increased Cmax in the presence of cells compared with the unseeded 
membranes. At 400µL/min, the highest observed Cmax was FD4 through seeded membranes, 
Cmax = 1.81±0.25µg/mL, a 7.7% increase on the peak concentration observed in the unseeded 
membranes, Cmax = 1.68±0.4µg/mL although this difference was not deemed statistically 
significant. FD40 and FD70 showed differences in peak concentration similar to those seen 
at 20µL/min although the values were lower in comparison to the lowest flow rate, however, 
only FD70 showed a significant (p<0.001) decrease in Cmax from 0.19±0.02µg/mL to 
0.12±0.02µg/mL.  
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Concentration Profiles of Fluorescently labelled Dextrans in Receptor Compartment of 
Kirkstall QV600 exposed to a Flow Rate of 400µL/min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-22: Concentration profiles of different molecular weight fluorescently labelled 
dextrans a) 4kDA, b) 40kDa and c) 70kDa in receptor compartment of Kirkstall QV600 
chamber. Studies carried out on unseeded and seeded NH3 treated ePTFE membranes. 
Experimental flow rate = 400µL/min. Data presented as mean ± 1 SD, n=6. 
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Concentration Curve Statistics for Dynamic Transport Studies at 400µL/min 
 Table 2-15: Concentration curve statistics for 4kDa fluorescently labelled dextran exposed 
to a flow rate of 400µL/min. 
 Table 2-16: Concentration curve statistics for 40kDa fluorescently labelled dextran exposed 
to a flow rate of 400µL/min. 
Table 2-17: Concentration curve statistics for 70kDa fluorescently labelled dextran exposed 
to a flow rate of 400µL/min. 
  
 
Area under 
Curve 
(AUC,  
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
NH3 ePTFE 11.27 1.68±0.40 1 0.65 
NH3 ePTFE + 
ARPE-19 cells 
11.32 1.81±0.25 1 0.63 
 
Area under 
Curve 
(AUC,  
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
NH3 ePTFE 6.80 0.82±0.18 1 0.38 
NH3 ePTFE + 
ARPE-19 cells 
6.78 0.62±0.19 1 0.30 
 
Area under 
Curve 
(AUC,  
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
NH3 ePTFE 2.42 0.19±0.02 1 0.11 
NH3 ePTFE + 
ARPE-19 cells 
1.11 0.12±0.02 1 0.05 
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2mL/min 
The results from section 2.2.3.2 show detrimental effects on the ARPE-19 cells exposed to 
the highest flow rate of 400µL/min, therefore only unseeded NH3 treated ePTFE membranes 
were used in the 2mL/min studies. Also, the increased risk of leakage and lack of appropriate 
media reservoirs meant that the 2mL/min experiments could only be conducted over 8 hours 
as opposed to 24 hours. This shorter time frame however, still allows the observation of the 
initial passage characteristics of the dextran particles to be observed. The peak and average 
concentrations observed in the receptor compartment were greatly reduced for each of the 
molecular weights compared with the lower flow rates. This is reflected in the AUC of each. 
As expected, the AUC and Cmax decreased with increasing molecular weight (Table 2-18, 
Table 2-19, Table 2-20) and qualitatively the curves became flatter as the molecular weight 
increased suggesting a shift from burst release to steady release across the membrane 
(Figure 2-22) 
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Concentration Profiles of Fluorescently labelled Dextrans in Receptor Compartment of 
Kirkstall QV600 exposed to a Flow Rate of 2mL/min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-23: Concentration profiles of different molecular weight fluorescently labelled 
dextrans a) 4kDA, b) 40kDa and c) 70kDa in receptor compartment of Kirkstall QV600 
chamber. Studies carried out on unseeded NH3 treated ePTFE membranes. Experimental 
flow rate = 2mL/min. Data presented as mean ± 1 SD, n=6. 
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Concentration Curve Statistics for Dynamic Transport Studies at 2mL/min 
Table 2-18: Concentration curve statistics for 4kDa fluorescently labelled dextran exposed 
to a flow rate of 2mL/min. 
Table 2-19: Concentration curve statistics for 40kDa fluorescently labelled dextran exposed 
to a flow rate of 2mL/min. 
Table 2-20: Concentration curve statistics for 70kDa fluorescently labelled dextran exposed 
to a flow rate of 2mL/min. 
  
 
Area under 
Curve 
(AUC,  
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
NH3 ePTFE 2.03 0.60±0.08 1 0.31 
 
Area under 
Curve 
(AUC,  
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
NH3 ePTFE 1.39 0.30±0.02 1 0.21 
 
Area under 
Curve 
(AUC,  
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
NH3 ePTFE 0.25 0.06±0.02 1 0.04 
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2.2.3.5 RELEASE OF IBUPROFEN FROM SILICONE OIL UNDER STATIC CONDITIONS 
The abundance of proteins within culture medium can cause interference in the UV-Vis 
absorbance spectrum of ibuprofen, therefore measurement of concentration in such 
samples is unachievable via this method. Other methods of measuring the concentration in 
culture medium are available, such as radio-labelling of the ibuprofen and quantifying using 
a scintillation counter, however such methods were outside the scope of this project. 
Ibuprofen release was, therefore, measured into PBS instead. The release of ibuprofen (ibu) 
from SiO was investigated with PBS being replenished every 24 hours or left standing over 3 
days. Percentage cumulative release was used to allow comparison between the two 
conditions. The effect of interfacial contact area between the aqueous PBS phase and the 
ibu-SiO was also investigated by using equal volumes of both in different size well plates (1mL 
ibu-SiO), 500µL PBS. 
Ignoring meniscus formation caused by surface tension between the two phases, the 
interfacial contact area of the ibu-SiO and PBS in a 12-, 24- and 48-well plate = 3.85, 1.91 and 
0.95cm2 respectively. This reduction in contact area was reflected in the cumulative release 
of ibu over 72 hours. In the first 24 hours there was a burst release of ibu observed in each 
of the well plates with the initial release being greater as the contact area increased. In the 
12-well plate, 58.1±3.82% of the ibu was released after 24 hours compared with just 
32.0±4.58% in the 48-well plate. There were negligible differences observed between the 
continuous and replenished conditions after 24 hours, these effects were more apparent 
over time (Figure 2-24).  
After 72 hours, 98.5±3.68% of the ibu was released from the oil in a 12-well plate when the 
PBS was replenished every 24 hours, compared with 84.0±5.52% in the samples where the 
PBS was unchanged. Similar differences were seen in the 24-well plates however the 
cumulative release was lower in both conditions by comparison. Only 82.0±5.25% ibu was 
released from the SiO after 72 hours when the PBS was replenished; this was further reduced 
to 71.5±5.70% when the PBS was unchanged. The lowest cumulative release was seen in the 
48-well plates however the difference between the replenished and continuous conditions 
was not as great. Following 72 hours, 57.7±2.58% of ibu was released when the PBS was 
replenished and 52.4±2.175 was released when the PBS was left to stand but in both 
conditions, the cumulative percentage released after 72 hours was still lower than that 
released in the 12-well plate after 24 hours (Figure 2-24).  
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Continuous Release vs Replenished Release Profiles of Ibuprofen from Silicone Oil 
1000 with different Interfacial Contact Areas 
 
Figure 2-24: Release profiles of ibu from SiO in different size well plates (a) 12-well, (b) 24-
well, (c) 48-well. Release presented as cumulative percentage release of ibu into PBS over 
time for PBS replenished every 24 hrs (black) and left to continuously stand (red). Data 
presented as mean ± 1 SD, n=9. 
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2.2.3.6 RELEASE AND TRANSPORT OF IBUPROFEN FROM SILICONE OIL UNDER FLUID FLOW 
As with the static release experiments, ibu-SiO was in direct contact with PBS. Fresh PBS was 
continuously perfused through the system at different flow rates and the concentration of 
ibuprofen released into the PBS was measured. The differences in receptor compartment 
concentration profile (Figure 2-25) seen for ibu-SiO exposed to varying flow rates were 
similar to that seen in the dynamic transport of fluorescently labelled dextran in section 
2.2.3.4 with a different response seen at 20µL/min compared to the higher flow rates.  
At the lowest flow rate, 20µL/min, the concentration in the compartment rose to a peak over 
the first 8 hours after which there was a small drop in concentration by 16 hours followed by 
a plateau up to 24 hours. The higher flow rates however, showed an initial spike in 
concentration after 1 hour, followed by a steep elimination phase over the following 23 
hours. Peak concentration was highest after 1 hour at 200µL/min, Cmax = 0.162±0.04µg/mL 
compared with 0.128±0.02µg/mL and 0.004±0.0004µg/mL for 20µL/min and 2mL/min 
respectively. 
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Concentration Profiles of Ibuprofen released from Silicone Oil into Receptor 
Compartment of Kirkstall QV600 exposed to different Flow Rates 
 
Figure 2-25: Concentration profiles of ibuprofen released from Silicone Oil into receptor 
compartment of Kirkstall QV600 chamber exposed to flow rates (a) 20µL/min, (b) 
200µL/min and (c) 2mL/min. Data presented as mean ± 1 SD, n=6. 
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Concentration Curve Statistics for Dynamic Release of Ibuprofen 
Figure 2-26: Concentration curve statistics for ibuprofen released from Silicone Oil exposed 
to flow rates of 20µL/min, 200µL/min and 2mL/min. 
 
 
  
Flow Rate 
Area under 
Curve 
(AUC,  
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
20µL/min 2.41 0.13±0.02 8 0.10 
200µL/min 1.62 0.16±0.04 1 0.07 
2mL/min 0.02 0.004±0.0004 1 0.002 
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2.3 COMPUTATIONAL MODEL OF OUTER BLOOD RETINAL 
BARRIER 
All of the computational analysis in this study was conducted using COMSOL Multiphysics 
software. COMSOL is a computational fluid dynamics software package which uses finite 
element analysis to calculate complex fluid flow solutions. As discussed in section 1, the finite 
element analysis method can crudely be described as a three phase process: (1) pre-
processing, where the subject geometry is divided into a discrete mesh of finite elements 
with defined material properties and boundary conditions and allows mathematical analysis 
of each element individually, (2) Solution, where the program uses a matrix of partially 
differentiated equations defined by the model to solve for defined values and (3) Post-
processing, where the user is able to extract and evaluate the solved quantities and uses 
various techniques to examine the validity of the model.  
Utilising the permeability and diffusion coefficients determined from the data compiled in 
section 2.2, representative computational models of the transport and release experiments 
for both the dextran and ibuprofen were able to be built using the COMSOL software.  By 
building a model using experimentally derived data and boundary conditions it is possible to 
predict and optimise the conditions of the drug release studies which will ultimately provide 
a more time and cost effective method for the development of the novel silicone oil 
tamponade drug delivery method. 
  
  Chapter 2 
93 
 
2.3.1 METHODS 
2.3.1.1 PHYSICAL AND MATHEMATICAL DESCRIPTION OF MODEL USED FOR DEXTRAN TRANSPORT STUDIES 
The model built was based on a two-dimensional (2D) projection of the Kirkstall QV600 cell 
culture chamber using COMSOL Multiphysics finite element analysis software. Using the 
schematic diagrams provided by Kirkstall Ltd, the input geometry was built within the 
software (Figure 2-27). 
The model itself consists of two parts. One part uses the laminar flow interface to compute 
the velocity flow and pressure fields of the single-phase fluid flow that occurs across the 
QV600 chamber. The second part uses the transport of diluted species interface which is able 
to calculate the concentration field of a dilute solute in a solvent, i.e. the fluorescently 
labelled dextrans diluted in culture medium. These two physics interfaces were applied 
across the three domains defined in the geometry: the donor compartment, the ePTFE 
membrane or ePTFE membrane/ARPE-19 cell complex, and the receptor compartment 
(Figure 2-27). The model was run to simulate both the absence and presence of cells using 
alterations in both the geometry and permeability boundary conditions that will be described 
in later sections. 
Modelling Laminar Flow 
Fluid flow can only be described as laminar if a parameter known as the Reynolds number 
remains below a critical value [171]. Above this critical value, disturbances in the flow occur 
which leads to turbulent flow patterns. The Reynolds number can be defined as the ratio of 
viscous forces and inertial forces within a fluid which is subjected to bounding surface forces, 
such as flowing through a pipe. Mathematically it can be defined as: 
𝑅𝑒 =  
𝜌𝑢𝐿
𝜇
 
Equation 2-5: Reynolds number 
where ρ is the density of the fluid, u is the velocity of the fluid, L is a linear dimension (i.e. 
diameter of a pipe) and µ is the viscosity of the fluid. Although it is dependent on the model, 
it is generally accepted that the critical Reynolds number for flow through a pipe ≤ 2000 is 
appropriate for most applications [172].  
  Chapter 2 
94 
 
 
The viscosity and density of the culture medium used in the model were measured 
experimentally (2.3.2.1) and found to be 0.754mPa.s and 0.955kg/m3 respectively. When 
applied to equation 2-5 for each flow rate used in the model, the critical value for Reynolds 
number was not exceeded, making a laminar flow physics interface appropriate for this 
model. 
The equations solved for by the laminar flow are the Navier-Stokes equations for the 
conservation of momentum and the continuity equation for conservation of mass. These are 
described in section 1.7.2. 
An additional physics node was included in modelling the transport of FD through the 
membrane into basolateral medium flow. Including fluid and matrix properties incorporates 
the Brinkman equations which define the behaviour of a fluid moving through a porous 
matrix, in this case the ePTFE membrane [173]. Similar to the Navier-Stokes equation for 
momentum, this particular model take into account the dissipation of kinetic energy 
experienced by the fluid moving through a porous matrix, through means of viscous shear. 
Including these additional equations allows the movement of the fluid on the apical side of 
the membrane to influence the distribution of the FD in that domain. This node was only 
applicable to the membrane part of the model and were therefore only applied to that 
domain. 
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Geometry input for Kirkstall Dextran Experiments 
 
 
Figure 2-27: Input geometry for Kirkstall QV600 dextran simulations. 
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Receptor Domain 
Membrane 
Domain 
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Modelling Transport of Diluted Species 
The transport of diluted species physics node solves for the concentration field of a diluted 
solute within a solvent. This includes movement of the species via diffusion using Fick’s Law, 
as well as transport via convection in the fluid flow field. The diluted species node assumes 
that the concentration of the solvent is more than 90mol% of the solution and that the 
presence of the solute has no impact on the density and viscosity of the solvent, making it 
an appropriate selection for this model.  
The model implements a diffusion equation: 
𝜕𝑐𝑖
𝜕𝑡
+  ∇. (−𝐷∇𝑐𝑖) + 𝒖 . ∇𝑐𝑖 =  𝑅𝑖 
Equation 2-6: Diffusion equation for transport of diluted species. 
This equation models diffusion and convection and solves the mass conservation equation 
for one or more chemical species ci. D is the diffusion coefficient which is based on the 
molecular size of the chemical species and can be calculated theoretically, u is the velocity 
vector and Ri is the reaction rate expression which in the case of this study is a sink condition. 
The details of this equation were discussed in section 1.7.2. 
2.3.1.2 INPUT PARAMETERS FOR DEXTRAN TRANSPORT STUDIES 
The majority of the input parameters required for the model were defined by the 
experimental conditions described in the in vitro experiments; these are outlined in Table 
2-21. Parameters were either experimentally defined or had been determined by the 
experiments carried out in section 2.2, for example the diffusion coefficients and 
permeability coefficients which were deduced from the static transport experiments.  
  
  Chapter 2 
97 
 
Input Parameters for Kirkstall QV600 Dextran Transport Simulations 
Table 2-21: Input parameters for Kirkstall QV600 dextran transport simulations. 
 
 
Parameter Value 
Diffusion coefficient of FD in RSC 
medium (4kDa, 40kDa, 70kDa) 
2.39 x10-11, 0.74 x10-11, 0.56 x10-11 m2/s 
Diffusion coefficient of FD across ePTFE  
(4kDa, 40kDa, 70kDa) 
1.2x10-6, 8.9x10-8, 4.9x10-8 m2/s 
Diffusion coefficient of FD across ePTFE 
ARPE-19 complex (4kDa, 40kDa, 70kDa) 
1.1x10-7, 5.2x10-8, 1.8x10-8 m2/s 
Initial concentration of FD in donor 
domain 
50 µg/mL 
Initial concentration of FD in membrane 
domain 
0 µg/mL 
Initial concentration of FD in receptor 
domain 
0 µg/mL 
Flow rate 20,200,400,2000 µL/min 
Permeability coefficient of ePTFE 
(4kDa, 40kDa, 70kDa) 
1.4x10-5, 8.0x10-6, 4.3x10-6 cm/s 
Permeability coefficient of ePTFE ARPE-
19 complex (4kDa, 40kDa, 70kDa) 
8.8x10-6, 5.9x10-6, 2.2x10-6 cm/s 
Porosity of ePTFE membrane 0.3 
Density of RSC medium at 37°C 994.12 kg/m3 
Dynamic viscosity of RSC medium at 
37°C 
0.636 mPa.s 
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2.3.1.2.1 Rheology 
The viscosity and density of RSC medium were unknown parameters which had to be 
experimentally derived. The dynamic viscosity of a range of fluids including RSC medium, 
were measured using a TA Instruments Rheolyst AR 1000N controlled-stress rheometer (TA 
Instruments, UK) and concentric cylinder geometry. The viscosity of each fluid was 
determined from the gradient of a shear stress versus shear strain plot. All viscosity 
measurements with this rheometer were conducted at 21°C. Due to unavailability of the 
equipment, repeats of the measurements at 37°C were unable to be obtained using the TA 
Instruments rheometer, therefore these measurements were conducted using a Rheosense 
Inc µVISC rheometer (Rheosense Inc., USA) with a 100N load cell. The 21°C viscosities were 
also measured with the Rheosense Inc µVISC rheometer to ensure consistency between the 
equipment. The rheometer provides a value for the viscosity as opposed to the TA 
Instruments machine which provides the shear stress of the fluid over a range of shear rates. 
All measurements were conducted in triplicate and the results are presented as the mean 
viscosity ± 1 SD. 
A handheld density meter (Anton Parr) was used to measure the density of the fluids at both 
21°C and 37°C. The fluids were heated to the relevant temperatures in a water bath and 
samples of each were measured using the density meter. The measurements were repeated 
in triplicate and the results are presented as mean ± 1 SD. 
2.3.1.3 BOUNDARY CONDITIONS FOR DEXTRAN TRANSPORT STUDIES 
Laminar Flow 
A no slip boundary condition was applied to the walls of the geometry (Figure 2-28); this is 
the default boundary condition in modelling solid walls and means the velocity of the fluid 
in relationship to the velocity of the wall is zero [174]. In this case, the adhesion forces at the 
wall are stronger than the fluid’s cohesion forces. Hence, in terms of a stationary wall, as is 
the case for the walls of the QV600 chamber, u = 0.  
The inlet was applied to the left-hand wall of the inlet tube of the QV600 chamber (Figure 
2-30). A range of inlet flow rates was investigated to coincide with the flow rates used in the 
in vitro experiments: 20µL/min, 200µL/min, 400µL/min, and 2mL/min. The outlet was 
applied to the right-hand wall of the outlet tube of the chamber (Figure 2-29). The outlet 
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condition was a pressure condition defined as a function of the density of the fluid and 
gravity. The value of this function is close to zero, however defining the value as a function 
rather than 0 allows proper convergence of the model. 
In addition to the wall, inlet and outlet conditions, a volume force was applied to the entire 
geometry which applies the effects of gravity to each domain.  
Transport of Diluted Species 
Two transport of diluted species nodes were used in the transport of dextran simulations. 
One for the donor and receptor domains and one for the membrane domain. This separate 
node for the membrane domain allowed the difference in diffusion in that domain to be 
accounted for. 
For the donor and receptor domains, a no flux boundary condition was applied to the 
exterior boundaries of the geometry on the same edges as the no slip conditions for laminar 
flow (Figure 2-28). This no flux condition prevents any mass flow across those boundaries. 
An outflow condition was applied to the outlet (Figure 2-29) to account for transport of FD 
out of the domain by the fluid motion. At the boundaries where the two domains meet the 
membrane domain, a pointwise constraint was applied to compute the transfer of mass 
across the membrane out of the donor domain into the receptor domain. The pointwise 
constraint was a function of the two concentrations at the boundaries which were defined 
by the diffusive and convective movements of the FD through the domains and computed 
the flux across the boundaries based on the concentration of FD and the diffusion coefficient 
for each domain.  
The second transport of diluted species node applied similar boundary conditions as above 
but across the membrane domain, therefore accounting for the difference in diffusion 
coefficient across the membrane. A no flux condition was applied on the exterior wall 
boundaries of the membrane. No outflow condition was applied because the concentration 
species was not leaving the system at any point in the domain. The same function for the 
pointwise constraint was applied to the boundaries which were shared with the other two 
domains to compute the passage of the FD across these boundaries through the membrane. 
The dimensions of the membrane domain were altered depending on whether the presence 
of the cells was being modelled or not. In the presence of cells, the membrane domain was 
70µm in height and the appropriate diffusion coefficient of the domain was used, as 
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described in table Table 2-21. In the absence of the cells, the domain was reduced to 50µm 
and the diffusion coefficient was altered to account for their absence.   
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Boundary Selections for Kirkstall QV600 Dextran Transport Studies 
Figure 2-28: Exterior boundary walls highlighted with no slip laminar flow condition and 
no flux transport condition. 
Figure 2-29: Outlet boundary highlighted with pressure defined outlet condition for laminar 
flow and mass outflow condition for transport. 
Figure 2-30: Inlet boundary highlighted with flow rate defined fluid inlet condition for 
laminar flow. 
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2.3.1.4 MESH USED FOR DEXTRAN TRANSPORT STUDIES 
The mesh was created within the COMSOL software and was generated by the software to 
be controlled by the physics of the system. It comprised of free triangular elements with 
boundary layers at the no slip walls. The total number of elements in the mesh was 38267 
with a greater refinement of elements at the membrane domain where the solution requires 
most accuracy (Figure 2-31) 
A grid independence analysis was conducted to ensure the mesh was refined enough to 
produce accurate results. Firstly, the velocities along a line from the centre of the inlet to the 
centre of the outlet were plotted for varying numbers of mesh elements from an extremely 
fine mesh of 108814 elements to an extremely coarse mesh of 18005 elements. Additionally, 
the velocities at two points in the centre of the chamber were further evaluated and the 
percentage difference in velocity at these two points compared to the most refined mesh 
was plotted. A percentage difference of ≤5% of the most refined mesh was deemed fine 
enough. This was reached at 38267 elements and all further simulations were carried out 
with this mesh. 
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Mesh generated for Kirkstall QV600 Dextran Transport Studies 
Figure 2-31: Mesh generated for Kirsktall QV600 chamber used in dextran transport 
simulations. Mesh consists of 38267 elements with a combination of free triangular 
elements and layered quadrilateral elements at the no slip boundaries. 
 
 
Figure 2-32: Mesh zoomed into membrane domain showing refinement of the mesh at the 
membrane domain and the changes in element shape at the boundaries. 
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2.3.1.5 PHYSICAL AND MATHEMATICAL DESCRIPTION OF IBUPROFEN RELEASE STUDIES 
The model was built based on the same Kirkstall QV600 chamber geometry described 
previously. The difference between the ibuprofen release studies and the dextran transport 
studies was the ibuprofen release studies require the model to simulate the interaction of 
two immiscible fluid phases: the aqueous PBS phase and the 1000 c.st silicone oil phase. This 
model also removes the membrane domain as the movement of drug was directly from the 
oil into PBS. As with the model described in section 2.3.1.1, the simulation model consists of 
two parts: a laminar flow solution and a transport of diluted species solution. These physics 
nodes produce solutions based on the equations previously described with some differences 
in the mesh design based on the requirement of a two phase model. 
Modelling Laminar Flow 
To model the two-phase nature of the model, the same laminar flow physics was used 
however this was in addition to a moving mesh physics interface. The laminar flow moving 
mesh physics node solves the same equations for velocity and pressure fields but also tracks 
the movement of the interface between two immiscible fluids by allowing deformation of 
the mesh during the solution. 
A free mesh deformation is prescribed to the domains either side of the interface, the oil 
domain and the PBS receptor domain. These are the regions where the mesh is allowed to 
deform. The inlet and outlet tubes of the geometry are prescribed a fixed mesh as only one 
of the fluid phases moves through these parts of the geometry. The mesh is also prescribed 
zero displacement at the exterior boundary walls to prevent collapsing of the solid wall 
boundaries. Those walls which are in contact with the fluid-fluid interface are prescribed free 
deformation of the mesh parallel to the exterior wall boundaries but with zero perpendicular 
displacement, again to prevent collapsing the solid exterior walls. 
The additional equation solved for in the laminar flow, moving mesh interface is the Navier 
slip equation [175]. This condition is applied to the boundaries which are in contact with the 
fluid-fluid interface and it is appropriate for the two-phase flow model. This condition adds 
a frictional force, F, at a stationary wall which allows the interface to move against the wall. 
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𝑭𝑓𝑟 =  −
𝜇
𝛽
𝒖 
Equation 2-7: Navier slip frictional force. 
Where β is the slip length, which is a function of the element size of the mesh. The fluid-fluid 
interface node also takes into account the interfacial tension of the two fluids and the 
contact angle between the wall and the fluids. 
Due to the nature of the two-phase model, a stationary solution for the velocity field could 
not be solved because of the movement at the interface, therefore a time-dependent 
solution was obtained over 9 seconds, at which point the flow stabilised. The solution for the 
stabilised flow field was used as the velocity field input for the transport of diluted species 
solutions. 
Modelling Transport of Diluted Species 
The transport of diluted species follows the same principles as described in section 2.3.1.1. 
The solution for the transport is simpler for the release of ibuprofen because the 
concentration species only moves through two domains and not through a fluid matrix 
domain therefore the movement is purely diffusion and convection in the two different 
fluids. An additional expression for the partition coefficient is included in the mass transport 
between the two phases. The partition coefficient is a measure of the difference in solubility 
of a compound in the two different phases and describes the ratio of concentrations of the 
compound in the two phases when equilibrium has been reached across the interface. 
To satisfy the convective terms of the mass balance equation, the solution for the laminar 
flow, moving mesh physics node was used to describe the velocity field in the model in order 
to solve for the concentration field of the ibuprofen across the model. 
2.3.1.6 MODELLING STATIC IBUPROFEN RELEASE IN WELL PLATES 
In addition to the modelling the dynamic release of ibuprofen from silicone oil within the 
Kirkstall QV600 chamber, the release was also investigated in static well plate models. 
Models were built to represent 12, 24 and 48-well plates and the transport of diluted species 
physics, input parameters and boundary conditions used for the solution were identical to 
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those used for the dynamic release models, however these models do not require the 
laminar flow physics as they were static. 
2.3.1.7 INPUT PARAMETERS FOR IBUPROFEN RELEASE STUDIES 
The input parameters were either experimentally defined or calculated. The values for the 
partition coefficient of ibuprofen and the interfacial tension of 1000 c.st silicone oil and PBS 
were taken from the literature. All of the input parameters used are detailed in Table 2-22. 
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Input Parameters for Ibuprofen Release Studies 
Table 2-22: Input parameters for Kirkstall QV600 ibuprofen release studies. 
  
Parameter Value 
Diffusion coefficient of ibuprofen in 
1000c.st silicone oil 
3.35 x10-11 m2/s 
Diffusion coefficient of ibuprofen in PBS 2.27 x10-13m2/s 
Partition coefficient of ibuprofen  2.2 [176] 
Initial concentration of ibuprofen in oil 
phase 
1 mg/mL 
Initial concentration of ibuprofen in 
aqueous phase 
0 µg/mL 
Flow rate 20,200,400,2000 µL/min 
Interfacial tension 1000c.st silicone oil/PBS 50 mN/m 
Wall contact angle of fluid interface 1.3 rad 
Density of PBS at 37°C 996.31 kg/m3 
Dynamic viscosity of PBS at 37°C 0.61 mPa.s 
Density of silicone oil at 37°C 967 kg/m3 
Dynamic viscosity of silicone oil at 37°C 790 mPa.s 
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2.3.1.8 BOUNDARY CONDITIONS FOR IBUPROFEN RELEASE STUDIES 
Laminar Flow 
A no-slip condition was applied to the exterior boundary walls as with the transport of 
dextran studies (Figure 2-33). However, those walls in contact with the fluid-fluid interface 
were assigned a Navier slip condition (Figure 2-34). This condition allows the fluid-fluid 
interface to move along the wall. Additionally, the top boundary of the oil phase, parallel to 
the fluid-fluid interface, was assigned a slip condition (Figure 2-35). This slip condition allows 
the deformation of the mesh to continue throughout the phase whilst still applying a no 
penetration condition, meaning the model allows the movement of the mesh without fluid 
leaving that domain. 
The inlet and outlet conditions were as previously describes and the same flow rates were 
investigated as with the dextran transport studies: 20µL/min, 200µL/min, 400µL/min and 
2mL/min. A volume force was also implemented across the entire geometry to account for 
gravity in the system. 
Transport of Diluted Species 
Two transport of diluted species nodes were used to investigate the release of ibuprofen 
from the silicone oil: one for the oil phase and one for the aqueous phase. As in the previous 
model, a no-flux condition was applied on the exterior boundary walls of the geometry. An 
outflow condition was applied to the right-hand wall of the outlet port of the chamber to 
allow the removal of ibuprofen via the fluid flow field. The appropriate diffusion coefficients 
as described in table Table 2-22 were applied to each fluid domain and a pointwise constraint 
was applied at the fluid-fluid interface. This pointwise constraint takes into account the 
concentration at the interfaces and solves for the mass flux across that boundary using a 
function of the concentration gradient and the partition coefficient.  
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Boundary Selections for Kirkstall QV600 Ibuprofen Release Studies 
Figure 2-33: Exterior boundary walls highlighted with no slip laminar flow condition. 
Figure 2-34: Boundaries in contact with fluid-fluid interface with Navier slip laminar flow 
condition. 
Figure 2-35: Oil phase boundary with slip laminar flow condition. 
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2.3.1.9 MESH USED FOR IBUPROFEN RELEASE STUDIES 
For the static release studies in the well plate, the mesh was made up of 1732 free triangular 
elements (Figure 2-36). A grid independence test was carried out to ensure the mesh was 
refined enough to produce accurate results. The concentration at two points within the well 
was compared across a range of increasingly finer meshes to evaluate the accuracy of the 
results compared with the finest mesh. A percentage error of 5% or less compared with the 
finest mesh was deemed sufficiently accurate. This was achieved at 1732 elements and this 
mesh was used for all well plate simulations. 
As previously discussed, the model for dynamic release of ibuprofen used a moving mesh 
which undergoes deformation at the fluid-fluid boundary and allows the interface between 
the two phases to be tracked. The mesh was generated by the software to be controlled by 
the physics of the system and consisted of 2258 free triangular elements (Figure 2-37). Again, 
a grid independence test was carried out. The velocity at the points within the centre of the 
chamber were compared across a range of mesh element numbers from an extremely coarse 
mesh of 345 elements to an extremely fine mesh of 3481 elements. The percentage different 
in velocity at the two points compared with the most refined mesh was used to evaluate the 
accuracy of the results. A percentage error of 5% or less was deemed accurate enough. This 
was reached at 2258 elements and this mesh was used for all the following simulations. 
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Mesh generated for Ibuprofen Release Studies 
Figure 2-36: Mesh generated for (a) 12-well plate, (b) 24-well plate, (c) 48-well plate used 
in ibuprofen release experiments. Mesh consists of 1732 free triangular elements. 
Figure 2-37: Mesh generated for Kirsktall QV600 chamber used in ibuprofen release 
simulations. Mesh consists of 2258 free triangular elements. 
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2.3.2 RESULTS 
2.3.2.1 RHEOLOGICAL EVALUATION OF FLUIDS 
The viscosities of a range of fluids used in in vitro experiments were investigated to 
determine the values of the viscosities required to input into the computer model to build 
an accurate simulation. Initial studies used a TA Instruments Rheolyst stress-controlled 
rheometer at 21⁰C. The results from these studies showed minimal differences between all 
of the fluids measured and water with the exception of 10% BSA solution which had a 
viscosity 50% higher than the other fluids (Figure 2-38). The fluids of greatest interest to this 
study were DMEM-F12 2% FCS and PBS. These two fluids were used in the Kirkstall QV600 
chamber and in the release studies. The viscosities of these two fluids were required for the 
input parameters of the model, the other fluids were used for reference. The TA Instruments 
Rheolyst rheometer measured the viscosities of DMEM-F12 2% FCS and PBS as 0.89 and 0.86 
mPa.s respectively. 
Evaluation of the viscosities at 37⁰C was unable to be carried out using the TA Instruments 
Rheolyst rheometer, therefore a different rheometer was used to obtain these data. The 
Rheosene Inc µVISC measures viscosity in a similar stress-controlled system however, it is 
less sophisticated and provides less data regarding the shear stress across a range of strains. 
It provides an instantaneous value for viscosity. The viscosities of the fluids were measured 
at 21⁰C again (Figure 2-39) with the µVISC system to ensure the values produced were 
comparable to the Rheolyst system. The differences in the values of viscosities produced 
between the two machines were ≤5%, this was deemed an acceptable difference and so the 
measurements at 37⁰C were carried out using the µVISC rheometer (Table 2-23). As 
expected, increasing the temperature to 37⁰C saw a decrease in viscosity across all of the 
fluids. The highest viscosity fluid remained 10% BSA which decreased from 1.463 mPa.s to 
0.934 mPa.s. PBS, 1% BSA and DMEM-F12 2% FCS all decreased in viscosity but remained 
within 5% of the value for water, 0.650 mPa.s (Figure 2-40). These values were then able to 
be used as input parameters for the computer model. 
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Viscosities of Biological Fluids 
 
Figure 2-38: Shear stress vs shear strain relationship of biological fluids. Measured using 
TA Instruments Rheolyst rheometer at 21⁰C. Data presented as mean shear stress, n=3. 
Figure 2-39: Viscosities of biological fluids at 21⁰C. Measured using Rheosense Inc. µVISC. 
Each data point represents one measurement, line = mean, n=3. 
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Viscosities of Biological Fluids 
Figure 2-40: Viscosities of biological fluids at 37⁰C. Measured using Rheosense Inc. µVISC. 
Each data point represents one measurement, line = mean,  n=3. 
Solution 
Viscosity (mPa.s) at 
21
o
C using 
TA Instruments 
Rheolyst 
Viscosity (mPa.s) at 
21
o
C using 
Rheosense Inc. 
µVISC 
Viscosity (mPa.s) at 
37oC using 
Rheosense Inc. µVISC 
Water 0.907 0.948 0.650 
PBS 0.861 0.915 0.613 
BSA 1% 0.898 0.922 0.612 
BSA 10% 1.393 1.473 0.934 
DMEM-F12 
+2% FCS 
0.886 0.886 0.636 
DMEM-F12 
+10% FCS 
0.896 0.909 0.730 
Table 2-23: Rheological measurements of viscosities of biological fluids at 21⁰C and 37⁰C 
using different rheometers. 
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2.3.2.2 GRID INDEPENDENCE TESTS 
A grid independence test was carried out for each geometry to assure the meshes that were 
generated were fine enough to produce accurate results.  
Dynamic transport of dextran in Kirkstall QV600 
The transport of dextran simulations used a steady state solution for the velocity field within 
the chamber, i.e. only the final stable velocity field was obtained. In this instance, the 
velocities along a line from the centre of the inlet to the centre of the outlet were analyzed 
for increasingly refined meshes to determine the effects of the mesh element density (Figure 
2-41). At the highest velocities, within the inlet and outlet ports, refining the mesh serves to 
smooth the velocity curve however the difference in velocities between the meshes is not 
dissimilar. At the lower velocities within the centre of the chamber, the effects of mesh 
refinement are more noticeable. The difference between the most refined mesh of 108814 
elements and the least refined mesh of 18005 was up to 20mm/s at points along the line.  
Two specific points within the geometry were also evaluated and the point at which the mesh 
element density reached velocity results with <5% error in comparison to the most refined 
mesh were assumed to satisfy the accuracy of the model. For these simulations, this was 
reached at 38267 elements (Figure 2-42). 
Static release of ibuprofen from silicone oil in well plates 
Given there was no velocity field to evaluate in the static release experiments, the 
concentration at two points within the geometry was evaluated. Again, when the 
concentration at those two points reached a percentage error of <5% in comparison to the 
most refined mesh, the mesh satisfied requirement. For the static release experiments this 
was reached at 1732 elements (Figure 2-43). 
Dynamic release of ibuprofen from silicone oil in Kirkstall QV600 
The velocity field for the ibuprofen release studies was a time-dependent solution due to the 
need to track the moving interface of the two fluids. Therefore measuring the velocity along 
a line is difficult because it is always changing with time. For this reason, the velocity at two 
points within the geometry was evaluated at the final time point of the solution, 9 seconds, 
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as this was the time at which a stable flow had been developed. The <5% error was used 
again as the limit of accuracy. This was achieved at 2258 elements (Figure 2-44).  
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Grid Independence Test for Dextran Transport in Kirkstall QV600 Studies 
 
Figure 2-41: Fluid velocity in Kirkstall QV600 chamber along a line from the centre of the 
inlet to the centre of the outlet for different mesh densities. Legend indicates number of 
elements in the mesh. 
Figure 2-42: Percentage difference in velocity at two points in the centre of the chamber 
compared with the finest mesh (108814 elements). A <5% error was deemed to be 
acceptable mesh density. 
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Grid Independence Test for Ibuprofen Release in Well Plate Studies 
Figure 2-43: Percentage difference in concentration at two points in the centre of the well 
compared with the finest mesh (6458 elements). A <5% error was deemed to be acceptable 
mesh density. 
Grid Independence Test for Ibuprofen Release in Kirkstall QV600 Studies 
Figure 2-44: Percentage difference in velocity at two points in the centre of the Kirkstall 
QV600 chamber compared with the finest mesh (3481 elements). A <5% error was deemed 
to be acceptable mesh density. 
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2.3.2.3 DEVELOPMENT OF VELOCITY FIELDS IN THE DEXTRAN TRANSPORT STUDIES 
The inlet flow rates investigated in these studies were 20µL/min, 200µL/min, 400µL/min and 
2000µL/min. For flow rates 20, 200 and 400µL/min the velocity fields produce similar 
patterns (Figure 2-45). A parabolic flow out from the inlet tube and in to the outlet tubes 
with considerably lower velocities in the main well of the chamber. Each of these flow rates 
shows areas of recirculating flow trapped in the corners of the receptor compartment on the 
inlet side, with these areas increasing in size as the inlet flow rate increased. The streamlines 
show that at the lowest flow rate, 20µL/min, the flow in the main chamber has little effect 
on the velocity field in the donor compartment of the chamber. As the flow rate increases, 
the flow profile of the donor compartment becomes more uniform as fluid from the main 
well penetrated through the membrane and caused fluid flow in the donor compartment. 
This phenomenon is most obvious in the highest inlet flow rate simulation, 2ml/min. In the 
donor compartment of this simulation, a parabolic flow regime is observed. The velocities in 
the main well of the chamber are also considerably higher than in comparison with lower 
inlet flow rates. Another feature of this high flow rate is the development of a dominating 
stream of fluid from the inlet tube to the outlet port and large area of recirculating fluid 
beneath this stream which occurs in the majority of the chamber volume. 
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Velocity Fields of Different Flow Rates in the Kirkstall QV600 Dextran Transport Studies 
 
 
Figure 2-45: Velocity fields for different inlet flow rates used in the Kirkstall QV600 chamber 
geometry for dextran transport studies. Inlet flow rates: (a) 20µL/min, (b) 200µL/min, (c) 
400µL/min and (d) 2mL/min. Colour scale bar indicates velocity (m/s). Streamlines show 
velocity field. 
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2.3.2.4 CONCENTRATION PROFILES OF DEXTRAN IN THE KIRKSTALL QV600 CHAMBER 
The concentration profiles which were obtained from the simulations were reliant on the 
coefficients which were acquired from the in vitro experiments. As discussed in section 
2.2.3.2, the presence of the fluid flow had varying effects on the efficiency of the ARPE-19 
cell monolayer as a barrier to compound transport. This was apparent in the results for the 
computational solutions which showed greater accuracy in the simulations which modelled 
the membranes without cells in comparison to those which modelled their presence.  
At 20µL/min, the computational solution produced the same concentration profile as seen 
in the in vitro results. The profile again showed similarities to a single dose response curve. 
For the unseeded membranes, the simulated results for AUC for each molecular weight of 
dextran was within 15% of the in vitro results, with the percentage error being 13.4, 10.0 and 
3.6% for FD4, FD40 and FD70 respectively. The error seen in the maximum concentrations of 
the receptor domain were smaller still with the differences being 2.3, 6.7 and 0.8% 
respectively. There were some discrepancies in the time at which the maximum 
concentration was reached. For FD4, the simulation predicted the maximum concentration 
would be reached after 3 hours, however, the experimental results showed this to be after 
4 hours. Similarly, for FD40, the simulation predicted the Tmax to be after 4 hours, however 
the experiment showed it to be after 3 hours (Figure 2-46, Table 2-24, Table 2-25, Table 2-
26)  
The seeded membranes showed greater differences in both AUC and Cmax values. The 
simulation showed an over-estimation in the concentration profile in the domain. The AUC 
was higher in the simulation for each molecular weight. The differences were 19.5, 28.3 and 
14.2% for FD4, FD40 and FD70 respectively. There appears to be no correlation between the 
molecular weight of the dextran and the accuracy of the model. The error in Cmax was also 
greater in the seeded membranes, particularly for FD4 and FD40. The simulation predicted 
the Cmax of these two molecular weights to reach 18.9 and 12.3% higher respectively. The 
simulated result for FD70 was only 1.2% higher in comparison to the in vitro result (Figure 
2-47, Table 2-27, Table 2-28, Table 2-29)  
At the higher flow rates, the simulated results were able to mirror the change in release 
profile exhibited in vitro which showed a shift to a burst release response followed by an 
exponential decay in concentration over time (Figure 2-48, Figure 2-49, Figure 2-50, Figure 
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2-51, Figure 2-52). Again for 200µL/min, 400µL/min and 2mL/min the results produced from 
the acellular studies were within a 15% difference of the in vitro data for AUC, with no 
correlation between molecule size or flow rate and simulation accuracy. The largest 
differences in simulation and experimental agreement were seen in both the AUC and Cmax 
results on the cell seeded studies at 200µL/min. For the largest molecular weight FD used, 
FD70, the error in AUC between the two data sets was 57%. Similarly, the predicted Cmax was 
46% different to the observed in vitro value (Table 2-35). At 400µL, the simulation was able 
to predict AUC and Cmax for both cellular and acellular studies to within 30% and at 2mL/min, 
this was reduced to 15% (2mL/min studies only conducted in acellular conditions).  
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Simulation vs Experimental Concentration Profiles of Dextrans in Receptor 
Compartment of Kirkstall QV600 exposed to 20µL/min Flow without ARPE-19 cells 
Figure 2-46: Concentration profiles of different molecular weight fluorescently labelled 
dextrans a) 4kDA, b) 40kDa and c) 70kDa in receptor compartment of Kirkstall QV600 
chamber. Studies carried out experimentally (red) and simulated (black) on unseeded NH3 
treated ePTFE membranes.  Experimental flow rate = 20µL/min. Data presented as mean ± 
1 SD, n=6. 
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Simulation vs Experimental Concentration Profiles of Dextrans in Receptor 
Compartment of Kirkstall QV600 exposed to 20µL/min Flow with ARPE-19 cells 
Figure 2-47: Concentration profiles of different molecular weight fluorescently labelled 
dextrans a) 4kDA, b) 40kDa and c) 70kDa in receptor compartment of Kirkstall QV600 
chamber. Studies carried out experimentally (red) and simulated (black) on seeded NH3 
treated ePTFE membranes.  Experimental flow rate = 20µL/min. Data presented as mean ± 
1 SD, n=6. 
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Concentration Curve Statistics for Simulated vs Experimental Dextran Transport 
Studies across Unseeded Membranes at 20µL/min 
Table 2-24: Concentration curve statistics for 4kDa fluorescently labelled dextran transport 
across unseeded NH3 treated ePTFE membranes exposed to a flow rate of 20µL/min. 
Table 2-25: Concentration curve statistics for 40kDa fluorescently labelled dextran 
transport across unseeded NH3 treated ePTFE membranes exposed to a flow rate of 
20µL/min. 
Table 2-26: Concentration curve statistics for 70kDa fluorescently labelled dextran 
transport across unseeded NH3 treated ePTFE membranes exposed to a flow rate of 
20µL/min. 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 16.63 1.72±0.15 4 0.81 
Simulation 19.20 1.68 3 0.83 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 15.89 1.59±0.11 3 0.69 
Simulation 17.65 1.49 4 0.75 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 14.76 1.34±0.11 3 0.81 
Simulation 15.30 1.33 3 0.66 
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Concentration Curve Statistics for Simulated vs Experimental Dextran Transport 
Studies across Seeded Membranes at 20µL/min 
Table 2-27: Concentration curve statistics for 4kDa fluorescently labelled dextran transport 
across ARPE-19 seeded NH3 treated ePTFE membranes exposed to a flow rate of 20µL/min. 
Table 2-28: Concentration curve statistics for 40kDa fluorescently labelled dextran 
transport across ARPE-19 seeded NH3 treated ePTFE membranes exposed to a flow rate of 
20µL/min. 
Table 2-29: Concentration curve statistics for 70kDa fluorescently labelled dextran 
transport across ARPE-19 seeded NH3 treated ePTFE membranes exposed to a flow rate of 
20µL/min.  
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 11.57 1.17±0.22 3 0.50 
Simulation 13.83 1.44 3 0.60 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 9.05 1.07±0.17 3 0.42 
Simulation 11.62 1.22 3 0.50 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 6.04 0.87±0.25 3 0.28 
Simulation 7.27 0.88 3 0.32 
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Simulation vs Experimental Concentration Profiles of Dextrans in Receptor 
Compartment of Kirkstall QV600 exposed to 200µL/min Flow without ARPE-19 cells 
Figure 2-48: Concentration profiles of different molecular weight fluorescently labelled 
dextrans a) 4kDA, b) 40kDa and c) 70kDa in receptor compartment of Kirkstall QV600 
chamber. Studies carried out experimentally (red) and simulated (black) on unseeded NH3 
treated ePTFE membranes.  Experimental flow rate = 200µL/min. Data presented as mean 
± 1 SD, n=6 
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Simulation vs Experimental Concentration Profiles of Dextrans in Receptor 
Compartment of Kirkstall QV600 exposed to 200µL/min Flow with ARPE-19 cells 
Figure 2-49: Concentration profiles of different molecular weight fluorescently labelled 
dextrans a) 4kDA, b) 40kDa and c) 70kDa in receptor compartment of Kirkstall QV600 
chamber. Studies carried out experimentally (red) and simulated (black) on unseeded NH3 
treated ePTFE membranes.  Experimental flow rate = 200µL/min. Data presented as mean 
± 1 SD, n=6 
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Concentration Curve Statistics for Simulated vs Experimental Dextran Transport 
Studies across Unseeded Membranes at 200µL/min 
Table 2-30: Concentration curve statistics for 4kDa fluorescently labelled dextran transport 
across unseeded NH3 treated ePTFE membranes exposed to a flow rate of 200µL/min. 
Table 2-31: : Concentration curve statistics for 40kDa fluorescently labelled dextran 
transport across unseeded NH3 treated ePTFE membranes exposed to a flow rate of 
200µL/min. 
Table 2-32: Concentration curve statistics for 70kDa fluorescently labelled dextran 
transport across unseeded NH3 treated ePTFE membranes exposed to a flow rate of 
200µL/min.  
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 13.70 1.60 1 0.77 
Simulation 11.83 1.52 1 0.44 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 1.00 0.131 1 0.05 
Simulation 1.14 0.14 1 0.05 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 3.03 0.81 1 0.19 
Simulation 3.49 0.82 1 0.17 
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Concentration Curve Statistics for Simulated vs Experimental Dextran Transport 
Studies across Seeded Membranes at 200µL/min 
Table 2-33: Concentration curve statistics for 4kDa fluorescently labelled dextran transport 
across seeded NH3 treated ePTFE membranes exposed to a flow rate of 200µL/min. 
Table 2-34: Concentration curve statistics for 40kDa fluorescently labelled dextran 
transport across seeded NH3 treated ePTFE membranes exposed to a flow rate of 
200µL/min. 
Table 2-35: Concentration curve statistics for 70kDa fluorescently labelled dextran 
transport across seeded NH3 treated ePTFE membranes exposed to a flow rate of 
200µL/min.  
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 9.91 0.95 1 0.44 
Simulation 7.30 0.99 1 0.33 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 1.58 0.20 1 0.07 
Simulation 2.46 0.29 1 0.10 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 0.48 0.05 1 0.02 
Simulation 0.87 0.08 1 0.04 
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Simulation vs Experimental Concentration Profiles of Dextrans in Receptor 
Compartment of Kirkstall QV600 exposed to 400µL/min Flow without ARPE-19 cells 
Figure 2-50: Concentration profiles of different molecular weight fluorescently labelled 
dextrans a) 4kDA, b) 40kDa and c) 70kDa in receptor compartment of Kirkstall QV600 
chamber. Studies carried out experimentally (red) and simulated (black) on unseeded NH3 
treated ePTFE membranes.  Experimental flow rate = 400µL/min. Data presented as mean 
± 1 SD, n=6 
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Simulation vs Experimental Concentration Profiles of Dextrans in Receptor 
Compartment of Kirkstall QV600 exposed to 400µL/min Flow with ARPE-19 cells 
Figure 2-51: Concentration profiles of different molecular weight fluorescently labelled 
dextrans a) 4kDA, b) 40kDa and c) 70kDa in receptor compartment of Kirkstall QV600 
chamber. Studies carried out experimentally (red) and simulated (black) on seeded NH3 
treated ePTFE membranes.  Experimental flow rate = 400µL/min. Data presented as mean 
± 1 SD, n=6 
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Concentration Curve Statistics for Simulated vs Experimental Dextran Transport 
Studies across Unseeded Membranes at 400µL/min 
Table 2-36: Concentration curve statistics for 4kDa fluorescently labelled dextran transport 
across unseeded NH3 treated ePTFE membranes exposed to a flow rate of 400µL/min. 
Table 2-37: Concentration curve statistics for 40kDa fluorescently labelled dextran 
transport across unseeded NH3 treated ePTFE membranes exposed to a flow rate of 
400µL/min. 
Table 2-38: Concentration curve statistics for 70kDa fluorescently labelled dextran 
transport across unseeded NH3 treated ePTFE membranes exposed to a flow rate of 
400µL/min.  
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 11.27 1.70 1 0.62 
Simulation 13.11 2.10 1 0.65 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 6.80 0.90 1 0.38 
Simulation 7.21 0.90 1 0.32 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 2.42 0.19 1 0.10 
Simulation 2.20 0.26 1 0.11 
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Concentration Curve Statistics for Simulated vs Experimental Dextran Transport 
Studies across Seeded Membranes at 400µL/min 
Table 2-39: Concentration curve statistics for 4kDa fluorescently labelled dextran transport 
across seeded NH3 treated ePTFE membranes exposed to a flow rate of 400µL/min. 
Table 2-40: Concentration curve statistics for 40kDa fluorescently labelled dextran 
transport across seeded NH3 treated ePTFE membranes exposed to a flow rate of 
400µL/min. 
Table 2-41: Concentration curve statistics for 70kDa fluorescently labelled dextran 
transport across seeded NH3 treated ePTFE membranes exposed to a flow rate of 
400µL/min.  
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 11.32 1.80 1 0.63 
Simulation 11.02 1.34 1 0.50 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 6.78 0.62 1 0.30 
Simulation 5.46 0.49 1 0.24 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 1.10 0.12 1 0.05 
Simulation 0.95 0.09 1 0.04 
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Simulation vs Experimental Concentration Profiles of Dextrans in Receptor 
Compartment of Kirkstall QV600 exposed to 2mL/min Flow without ARPE-19 cells 
Figure 2-52: Concentration profiles of different molecular weight fluorescently labelled 
dextrans a) 4kDA, b) 40kDa and c) 70kDa in receptor compartment of Kirkstall QV600 
chamber. Studies carried out experimentally (red) and simulated (black) on unseeded NH3 
treated ePTFE membranes.  Experimental flow rate = 2mL/min. Data presented as mean ± 
1 SD, n=6 
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Concentration Curve Statistics for Simulated vs Experimental Dextran Transport 
Studies across Unseeded Membranes at 2mL/min 
Table 2-42: Concentration curve statistics for 4kDa fluorescently labelled dextran transport 
across unseeded NH3 treated ePTFE membranes exposed to a flow rate of 400µL/min. 
Table 2-43: Concentration curve statistics for 40kDa fluorescently labelled dextran 
transport across unseeded NH3 treated ePTFE membranes exposed to a flow rate of 
400µL/min. 
Table 2-44: Concentration curve statistics for 70kDa fluorescently labelled dextran 
transport across unseeded NH3 treated ePTFE membranes exposed to a flow rate of 
400µL/min. 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 2.02 0.59 1 0.31 
Simulation 1.88 0.52 1 0.28 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 1.39 0.30 1 0.21 
Simulation 1.20 0.30 1 0.17 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 0.25 0.06 1 0.04 
Simulation 0.29 0.07 1 0.04 
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2.3.2.5 STATIC RELEASE OF IBUPROFEN IN WELL PLATE SIMULATIONS 
The concentration profile of ibuprofen was plotted graphically to determine the change in 
release profile that occurs with a simple change in geometrical arrangement of the SiO and 
aqueous phases. For each well plate simulation, equal volumes of aqueous and SiO were 
used however, given the different dimensions of the well plates, the interfacial contact areas 
decreased as the number of wells in the plate increased. The ibuprofen distribution in the oil 
domain creates a concentration gradient that tends to its lowest concentration at the 
interfacial boundary with the aqueous domain. This is most apparent in the 48-well plate 
simulation. In the 12-well plate, the concentration of ibuprofen is evenly distributed 
throughout the oil domain from 48hrs onwards, whereas the gradient is maintained in the 
24 and 48-well plate up to 72hrs (Figure 2-53).  
Comparing the quantified percentage release of ibuprofen from the oil into the aqueous in 
the simulation with the in vitro results, the maximum error observed was 15%. This was in 
the 24-well plate after 24 hours. For the 12-well plate, the difference in percentage release 
between the simulated and experimental results was 12%, 7% and 7% for 24hr, 48hr and 
72hr respectively. Similar low percentage error values were observed in the 48-well plate 
which had percentage differences of 5%, 5% and 2% at each respective time point. The 24-
well plate simulations produced results with the greatest differences in comparison with the 
in vitro data, with the results having 15%, 10% and 7% difference at 24hr, 48hr and 72hr 
respectively (Figure 2-55). 
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Concentration Fields of Ibuprofen Release in Well Plates over 72 Hours 
Figure 2-53: Concentration fields of ibuprofen released from silicone oil over 72 hours in a 
12-well, 24-well and 48-well plate simulation. Colour scale bar = concentration in mol/m3. 
 
 
 
 
Figure 2-54: Well plate experiment set up.  
12-well plate 24-well plate 48-well plate 
0hr 
24hr 
48hr 
72hr 
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Simulation vs Experimental Concentration Profile of Ibuprofen Release in Well Plates 
Figure 2-55: Percentage cumulative release of 1mL of 1mg/mL ibu-SiO  into 500µL  PBS in 
(a) 12-well plate, (b) 24-well plate, (c) 48-well plate over 72 hours. Studies carried out 
experimentally (black) and simulated (red). Experimental data presented as mean 
percentage cumulative release ± 1SD. 
T im e  (h r )
C
u
m
u
la
ti
v
e
 R
e
le
a
s
e
 (
%
)
0 2 0 4 0 6 0 8 0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
E x p e r im e n ta l
S im u la tio n
T im e  (h r )
C
u
m
u
la
ti
v
e
 R
e
le
a
s
e
 (
%
)
0 2 0 4 0 6 0 8 0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
E x p e r im e n ta l
S im u la tio n
T im e  (h r )
C
u
m
u
la
ti
v
e
 R
e
le
a
s
e
 (
%
)
0 2 0 4 0 6 0 8 0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
E x p e r im e n ta l
S im u la tio n
A 
B 
C 
  Chapter 2 
140 
 
2.3.2.6 TRACKING THE FLUID-FLUID INTERFACE AND VELOCITY FIELD DEVELOPMENT IN KIRKSTALL QV600 
IBUPROFEN RELEASE STUDIES 
Using a moving mesh physics interface to solve for the two-phase (SiO and PBS) system 
described by this model allows us to track the movement of the interface between the two 
phases. As the position of this interface could have implications on the flow field and drug 
release, it was important to be able to trace the movement of this boundary to ensure an 
accurate representation. As the flow field developed over time, the boundary between the 
oil domain and the aqueous domain collapsed forming a meniscus between the two phases. 
This phenomenon is what we observe in vitro (photographic image could not be obtained 
due to translucency of the QV600 chamber) and is expected given the interfacial tension 
between the two phases described in Table 2-22. After approximately 2 seconds, this system 
forms a stable arrangement between the two domains and the meniscus remains constant 
(Figure 2-56). 
The flow fields formed at 20µL/min, 200µL/min and 400µL/min (Figure 2-57) show 
similarities to those formed in the single phase, membrane system (Figure 2-44) shown in 
section 2.3.2.3. At 20µL/min, however, we see that the low flow rate inlet stream within the 
aqueous phase appeared to bounce of the oil phase and create a ripple within the primary 
flow stream.  The interaction between the main flow stream and the oil phase also created 
two recirculating streams within the oil domain itself. This phenomenon is observed for each 
of the flow rates studied with the split in the two streams shifting towards the inlet as the 
inlet flow rate increased. Unlike the 2mL/min flow field in the single phase system, the 
2mL/min flow profile for the two phase model did not develop large regions of recirculating 
flow and maintained a single dominating fluid stream from inlet to outlet.  
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Deformation of the Mesh to Track the Fluid-Fluid Interface 
 
 
Figure 2-56: Deformation of the mesh over time up to a stable solution indicated by the 
collapsing of the boundary at the fluid-fluid interface of the two phases (green boundary). 
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Velocity Fields of Different Flow Rates in the Kirkstall QV600 Ibuprofen Release Studies 
 
Figure 2-57: Velocity fields for different inlet flow rates used in the Kirkstall QV600 chamber 
geometry for ibuprofen release studies. Inlet flow rates: (a) 20µL/min, (b) 200µL/min, (c) 
400µL/min and (d) 2mL/min. Colour scale bar indicates velocity (m/s). Streamlines show 
velocity field. 
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2.3.2.7 CONCENTRATION PROFILES OF IBUPROFEN IN KIRKSTALL QV600 CHAMBER 
At the higher flow rates, the concentration of ibuprofen in the aqueous PBS phase showed 
the same burst release response and exponential decay as the concentration of dextran and 
this was mirrored in the simulation data. At 20µL/min, there was a rise in concentration up 
to Cmax after which a very slow decay in concentration, this was also shown by the computer 
model which was able to predict the AUC and Cmax to within 3% and 8% respectively for this 
given flow rate (Table 2-45). The agreement between the simulated and experimental 
profiles at 200µL/min was also strong for the total exposure in the aqueous domain over the 
24 hour time period with AUC data within 8%, however there was a 35% overestimation in 
maximum concentration within the same domain (Table 2-46). Interestingly, at 2mL/min the 
simulated data underestimated Cmax by 17% (Table 2-48) and appeared to underestimate the 
concentration in the receptor domain across each time point, again suggesting no correlation 
between the accuracy of the computer model and the inlet flow rate prescribed to it (Figure 
2-58B, Figure 2-59B, Figure 2-60B, Figure 2-61B) 
The concentration fields within the oil domain showed little difference as the flow rate 
increased other than to shift the centre of diffusion either towards the outlet (200µL/min 
and 400µL/min) or towards the inlet (2mL/min) (Figure 2-58, Figure 2-59, Figure 2-60, Figure 
2-61). For each flow rate the ibuprofen was never completely cleared from the oil domain by 
the final 72 hour time point. The simulation predicted that a small region of oil at the top of 
the domain, in contact with the exterior wall of the chamber through to the centre of the 
domain, maintained a low concentration of ibuprofen.   
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Concentration Fields and Receptor Domain Profile of Ibuprofen in the Kirkstall QV600 
Chamber at 20µL/min 
Figure 2-58: (a) Concentration field solution for ibuprofen concentration across the Kirkstall 
QV600 chamber at 0, 24, 48 and 72 hr. Colour scale bar indicates concentration in mol/m3. 
(b) Experimental vs simulated concentration profiles of ibuprofen in receptor compartment 
of Kirkstall QV600 chamber. Flow rate = 20µL/min. Experimental data presented as mean 
concentration ± 1 SD, n = 6  
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Concentration Fields and Receptor Domain Profile of Ibuprofen in the Kirkstall QV600 
Chamber at 200µL/min 
Figure 2-59: (a) Concentration field solution for ibuprofen concentration across the Kirkstall 
QV600 chamber at 0, 24, 48 and 72 hr. Colour scale bar indicates concentration in mol/m3. 
(b) Experimental vs simulated concentration profiles of ibuprofen in receptor compartment 
of Kirkstall QV600 chamber. Flow rate = 200µL/min. Experimental data presented as mean 
concentration ± 1 SD, n = 6. 
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Concentration Fields and Receptor Domain Profile of Ibuprofen in the Kirkstall QV600 
Chamber at 400µL/min 
Figure 2-60: (a) Concentration field solution for ibuprofen concentration across the Kirkstall 
QV600 chamber at 0, 24, 48 and 72 hr. Colour scale bar indicates concentration in mol/m3. 
(b) Simulated concentration profile of ibuprofen in receptor compartment of Kirkstall 
QV600 chamber. Flow rate = 400µL/min.  
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Concentration Fields and Receptor Domain Profile of Ibuprofen in the Kirkstall QV600 
Chamber at 2mL/min 
Figure 2-61: (a) Concentration field solution for ibuprofen concentration across the Kirkstall 
QV600 chamber at 0, 24, 48 and 72 hr. Colour scale bar indicates concentration in mol/m3. 
(b) Experimental vs simulated concentration profiles of ibuprofen in receptor compartment 
of Kirkstall QV600 chamber. Flow rate = 2mL/min. Experimental data presented as mean 
concentration ± 1 SD, n = 6.  
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Concentration Curve Statistics for Simulated vs Experimental Ibuprofen Release 
Studies across a Range of Flow Rates 
Table 2-45: Concentration curve statistics for ibuprofen release from silicone oil in the 
Kirkstall QV600 chamber exposed to a flow rate of 20µL/min. 
 Table 2-46: Concentration curve statistics for ibuprofen release from silicone oil in the 
Kirkstall QV600 chamber exposed to a flow rate of 200µL/min 
Table 2-47: Concentration curve statistics for ibuprofen release from silicone oil in the 
Kirkstall QV600 chamber exposed to a flow rate of 400µL/min 
Table 2-48: Concentration curve statistics for ibuprofen release from silicone oil in the 
Kirkstall QV600 chamber exposed to a flow rate of 2mL/min. 
 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 2.41 0.13 8 0.10 
Simulation 2.48 0.12 10 0.10 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 1.62 0.16 1 0.07 
Simulation 1.64 0.22 1 0.06 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Simulation 0.46 0.06 1 0.02 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 0.02 0.003 1 0.001 
Simulation 0.01 0.003 1 0.001 
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2.4 DISCUSSION 
2.4.1 SUCCESSFUL GROWTH OF ARPE-19 CELL MONOLAYERS ON 
AMMONIA GAS PLASMA TREATED EPTFE MEMBRANES 
ARPE-19 cells are a non-immortalised spontaneously arisen human RPE cell line with 
characteristics which make them a useful tool in in vitro modelling. It is a well-established 
and well-characterised cell line which demonstrates the normal phenotype of primary RPE 
cells in vivo and has been shown to express RPE-specific markers such as RPE65 and CRALBP. 
A major benefit of the ARPE-19 cell line for this present study is that it is able to form 
differentiated polarised monolayers which allow for the evaluation of the transport of 
molecules and drugs through the cell monolayer barrier [177, 178]. Ultimately, in order to 
build a truly representative in vitro model of the outer blood retinal barrier, a more 
appropriate cell type would need to be investigated, such as primary RPE cells, or a co-culture 
model incorporating other cell types found within the outer BRB structure, such as those 
found in the choroidal vasculature, but this was beyond the scope of this project.  
In vivo, the RPE cells sit atop of a thin layer of extracellular matrix, known as Bruch’s 
membrane, which separates the epithelial layer from the choroid. The integrity of this 
membrane is vital in supporting an intact, functional monolayer of healthy RPE cells. Previous 
studies involving models of the outer blood retinal barrier have used materials such as 
amniotic membrane [104, 179], fibrin gel [180], and poly(ethylene terephthalate) [181] with 
varying success. Expanded polytetrafluoroethylene (ePTFE) is a porous, synthetic material 
that has been widely used in medical devices and biomaterials for many years and there have 
been previous studies to assess its suitability as a transplantable replacement for the native 
Bruch’s membrane (BM). Its material properties make it an ideal candidate as a substitute 
for the BM. It is biocompatible, stable, flexible and porous although ‘as received’ ePTFE is 
hydrophobic and does not promote cell adhesion which is an undesirable property for this 
study [182, 183]. There are methods available to overcome this problem which involve 
surface modification of the ePTFE to alter the surface chemistry and provide more favourable 
cell support whilst also maintaining the bulk properties of the material which make it an 
appropriate substrate.  
It has been shown that ammonia gas plasma treatment of ePTFE increases the hydrophilicity 
of the membrane and promotes the growth of both ARPE-19 cells and human primary RPE 
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(hRPE) cells [146, 150, 184]. The plasma technology allows the fibrous, porous structure of 
ePTFE membrane to be maintained whilst varying the chemistry of the surface to enhance 
desirable properties in the material, for example decreased water contact angle [184]. The 
principle of this method involves defluorination of the fluoropolymer surface which then 
allows incorporation of polar groups following storage in distilled water, these polar groups 
on the surface are what contribute to increased ability of the cells to adhere [185, 186]. This 
study utilised ammonia gas plasma treated ePTFE membranes and compared the growth of 
ARPE-19 cells on these membranes with their growth on tissue culture plastic, with the aim 
of determining the time required for the ARPE-19 cells to form stable monolayers required 
to study the transport of molecules and drugs across the cell/material barrier.  
Similarities in the growth curves of the ARPE-19 cells grown on NH3 treated ePTFE 
membranes and the TCP were observed. Although the cell number was lower on the 
membranes at each time point measured over the 14 days, the difference was not 
statistically significant suggesting that the growth of the cells was not dependant on the 
culture substrate. These results corroborate the results of a study by Krishna et al. who also 
showed a small decrease in cell numbers on NH3 treated ePTFE compared with TCP over 15 
days [150]. Both substrates showed an increase in cell number up to day 10 when the 
numbers appear to plateau which is an indication that the ARPE-19 cells have formed a stable 
monolayer and have reduced their growth rate although some overgrowth of the cells was 
observed in the phase contrast images of the cells cultured on TCP at 14 days. Due to the 
opacity of the NH3 treated ePTFE membranes, the phenotype of the cells grown on this 
substrate was observed using immunofluorescence.  
To determine the integrity of the epithelial monolayer barrier, the cells were stained for the 
tight junctional protein zonula occludin-1 (ZO-1). ZO-1 is a transmembrane protein found on 
the peripheral membranes of epithelial cells and is vital in the formation of tight junctions 
required for cell-cell adhesion. There are over 40 different proteins that are involved in the 
formation of tight junctions. ZO-1 is one of a group of intracellular plaque proteins which 
provide support between the transmembrane proteins and the actin cytoskeleton [187]. 
Both substrates exhibited positive staining of ZO-1 across the entirety of the substrate at day 
10, with clear, distinct expression at the cell borders suggesting cell-cell adhesion and intact 
barrier formation of the monolayer. This qualitative analysis of the barrier was further 
supported by the TEER results which increased to day 10 after which there was a plateau. 
Other studies have shown similar results with the reported time to reach maximum TEER 
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ranging from 7 days to 14 days [163, 188]. The TEER of ARPE-19 cells grown on filter 
membranes has been shown to reach a maximum of 50-100 Ω/cm2  in culture although the 
addition of supplements to the culture medium can increase this value further [141, 163]. 
This study has shown that ARPE-19 cells can reach a TEER of 59.4 Ω/cm2 after 10 days when 
cultured on NH3 treated ePTFE membranes in DMEM-F12 medium supplemented with 2% 
FBS. Given the values for TEER obtained using these conditions, in comparison to those 
reported in the literature, and the positive expression of ZO-1 across the monolayer, day 10 
was determined as the point at which the cells had formed a functional barrier and could be 
used in dynamic flow cultures and permeability studies. 
2.4.2 THE INTEGRITY OF ARPE-19 CELL MONOLAYERS CULTURED UNDER 
FLOW CONDITIONS IS DEPENDENT ON THE FLOW RATE OF THE 
CULTURE MEDIUM 
In vivo, the vascular requirements of retina are supplied by two types of capillary; (1) the 
central retinal capillaries and (2) the choriocapillaris. The choriocapillaris is a network of 
capillaries which sit adjacent to the Bruch’s membrane and serve to provide the nutritional 
needs of the RPE cell layer. The retinal-facing side of these capillaries is fenestrated and 
supports the transport of nutrients to the RPE as well as the clearance of waste products 
away from the cells [189, 190]. The flow of plasma within these vessels provides the 
clearance mechanism for waste products produced by the RPE cells which are secreted 
basally across the Bruch’s membrane. Previous studies have reported the flow rate within 
the choriocapillaris to be 9.45mL/hr or 160µL/min [191] and disruptions or alterations in the 
flow have been attributed to problems with homeostasis within the RPE [192, 193]. Few 
studies have investigated the in vitro culture of ARPE-19 cells in the presence of fluid flow 
however there have been studies that show the benefits of flow in other epithelial cells types 
[194, 195].  
In these studies, ARPE-19 cells grown on NH3 treated modified ePTFE membranes for 10 days 
were then cultured within microfluidic bioreactor chambers for a further 24 hours. Culture 
medium was perfused through the system and the basal side of the membranes was exposed 
to a range of medium flow rates. In comparison with the static cultures, exposing the cultures 
to flow had no effect on the number of cells regardless of the flow rate, suggesting the flow 
had no influence on the growth rate of the cells nor detached any of the cells and removed 
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them from the system. However, the metabolic activity of the cells was decreased in the 
cultures exposed to the highest flow rate of 400µL/min. Given that there was no decrease in 
cell number, the decrease in metabolic activity suggests that the highest flow rate has a 
different effect on the cells. This could be because the cells have formed a fully stable 
monolayer quicker and require less metabolic turnover or the higher flow may have had 
some detrimental effect on the cells. It would be interesting to investigate this further to 
gain a better understanding of the effects of basal flow on the cellular activity.  This was 
echoed in the ability of the cells to maintain the integrity of their monolayer barrier. After 24 
hours exposure to 400µL/min, the TEER of the monolayers significantly decreased in 
comparison to the static cultures and clusters of the mesenchymal cell marker, αSMA also 
appeared across the monolayers. The presence of αSMA within polarised epithelial cell 
cultures suggests the cells are undergoing a process known as epithelial-mesenchymal 
transition (EMT)[196]. During EMT, polarised epithelial cells whose basal surface normally 
remains in contact with the basement membrane undergo biochemical changes which allow 
the cells to assume a mesenchymal phenotype and increases there proliferative and 
migratory capacity [197]. This behaviour is seen in RPE cells in patients with proliferative 
vitreoretinopathy. 
At 400µL/min, the fluid creates greater shear stresses on the basal surface of the ARPE-19 
cell monolayer than the lower flow rates. This is due to the increased velocities which are 
established from the higher flow causing greater shear forces at the boundaries within the 
chamber. Previous studies have shown that continuous exposure to abnormally high fluid 
shear stresses causes alterations in the structure of epithelial cell monolayers and 
organisation of the tight junction proteins [195, 198]. It has also been suggested that high 
shear stresses act as a stimulus which can trigger the EMT process [199]. However, at lower 
flow rates, significant increases in the TEER were observed and many other studies have 
reported decreased permeability and improved barrier function after exposing cultures to 
fluid shear stresses. Venkatamarana et al. show that low level shear stresses enhanced the 
epithelial barrier function of human bronchial epithelial cells [200]. Similar results have been 
shown in endothelial cultures as well, with Cucullo et al. showing upregulation of tight 
junction proteins following exposure to low level shear stresses [201].  
The results suggest that the introduction of flow to ARPE-19 cultures can enhance the barrier 
function of the monolayer up to a limiting point after which the shear stresses created cause 
a breakdown in the monolayer. The effects of flow therefore become important when 
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investigating the permeability of the barrier as different flow rates have different effects. 
This study only calculated the permeability of the cultures after 10 days in static culture. In 
order to produce permeability and diffusion coefficients to use in a computer model which 
is a true representation of the barriers, the coefficients would also need to be calculated 
post- exposure to fluid flow. These experiments were not done in this study. 
2.4.3 FLUORESCENTLY LABELLED DEXTRANS TRANSPORTED THROUGH 
THE MEMBRANES EXHIBIT DIFFERENT CONCENTRATION PROFILES 
DEPENDANT ON FLOW RATE 
This study aimed to provide data which could be used to validate a complementary computer 
simulation of the system based on input parameters defined by the experimental conditions. 
The parameter which was easily measureable across both the in vitro and computer models 
was concentration in the receptor compartment of the chamber over time. At 2 hour 
intervals, samples were taken from the receptor compartment and the concentration of FD 
in the compartment at that time point was measured, this was repeated over 24 hours. Given 
the nature of the study, there were certain time points at which samples were unable to be 
taken due to time of day and also in an attempt to minimise contamination risk. This is one 
of the motivations behind using computer simulations for such studies as they allow data to 
be obtained which may be unable to be obtained in the physical experiment.  
The permeability of the RPE/ePTFE complex affects the elimination rate of drugs from the 
vitreous cavity. In order to predict the permeabilities of new drugs and compounds, a 
systemic data approach on the permeability of a range of molecules as a function of their 
size is needed. There are other features of compounds which affect their permeability across 
the barrier, these include charge and lipophilicity, however these were not investigated here. 
This study investigated the permeability of three different molecular weight FITC-conjugated 
dextrans: 4kDa, 40kDa and 70kDa. The results from the static transport studies showed that 
4kDa and 40kDa FD were able to move through the barrier, to the point of equilibrium, 
regardless of the presence of cells. The passage of 70kDa FD was considerably decreased in 
comparison to the smaller molecules, this was to be expected as previous studies have 
reported 70kDa to be the limit at which diffusion can occur across RPE cells [202]. The results 
for permeability achieved in this study are in keeping with those found in the literature and 
so the values obtained from the static experiments were carried forward for use in the 
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computational simulations [202, 203]. It is important to note that RPE cells are able to 
transport larger molecules across the OBRB via mechanisms such as active transport. Studies 
have shown that RPE cells are able to transport dextran as big as 155kDa [184, 204], however 
only passive diffusion was of interest for this study. 
Introducing flow to the permeability experiments allowed the investigation of its impact on 
the clearance of the molecules away from the cell layer, analogous to the choriocapillaris 
flow present in vivo. The results showed that changing the flow rate can alter the 
concentration profile in the receptor chamber. At the lowest flow rate, the concentration of 
FD in the receptor compartment rose to a peak concentration over the first 3-4 hours after 
which the FD is continuously cleared from the chamber, this was consistent across all 
molecular sizes of FD. In pharmacokinetics, this concentration profile is normally seen in 
plasma samples taken after a single oral dose of a drug, i.e. an administration technique 
which requires absorption into the bloodstream. In this case there is an initial absorption 
phase up to the maximum concentration which is followed by an elimination phase [205]. 
This pattern was not repeated at the higher flow rates. The 200µL/min to 2mL/min 
experiments had concentration profiles comparable to those seen after a single intravenous 
dose, i.e. the drug is immediately administered to the bloodstream, a constant elimination 
phase. These results suggest that at very low flow rates, the diffusion of the dextran is the 
overriding transport physics within the system. At higher flow rates, the convection of the 
molecules in the fluid flow field dominates. This could be an important factor to consider 
when designing dynamic drug release and transport studies. In order to understand how 
compounds are transported through the in vivo environment, these dynamic factors need to 
be accounted for in in vitro models. 
Previous studies have tried to determine which structure within the outer BRB provides the 
greatest barrier to compound movement across it. Miller et al. showed that the choroidal 
resistance, including the Bruch’s membrane, provided only 10% of the resistance measured 
across a choroid-RPE complex isolated from bovine samples [206]. They suggest that it is the 
tight junctions between the RPE cells which provide the greatest resistance to transport 
across the barrier. In the presence of an ARPE-19 cell monolayer, the concentration in the 
receptor compartment is consistently lower than in the acellular membrane experiments. 
The exception to this pattern was the experiments conducted at 400µL/min. Here the 
concentration curves of the membrane and membrane/cell complex cross at points and 
similar concentrations are observed in the chambers. This could be attributed to the 
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breakdown of the tight junctions between the cells caused by the shear stress from the fluid 
flow as shown in section 2.2.3.2. The decrease in TEER observed and the distortion in ZO-1 
staining at the cell-cell borders imply a loss of barrier functionality of the monolayer which 
would increase permeability of the barrier and allow a greater concentration of FD to move 
into the receptor compartment.  
2.4.4 IBUPROFEN CONTAINING SILICONE OIL AS AN IMPLANTABLE DRUG 
DELIVERY DEVICE 
Silicone oil (SiO) tamponades are currently used clinically to replace the vitreous following 
complicated or severe cases of retinal detachment, particularly in patients who have a high 
risk of developing fibrotic diseases such as proliferative vitreoretinopathy (PVR) following 
treatment.  The placement of the tamponade creates an aqueous exclusion zone around the 
wound site as the SiO bubble maintains contact with the retina. The exclusion of aqueous 
fluid hinders its movement into the subretinal space and looks to prevent any inflammatory 
factors found within the aqueous from entering the wound site and initiating the 
inflammation process, which can lead to the migration of RPE cells into the vitreous cavity.  
It has been proposed that adjunctive drug treatments could improve outcomes in patients 
treated for RD and PVR. Repeated intravitreal injections of therapeutic drugs into the 
vitreous of the eye is currently one of the best clinical approaches to attaining sustained 
exposure of drugs in the posterior segment for the treatment of such conditions. By 
incorporating therapeutic agents into the silicone oil tamponades it may allow the oil to serve 
a subsidiary purpose as an extended-release drug delivery device, which could prolong 
therapeutic levels of the drug at the back of the eye compared with the current techniques. 
The majority of drugs that have been studied as potential treatments for PVR, such as 
triamcinolone, daunomycin and growth factor inhibitors are water soluble and therefore 
have poor solubility in SiO [37]. Ibuprofen is a lipophilic drug and thus is readily soluble in 
SiO. It is classified as a non-steroidal anti-inflammatory drug (NSAID) and although it has yet 
to be studied as a treatment in PVR, its characteristic anti-inflammatory response and 
lipophilic nature made it a suitable candidate for this study [207].  
The results observed in the release of ibuprofen from silicone oil in static well plates (section 
2.2.3.5) showed that in a 12-well plate, the majority of the ibuprofen had been released from 
the silicone oil into the PBS after 72 hours. Where the PBS had been replenished at each 24 
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hour time point, the cumulative percentage release of ibuprofen was 98% after 72 hours 
compared with 84% in those experiments where the PBS was not replenished. In vivo, 
aqueous humor turnover in the anterior segment is estimated to occur at approximately 
2.4µL/min [208] therefore it is likely that the replenishment of the PBS in the well every 24 
hours more accurately represents the concentration gradient that would be found in vivo. In 
those conditions, the percentage release of ibuprofen from the SiO over 72 hours is equal to 
98%, 82% and 58% in the 12-well, 24-well and 48-well plates respectively. In each case, the 
volumes of ibu-SiO and PBS in each well were equal, however, due to the dimensions of the 
wells, the interfacial contact areas between the two fluids decreased as the number of wells 
in the plate increased. This decrease in interfacial contact area reduces the area across which 
diffusion of the ibuprofen can take place which gives rise to the differences in cumulative 
release of the drug over the 72 hours. This is an important factor to consider when scaling 
experiments of this nature and highlights the need for consistency in the testing of such drug 
delivery materials. This is one of the motivations of developing complementary in silico 
models of such systems as they can provide estimations of changes in release profiles across 
vast ranges of different parameters in a more time efficient manner. In comparison with a 
study conducted by Steffansen et al. which also investigated the release of a lipophilic drug, 
5-flurouracil (5FU), from silicone oil, the release of ibuprofen is much slower in comparison 
to the half-life of 3.5 hours that they report [91]. However, treatment courses for PVR are 
normally conducted over a 6-8 week period, therefore the release of ibuprofen from SiO 
would need to be extended in order to make this a viable technology. Cauldbeck et al. 
showed that by modifying the SiO to include solubilised copolymers, the release of ibuprofen 
as well as another lipophilic drug, retinoic acid (RA), which has anti-proliferative effects, can 
be extended up to 9 days for ibu and as long as 72 days for RA [209]. Additionally, the same 
group they have shown that polymeric modification of the drug, in this case all-trans retinoic 
acid (atRA), can also extend the release up to a clinically relevant 7 weeks [71]. In both of 
these studies, the release experiments were conducted in 24-well plates. It would interesting 
in the future to investigate modified SiO/drug systems using the in silico models, which, could 
potentially aid in predicted and identifying the most suitable modifications in a more time 
and cost-effective manner, assuming that the degradation and release mechanisms of the 
systems were well characterised. 
Static release experiments cannot truly represent the natural dynamic environment of drug 
movement that occurs in vivo. Studying the ibu-SiO device within the Kirkstall QV600 
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chamber allows us to observe the flow-dependent release and clearance of the ibuprofen 
from the SiO. The results observed in this study show that the inlet flow rate of the flow field 
present can alter the concentration profile of ibuprofen within the PBS containing receptor 
compartment. As with the dextran movement across the membrane discussed in section 
2.4.3, at the lowest flow rate, 20µL/min, there was a sharp increase in concentration over 
the first 8 hours after which there was a very slow decrease in concentration of the following 
16 hours which appears to plateau over the later time points. In contrast, the higher flow 
rates show a burst release and then constant decay in concentration. This change in release 
profile could be important to consider in terms of maintaining a therapeutic range of 
ibuprofen in the target area. One of the limitations of these experiments is that the release 
of ibu from SiO across a cell barrier was unable to be measured. The proteins present within 
the culture media needed to maintain a healthy, viable cell monolayer, produce peaks in the 
UV absorbance spectrum used to measure ibu concentration within the samples. These 
peaks interfere with the signal produced by the ibu in the sample and produce 
incomprehensible results. For this reason the release of ibu was measured into PBS. Future 
work should incorporate the desirable features of both of the systems described in this study, 
i.e. the dextran permeability and the ibuprofen release from SiO. Using an ibuprofen 
detection method that can measure the concentration in culture medium would allow the 
cells to be maintained within the chamber but also to measure the ibuprofen release from 
the SiO across the cell barrier.  
2.4.5 AGREEMENT BETWEEN SIMULATED AND EXPERIMENTAL RESULTS 
SHOWS COMPUTER MODELS CAN BE USEFUL PREDICTIVE TOOLS 
Computational models, such as the ones incorporating fluid dynamics, present the 
advantage of accurately describing the system behaviours when its constitutive parameters 
are varied. Unlike the traditional experiments, after thorough validation and benchmarking, 
these models can be used to describe complex systems in a fast, inexpensive, accurate and 
reliable manner. Moreover, a vast parameter field can be tested and considered, enabling 
the analysis and comparison of different physical processes such as fluid flow or drug 
transport and diffusion. Computational models have the potential to help towards 
understanding the complex structure of biological systems and their behaviour. The accuracy 
of the input parameters and boundary conditions applied to the computational model 
dictate the accuracy and reliability of the results that the simulation will produce. In this 
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study, parameters such as the permeability/diffusion coefficients and rheological properties, 
were determined from data collected experimentally. After collecting all the necessary 
parameters, these could then be applied to a computer model which includes mechanisms 
which investigate the evolution of both, dextran diffusion across an ARPE-19 monolayer and 
NH3 treated ePTFE membrane, and distribution of ibuprofen concentration across the 
Kirkstall QV600 chamber. 
The fluid flow set up used in this study was designed to emulate the mechanism of 
elimination of molecules via convectional clearance analogous to the systemic circulation 
present in choroidal tissue in vivo. To validate the computer model, comparisons of the 
average concentration in the receptor compartment of the Kirkstall QV600 chamber were 
made between predicted and experimental data. It is important to note that previous studies 
have used computer models to study drug delivery and distribution in the posterior segment 
of the eye [130-132] however these studies are mostly theoretical or based on experimental 
data published by Palestine and Brubaker which investigated the pharmacokinetics of 
fluorescein in the vitreous of humans [135]. In this study I looked to create an in silico model 
which could predict drug distributions in an in vitro model which hopefully could be used in 
the development of this novel ibu-SiO drug delivery device. 
To build a validated model to work from in the study of the SiO, it was decided to first build 
a permeability model which could predict the movement and transport of dextrans through 
the ARPE-19 cell/ePTFE membrane. The permeability coefficients of each of the molecular 
weight FDs used were determined by the static transport experiments (2.2.3.3). These 
numbers were then applied to the computer model to simulate the transport in the dynamic 
flow environment. To validate the model, experiments were conducted under the same 
conditions described in the model and concentration of dextran in the receptor 
compartment was used as the measureable outcome.  
This computer model was able to predict the maximum concentration observed in that 
chamber to within 15% of the acellular experimental data, with the exception of 70kDa FD 
at 400µL/min which was as high as 30%. The introduction of cells to the system increased 
the error observed in Cmax to 30%, with the exception of 70kDa FD at 200µL/min which 
reached 46%. Interestingly a study conducted by Hsu et al., which simulated permeability of 
different molecular weight FITC-dextrans in a static set-up similar to that described in section 
2.2.2.12 but across collagen or agarose gel, showed an increase in error between their 
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simulated and experimental results with increasing molecular weight [210]. In this model the 
least agreement is seen in those experiments which used 70kDa FD, the highest molecular 
weight. Also the inclusion of cells decreased the agreement between the simulated and 
experimental data. It is possible that this is due to the effect culturing the cells under flow 
has on the barrier functionality of the ARPE-19 cell monolayer. As seen in section 2.2.3.2, it 
appears that the barrier functionality is increased in the monolayer when the cells were 
exposed to flow rates up to 200µL/min as increased TEER is observed across the barrier. 
Conversely, when the flow rate was increased to 400µL/min, there appeared to be 
impairment of barrier function with decreased TEER and a breakdown in the tight junctions 
across the monolayer. This simulation does not take these biological effects in to account 
and is one of the major limitations of the current model. An experiment which could 
investigate whether this is a source of error would be to conduct the static transport 
experiments following exposure to flow, to determine the changes in permeability that is 
caused by the cells’ exposure to it, and to use these values to build the computational model 
in the hope of reducing the error observed. There are studies which have investigated 
biological effects on epithelial tissues in computer simulations, such as Barber et al. who 
modelled inflammatory effects on intestinal epithelium in necrotising enterocolitis, [211] 
and Reijniak et al., who produced computer models to investigate links between epithelial 
morphogenesis and cancer mutations [212]. In the future I think it would be interesting to 
combine the computational fluid dynamics models designed in this study with a more 
computational biology approach to investigate cell dependent changes in transport and 
clearance of molecules. 
To model the release of ibu from SiO the physics controls of the computer model had to be 
redesigned to allow the interaction of two immiscible fluid phases within the QV600 
chamber. COMSOL Multiphysics software provides three methods for tracking interfaces in 
multi-phase flow models: level set, phase field and moving mesh. Each method has 
advantages and disadvantages depending on which feature of your model you have most 
interest in. For this ibu-SiO model, the moving mesh method was applied. COMSOL report 
that this method is best when tracking the interface between the phases is of importance. It 
also allows mass transport across the interface which is difficult to implement using the other 
methods [213]. The latter feature is what made this method most applicable to the 
simulation in this study as I was interested in the transport of ibuprofen across the two 
phases. Weisbrod et al. presented a study with similar requirements which modelled the 
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flow of kerosene in water, and within the kerosene phase was a concentration of acetic acid 
which diffused in to the water phase over time. They suggest that although the phase field 
method has improved performance in comparison with the level-set method in terms of flow 
within multi-phase systems, it is not suitable for applications where mass transfer is required 
and as such suggest the moving mesh method is most appropriate [214].  
The results produced by the simulation showed realistic fluid flow profiles which one could 
expect to see under the same experimental conditions. At 20µL/min, the flow entering the 
main chamber bounces of the bottom off the meniscus formed by the oil phase and creates 
a ripple in the main stream of flow. The interaction of the main stream of flow with the oil 
domain also creates very low velocity recirculating flow patterns within the oil which are 
separate to the main flow stream. The movement within the oil could be expected to have 
implications on the distribution of ibuprofen within the oil phase but it appears that because 
the velocities are so low that the diffusion of the ibuprofen from the oil still occurs 
symmetrically out from the centre of the domain. As the inlet velocity increases, more 
asymmetrical diffusion patterns appear, however, the recirculation velocities within the oil 
remain very low in comparison with the velocity observed in the main stream of flow and so 
the distribution of ibu in the oil domain appears to be controlled by the concentration 
gradient between the two phases. This in turn is controlled by the convection of ibuprofen 
away from the interface by the fluid flow. The flow profiles in the aqueous phase of the two 
phase model were not comparable with those seen in the dextran transport model. In that 
model, the membrane was modelled as a fluid matrix domain whereby the fluid can move 
through the domain at a retarded rate based on the porosity and permeability of the 
membrane. For this reason only a small percentage of fluid actually passes through the 
membrane and interacts with the donor domain. The majority of the flowing fluid sees this 
as a walled domain and so this reduces the height of the chamber which is the reason for 
recirculating flows to develop in a turbulent fashion. In the two-phase, oil/PBS model, the 
force of the aqueous flow is partially absorbed by the oil which causes the recirculation 
within the oil but also reduces the velocity of the aqueous flow in comparison with the single 
phase model. This reduction in velocity also removes the secondary recirculating streams 
which occur in the single phase model. 
The Kirkstall QV600 chamber is made of moulded polydimethylsiloxane (PDMS), sometimes 
referred to as silicone rubber. PDMS is a highly inert elastomer and as such makes it useful 
in many medical device and implant applications [215, 216]. In terms of its biocompatibility 
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and chemical stability, it is ideal for use in a microfluidic device, however, to validate the flow 
profiles observed in the computer model, visual and quantifiable data needs to be collected 
from the representative experiments. It was not possible to obtain that data in this project. 
In order to obtain quantitative data in such flow models, particle tracing technologies such 
as particle image velocimetry (PIV) would need to be implemented. PIV is an optical method 
used to visualise flow and obtain instantaneous velocity measurements within flow streams 
using scattered particles suspending within the flow medium. A layer of fluid is illuminated 
with a 2D light sheet whilst a camera simultaneously captures the illuminated particles within 
that layer. This is repeated over time to determine displacement of particles over time which 
allows calculation of the velocity within the field [217, 218]. This method was considered for 
the QV600 chamber to provide comparison with the computer simulation however, the lack 
of optical transparency of the chamber and the small scale and volumes used within it made 
it unsuitable as a subject for PIV. In future I think it would be important to confirm the flow 
profile within the chamber using an experimental method, not only for this particular study 
but for any study which intends to use the QV600 chamber for flow models.  
As with the dextran transport simulations, to quantitatively validate the computer model of 
the ibu-SiO device within the QV600 chamber the concentration of ibuprofen in the receptor 
domain over time was measured. The accuracy to which the model was able to predict the 
concentration of ibu varied with the inlet flow rate. For the lowest flow rate, 20µL/min, the 
prediction was within 8% of the Cmax of the experimental and also predicted the total 
exposure (AUC) to within 3%. At 200µL/min, which closely resembles the in vivo choroidal 
blood flow rate, the total exposure was within 8%, however there was a 35% overestimation 
in the Cmax reached. Conversely at the highest flow rate, which is unrealistic in comparison 
with the in vivo environment, the Cmax was underestimated by the simulation and there was 
a very large percentage error in the AUC. However, the values for concentration under these 
conditions were very low, Cmax = 0.0039µg/mL, so at the very lower measurement limit of the 
UV-Vis spectrophotometer. Also the differences in absolute value of Cmax was 0.0007µg/mL, 
which is negligible in comparison to the 1mg/mL initial concentration present in the SiO. 
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2.4.6 LIMITATIONS OF THE MODEL 
In Vitro Model 
The design of the in vitro model used in this study uses a human RPE cell line, ARPE-19, 
cultured on a synthetic Bruch’s membrane replacement, NH3 treated ePTFE. ARPE-19 cells 
have been used as a model for the RPE in many studies however they have limitations in 
terms of the comparability with in vivo RPE. It has been suggested that they more resemble 
an aged or pathologic RPE which lack natural pigmentation, whereas primary human RPE 
cells or foetal primary RPE cell have be shown to have greater barrier functionality and 
express increased levels of RPE markers [219]. Also, other cell types are involved in the outer 
blood retinal barrier which have not been considered here. Choroidal endothelial cells 
occupy the basal side of the Bruch’s membrane and it has been shown that the incorporation 
of an endothelial cell layer, human umbilical vein-derived endothelial cells (HUVECs), within 
a similar in vitro model of the OBRB decreased the permeability of the barrier to 4kDa FITC-
dextran [104]. In order to establish a more robust and representative model of the OBRB, 
future work should investigate the inclusion of a choroidal endothelial cell type. 
Computer Model 
From section 2.2.3.2, it can be seen that culturing of ARPE-19 cells under flow conditions can 
have either beneficial or detrimental effects on the barrier functionality and phenotype of 
the cells. The current computer model does not consider these alterations in parameters 
created by the biology of the cells and thus does not adapt to the changing conditions. 
Additionally, metabolism and active transport of compounds by the cells is not considered. 
This is particularly important in the assessment of drug transport across the barrier. It would 
be interesting in the future to combine a mathematical model of cell behaviour and 
metabolism with the fluid dynamics of drug clearance to provide a full picture of the 
movement of drugs through such a system. 
The current model is conducted under 2 dimensional conditions and provides a planar 
projection of the mechanisms occurring within the system. Although good agreement was 
seen between the simulated and experimental results, this could be a source of error as the 
model extrapolates the concentration results out into 3 dimensions. Ultimately the model 
would need to be built in 3D to provide the most accurate representation of the in vitro 
model. 
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As robust and mathematically stringent as computer models are able to be built, they will 
never be able to provide a fully accurate representation of a biological environment due to 
the variability and continually dynamic environment of nature. What they are able to do is 
provide estimated predictions of results across a vast number of parameters in a fast and 
inexpensive manner. In terms of developing drug delivery devices such as the ibu-SiO 
described here, it allows us to vary conditions such as initial concentration, drug permeability 
and material properties and produce estimations which can narrow the range of expensive 
and time consuming experimental work that would otherwise need to be conducted. 
Ultimately it would be of interest to apply the knowledge and understanding of drug release 
from SiO gained from these complementary in silico and in vitro models to build a 
computational model of the eye which could help us predict how this system might work in 
vivo in a human eye. 
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 CHAPTER 3 
MODELLING AQUEOUS    
FLOW AND SACCADIC EYE 
MOVEMENTS 
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3.1 AIMS AND OBJECTIVES 
AIM 
To design complimentary in vitro models and computer simulations for use in the study 
release and transport of ibuprofen from a silicone oil tamponade through models of the eye 
that mimic aqueous flow movements and saccadic eye movements. 
OBJECTIVES 
 Develop and optimise a geometrically relevant in vitro model of aqueous flow. 
 Study the effects of release of ibuprofen from a silicone oil tamponade within this 
model.  
 Develop, optimise and validate a complimentary CFD model of the in vitro model. 
 Determine whether the CFD model can be used to predict molecule concentrations 
across the in vitro model.  
 Experimentally simulate the effects of saccadic eye movements on the release of 
ibuprofen. 
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3.2 IN VITRO MODEL OF AQUEOUS FLOW AND SACCADIC EYE 
MOVEMENTS 
Following tamponade surgery, three different phase interfaces occur within the patient’s 
eye; the silicone oil-retina interface, the retina-aqueous interface and the silicone oil-
aqueous interface. The movement of the aqueous phase around the silicone oil could have 
implications for the release of the ibuprofen from the tamponade.  
Chapter 2 investigated the clearance of molecules across the outer blood retinal barrier 
model. The other mechanism of drug clearance from the posterior segment is via aqueous 
outflow in to the anterior segment and out through either the trabecular meshwork or uveo-
scleral vasculature. The aqueous fluid is secreted by the ciliary body to the posterior segment 
and flows into the anterior chamber. The path taken by the fluid creates interaction between 
the aqueous fluid and the vitreous or vitreous substitute and this interaction could have 
implications on drug release profiles and concentrations.  
Another mechanism which can induce movement of fluids within the eye is saccades. 
Saccadic eye movements are rapid movements which abruptly change the point of fixation 
and also include the rapid eye movements that occur during sleep. These saccades last no 
longer than 100ms, the reported response time of the visual system, however, the duration, 
amplitude and velocity varies with each movement [220]. Saccades can occur up to 
amplitudes of 90°, however the majority occur below 20°with peak velocities in this range 
reaching up to 500°/second. The acceleration and jerk nature of saccades distinguish them 
from other types of eye movement, such as smooth pursuit movements, and are likely to 
affect the distribution of drugs within the posterior segment [221].  
The following studies investigate the effects of flow around the Ibu-SiO oil and the 
subsequent differences in ibuprofen release profiles that occur due to either laminar flow 
around the oil (to represent aqueous outflow) or using simulated saccadic movements. These 
studies were done using two different in vitro models which have both previously been used 
to investigate the motion effects on the emulsification of silicone oils.  
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3.2.1 THE SPHERICAL EYE MODEL 
Models of the eye were made by machining spheres of equivalent size to the eye into Perspex 
blocks with 0.8mm diameter inlet and outlet ports at the equator of the spheres. The model 
was made in two halves which were held together with screws. These models had previously 
been used by Fawcett et al. to study the emulsification of silicone oil tamponades [222]. The 
design of the model (Figure 3-1) allows for injection of the tamponade via the ports whilst 
enabling fluid flow to be introduced via the ports. The model simplifies the geometry of the 
eye to assume it adopts a spherical shape, however the volume the sphere can hold is 
designed to be equal to that of the human eye, 5mL. The model allowed a bubble of silicone 
oil to be surrounded by an aqueous phase, equivalent to the phase interface seen in vivo. 
The existence of the ports allowed fluid to be perfused through the system, therefore 
enabling the study of a dynamic fluid environment. Although the geometry is simplified in 
comparison to the in vivo eye, it is still a better representation in comparison to the previous 
Kirkstall QV600 chamber used. A disadvantage of this model, however, is it is not designed 
to be used for cell culture. Therefore all experiments using this model are in the absence of 
any cells. 
3.2.2 EYE-ON-A-CHIP MODEL 
The eye-on-a-chip model was designed by the fluid engineering group at the University of 
Hong Kong again to be used to investigate the emulsification of silicone oil tamponades 
(Figure 3-2). This model provides a two-dimensional (2D) projection the cross-section of the 
human eye.  Over recent years the development of microfluidic cell culture platforms has 
seen a drastic increase, with these technologies reporting to provide a greater 
representation of the dynamic microenvironments of organs in vivo.  These ‘organ-on-a-chip’ 
models have been successfully used to study organs such as kidney [223], heart [224] and 
lungs [225], however relatively little work has been done with eye-on-a-chip devices, in 
particular, the posterior segment.  
The device used in these studies was previously used to study the effects of eye movements 
on the emulsification of a range of silicone oil tamponades. The design of this device is 
described by Chan et al. and includes a medium perfusion channel around the outside of a 
central inner chamber, connected by a series of micro-channels. Both the perfusion channel 
and the central inner chamber have individual inlet and outlet ports for independent control 
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of medium perfusion and injection of silicone oil. The purpose of the perfusion channel is to 
allow to exchange of nutrients through the micro-channels to and from retinal cells which 
can be cultured in the inner chamber. The geometry also includes an exclusion area within 
the inner chamber, representative of the lens [226]. 
The eye-on-a-chip device is another model which provides an opportunity to study drug 
release from silicone oil tamponades. Combining the results from the different models used 
in all of these studies should provide a greater understanding of drug release profiles of this 
delivery method. 
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In Vitro Spherical Eye Model and Eye-on-a-chip Model 
 
Figure 3-1: Spherical Eye Model. 
 
Figure 3-2: Eye-on-a-chip model and schematic diagram. Detailed description of device 
design is described by Chan et al. [226].  
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3.2.3 MATERIALS AND METHODS 
3.2.3.1 VISUALISING THE FLOW IN THE SPHERICAL EYE MODEL 
To fill the spherical model for use, the walls of the sphere were first coated with 1% bovine 
serum albumin (BSA) solution (diluted in PBS) (Sigma, A4161). The 1% BSA solution was 
injected into the sphere via the inlet port until filled and kept at room temperature for 30 
minutes to allow the protein in the solution to adsorb to the wall. The adsorption of the 
protein onto the wall of the Perspex reduces any shear effects on the silicone oil caused by 
the roughness of the wall. After 30 minutes, the BSA solution was syringed out of the system. 
The system was then flushed through with distilled water (ddH2O) after which the sphere 
was filled with fresh ddH2O. Once filled with, 3.5mL of Ibu-SiO was injected via syringe in 
through the outlet port of the system, with care taken to ensure that only one continuous 
stream of oil was injected to produce a single bolus of Ibu-SiO. 
The inlet port of the spherical chamber was connected to a syringe pump (Harvard 
Apparatus, PHD ULTRA 2.0.4) with 1mm diameter silicone tubing. The pump was set to infuse 
a tracer dye, 0.1% Methylene Blue (Sigma, M9140) diluted in distilled water, at a range of 
flow rates to evaluate the flow profile in the chamber. A dilution of 0.1% methylene blue in 
ddH2O produces a solution with equal density and viscosity as water so the dye has no impact 
on the fluid properties of the solution. Flow rates of 20µL/min, 200µL/min and 2mL/min and 
20mL/min were investigated at room temperature. Images of the chamber were taken every 
2 seconds using a Nikon D3500 digital SLR camera.  
3.2.3.2 STATIC RELEASE OF IBUPROFEN FROM SILICONE OIL IN SPHERICAL EYE MODEL 
The release of Ibuprofen (Ibu) from silicone oil (SiO) was measured over time to determine 
a static release profile within the model. As in section 2.2.2.14, an experimental 
concentration of 1mg of Ibu (Tokyo Chemical Industry UK, I0415) was added to 1mL of 
1000c.st silicone oil (Fluoron Ltd) and the mixture was stirred for a minimum of 72 hours in 
a sealed flask. Following stirring, the Ibu-SiO was filtered in a Class II biological safety hood 
to sterilise and stored at RT. The model was primed and filled using the same method as 
described in section 3.2.3.1 with PBS used as the aqueous solution as opposed to ddH2O to 
maintain consistency across the release experiments. These studies used 4.5mL of Ibu-SiO. 
All static release experiments were carried out at RT and 37⁰C.  
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After 24 hours, the PBS in the chamber was removed using a syringe, 3 x 100µL samples were 
taken from the PBS and transferred to UV transparent cuvettes (UVette, Eppendorf) and the 
Ibu concentration was measured using a UV spectrophotometer (SPECTROstar Nano, BMG 
Labtech) λabsorption = 264nm. The system was then cleaned and refilled and left for 48 hours, 
after which samples were taken. The whole process was then repeated again for 72 hours. 
Each of these time frames were repeated in triplicate. The concentration in the samples was 
determined by comparison with a standard curve and used to calculate the cumulative 
percentage release of ibuprofen from the oil. The results are presented as mean percentage 
release ± 1 SD, n=3.  
3.2.3.3 RELEASE OF IBUPROFEN FROM SILICONE OIL UNDER LAMINAR FLOW IN SPHERICAL EYE MODEL 
The spherical eye chamber was used to investigate the effects of dynamic flow on the release 
of Ibu from SiO. As in section 3.2.3.1, a syringe pump was used to produce PBS flow through 
the model. The system was set up in a single pass formation, with the outlet port open, 
allowing the waste PBS to flow into a collection pot. The use of the syringe pump to 
implement the flow became unsuitable for the long term nature of these studies due to the 
limited volume held by a syringe, thus the peristaltic pump from section 2.2.2.8 was used to 
allow continuous perfusion of PBS without the interruption caused by the need to change 
the syringe. In order to produce a steady stream of aqueous without the silicone oil bolus 
interfering, only 3.5 mL of ibu-SiO was injected into the system. After 24 hours, the flow was 
stopped and the PBS was removed from the sphere. Three 100µL samples were taken from 
the PBS and transferred to individual UV-clear cuvettes. The system was then cleaned and 
reset and the process repeated for 48 and 72 hours. Flow rates of 20µL/min, 200µL/min, 
400µL/min and 2mL/min were investigated. For 2mL/min, the experiments were conducted 
over 8 hours to prevent leakage from the system.  
The UV light absorption of the samples was measured using a UV spectrophotometer 
(SPECTROstar, BMG Labtech) λabsorption = 264nm. The absorption of each of the samples was 
compared to a standard curve and the concentration of the ibu present in each sample was 
determined. After simulating these experiments using a computer model, described in 3.3, 
the results suggested that the dominating features of the concentration profile occurred in 
the first 8 hours of flow. Therefore, the experiments were repeated with samples taken at 2, 
4, 6 and 8 hours. All studies were repeated in triplicate at 37⁰C, results are presented as 
mean concentration at each time point ±1 SD. 
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3.2.3.4 RELEASE OF IBUPROFEN FROM SILICONE OIL UNDER SACCADIC SIMULATION IN SPHERICAL EYE 
MODEL 
Normal saccadic eye movements in humans produce fluid flow and shear stress profiles 
which could have implications for the oil-aqueous interface of the silicone oil tamponade, 
thus potentially having an effect on the release profile of drugs from the oil. A mechanical 
device designed to generate motion to simulate saccadic eye movements by Chan et al. at 
the University of Hong Kong, in collaboration with the University of Liverpool, was used with 
the spherical eye model to investigate the effects of this motion on the release of ibuprofen 
from a silicone oil tamponade [227]. 
The system had three principle parts; a stepper motor C4/MD2 Step Motor System, Arrick 
Robotics, Tyler, TX), a shaft encoder (Baumer Electric AG, Frauenfeld, Switzerland), and a 
data acquisition device (National Instruments Corp., Austin, TX). A platform was attached to 
the shaft of the stepper motor to allow the model to be fixed in position and provide 
rotational motion in a single plane. In order to execute repetitive motions, with specified 
angular displacement, velocity and acceleration, a dedicated software program was used to 
send instructions to the machinery and the shaft encoder enabled the actual motion being 
performed to be recorded. The system was instructed to execute movements with an 
amplitude of 10⁰, angular velocity of 390⁰/s and a duration of 50ms. These values were 
based on typical velocity profiles of the most frequent saccades observed in healthy, adult 
humans. 
The spherical eye models were filled with PBS and 4.5mL ibu-SiO as previously described 
with the inlet and outlet ports sealed and the model fixed to the rotating platform (Figure 
3-3). The movement program was executed and the models were exposed to the motion 
for 24 hours. The PBS was then removed from the model and 3 x 100µL samples were 
taken. These studies were undertaken at the University of Hong Kong and so a NanoDropc 
UV spectrophotometer was used to measure the UV absorbance of 10 x 2µL samples from 
each of the 100µL taken at wavelength 264nm. The process was repeated with the models 
fixed to the machinery for 48 and 72 hours. All studies were repeated in triplicate at RT. 
The concentration in the samples was determined by comparison with a standard curve 
and used to calculate the cumulative percentage release of ibuprofen from the oil. The 
results are presented as mean percentage release ± 1 SD, n=3.  
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Spherical Eye Model on Saccadic Simulator Device 
 
Figure 3-3: Schematic of spherical eye model on saccadic simulator. 
3.2.3.5 MANUFACTURING THE EYE-ON-A-CHIP MODEL 
Computer-aided design software (AutoCAD 2014, Autodesk, USA) had previously been used 
to create the inner geometry of the eye-on-a-chip model by the Fluid Engineering group at 
the University of Hong Kong. The chip device was composed of five layers of 1mm thick 
poly(methyl methacrylate)(PMMA) which each had an individual part of the inner structure 
laser engraved (model VLS2.30; Universal Laser Systems, USA)  into them. Each layer of the 
chip was cleaned with lens tissue and the five layers were then stacked in a specific order to 
complete the chip. The layers were bonded by applying chloroform solution to the edges and 
once completed, compressed air was forced through each port to remove any dust from the 
channels. The chips were then flushed with sterile PBS solution to ensure none of the 
channels were blocked and stored at RT until use. 
The main chamber of the device, designed to hold the silicone oil tamponade, was a 25mm 
diameter circle with an indentation to represent the lens. These dimensions are 
representative of the cross-section of the posterior segment of the human eye.  Surrounding 
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the central chamber were a series of 100µm wide microchannels, designed to join the outer 
perfusion channel with the central chamber. The outer perfusion channel allowed the 
aqueous phase to be injected around the outside of the inner chamber and enable its 
removal for sampling.  
3.2.3.6 STATIC RELEASE OF IBUPROFEN FROM SILICONE OIL IN EYE-ON-A-CHIP MODEL 
As with the spherical eye model, the inner walls of the chips were first coated with 1% bovine 
serum albumin (BSA) solution (diluted in PBS) (Sigma, A4161). The 1% BSA solution was 
injected into the central chamber and the perfusion channel via the inlet port until filled and 
kept at room temperature for 30 minutes to allow the protein in the solution to adsorb to 
the wall. This again was to reduce any shear effects on the silicone oil caused by the 
roughness of the wall. After 30 minutes, the BSA solution was syringed out and the chip was 
flushed with fresh PBS. After the chips were primed, sterile PBS solution was injected in both 
the aqueous inlet port and SiO inlet port to fill the chips. Once filled, the aqueous ports were 
sealed with Parafilm (Sigma, P7793) and 500µL of 1mg/mL ibu-SiO was injected into the 
central chamber via the SiO inlet port using an 18G needle. The ports to the central chamber 
were then sealed with Parafilm. 
The release of ibuprofen into the surrounding aqueous was measured over 24, 48, 72 ad 168 
hours. A 30µL sample was taken from the perfusion channel of each chip and the UV 
absorption of each sample was measured by analysing 10 x 2µL drops from each sample with 
a NanodropC UV spectrophotometer. The concentration of Ibuprofen present in each of the 
samples was determined by comparison with the standard curve. Concentration gradient 
effects were investigated with experiments being carried out with the PBS completely 
replaced following sample removal, or just the 30µl sample volume replaced with fresh PBS. 
Experiments were carried out in triplicate with 3 chips used in each experiment and results 
are presented as the mean cumulative release ± 1 SD. 
3.2.3.7 RELEASE OF IBUPROFEN FROM SILICONE OIL UNDER SACCADIC SIMULATION IN EYE-ON-A-CHIP 
MODEL 
The same method was used to simulate saccadic eye movements in eye-on-a-chip model as 
described for the spherical eye model in section 3.2.3.4. Once filled using the method 
described above, the chips were mounted onto the rotating platform and exposed to the 
motion for 24, 48, 72 ad 168 hours with the PBS in the chips either replenished every 24 
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hours or with only the sample volume replaced. A 30µL sample was taken from the perfusion 
channel of each chip and the UV absorption of each sample was measured by analysing 10 x 
2µL drops from each sample with a NanodropC UV spectrophotometer. The concentration of 
Ibuprofen present in each of the samples was determined by comparison with the standard 
curve. Experiments were carried out in triplicate with 3 chips used in each experiment and 
results are presented as the mean cumulative release ± 1 SD. 
3.2.3.8 STATISTICS 
GraphPad Prism statistical analysis software was used to analyse all data. 
Two-way ANOVA 
 Release profile of ibuprofen in spherical eye model under static conditions. 
 Effects of saccadic simulation on ibuprofen release in spherical eye model. 
 Effects of saccadic simulation on ibuprofen release in eye-on-a-chip model.  
A two-way ANOVA was used because for each experiment there were two factors to 
consider: concentration and time. For each case the factors were treated as within subjects. 
Bonferroni’s post hoc test was used. A minimum significance level of P < 0.05 was set for 
each experiment.   
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3.2.4 RESULTS 
3.2.4.1 FLOW PROFILE IN SPHERICAL EYE MODEL AT DIFFERENT LAMINAR FLOW RATES 
Dye studies were conducted to analyse the pattern and path that the fluid took when 
exposed to laminar flow of different flow rates. These dye experiments were designed to 
imitate mass transfer in the posterior segment of the eye which is caused by aqueous flow 
around the silicone oil tamponade. This flow is necessary to clear the drug away from the 
tamponade following release. Methylene blue solution diluted 0.1% in ddH2O was infused 
through the system and the dye was traced through the chamber using a series of images 
taken 2 seconds apart using a digital camera. 
For the lowest flow rate studied, 20µL/min, the dye entered the main chamber from the inlet 
port and traced a path through the aqueous phase along the circumference of the sphere 
before being cleared out of the outlet port (Figure 3-4). This pattern was observed for flow 
rates of 200µL/min and 2mL/min also (Figure 3-4), with the infused dye replacing the initial 
aqueous phase earlier as the flow rate increased. At 2mL/min, the centre of the silicone oil 
bolus is dragged towards the outlet under the force of the flow. This drag creates 
dissymmetry within the system, however the oil is still not forced out through the outlet as 
the flow reaches equilibrium. An extremely high flow rate of 20mL/min was also studied to 
observe what would happen to the silicone oil tamponade under extreme flow. After 4 
seconds of aqueous flow, the silicone oil began to be removed from the chamber through 
the outlet under the force of the fluid, showing destruction of the system (Figure 3-4).  
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Visualisation of Flow through Spherical Eye Model 
 
Figure 3-4: Visualisation of flow within the model at flow rate 20μL/min, 200µL/min, 
2mL/min and 20mL/min visualised using dye. Up to 2mL/min, dye moves circumferentially 
around the oil bolus. At an exaggerating rate of 20mL/min, the system is destroyed and 
the oil is removed via the outlet port.  
  
20µL/min 
200µL/min 
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3.2.4.2 RELEASE OF IBUPROFEN IN SPHERICAL EYE MODEL UNDER STATIC CONDITIONS 
To understand the release of ibuprofen from silicone oil in a more geometrically relevant 
system, release studies were conducted in the spherical eye model under static conditions. 
The release of ibuprofen was measured every 24 hours for 72 hours and release at both RT 
and 37⁰C was investigated.  
In PBS, ibuprofen has a saturation limit of 2mg/mL [228]. For the volume ratio of PBS to 
silicone oil used the saturation limit of ibuprofen in PBS in this model, equates to 44.4% 
release. For both temperatures, there was an initial burst release of ibuprofen after the first 
24 hours, 24.2% at RT and 32.3% at 37⁰C, after which the release rate appeared to slow as 
the concentration approached the saturation limit. As expected, the percentage release 
appeared to be higher at each time point for those experiments conducted at 37⁰C. When 
tested with a repeated measures ANOVA with temperature (RT vs 37°C) as a between and 
time as a within-subjects factor, temperature returned a statistically significant main effect 
(F (1, 5) = 42.07, p = 0.0013), time also did (F (2, 10) = 63.5, p < 0.0001) and the time x 
temperature interaction was statistically significant (F (2, 10) = 6.26, p = 0.0173). Bonferroni’s 
post hoc test indicated that the only significant difference in percentage release was seen 
after 24 hours (p=0.0013). Release at both temperatures reached near saturation after 72 
hours, 41% and 42.5% for RT and 37⁰C respectively (Figure 3-5).  
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Release Profile of Ibuprofen in Spherical Eye Model under Static Conditions 
 
Figure 3-5: Release profiles of ibu from SiO in spherical eye model. Release presented as 
cumulative percentage release of Ibu into PBS over time at RT (circles) and 37⁰C (squares). 
Data presented as mean ± 1SD, n=6. * p = 0.0013 (Repeated measures Two-way ANOVA; 
Bonferroni post hoc test). 
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3.2.4.3 RELEASE OF IBUPROFEN FROM SPHERICAL MODEL UNDER LAMINAR FLOW 
Fresh PBS was continuously perfused through the system at different flow rates and the 
concentration of ibuprofen released into the PBS was measured. At each time point the flow 
was stopped and the PBS from inside the spherical model was removed and the 
concentration of ibuprofen measured. 
At the lowest flow rate, 20µL/min, the concentration in the PBS rose to a peak over the first 
8 hours after which there was a small drop in concentration by 24 hours followed by a 
continuous decrease up to 72 hours. At 200µL/min, the concentration peaked at 4 hours 
after which there was an immediate steep elimination phase up to 24 hours where the 
concentration in the PBS was close to zero. This trend was followed for 400µL/min also, 
however the time to reach the peak concentration of 40.4µg/mL was only 2 hours.  For 
2mL/min, the peak concentration was also reached after 2 hours but the elimination of the 
drug from the aqueous phase appeared to be complete by 8 hours. 
The peak concentrations followed the same pattern as seen in the Kirkstall QV600 
experiments described in 2.2.3.4. The highest peak concentration was seen under 20µL/min, 
which reached Cmax=132µg/mL compared with 2mL/min which reached a peak of only 
24.5µg/mL. The difference between 200µL/min and 400µL/min was not as extreme with the 
Cmax=49.6 and 40.4µg/mL (Figure 3-6). 
3.2.4.4 STATIC VS SACCADIC SIMULATION RELEASE OF IBUPROFEN IN SPHERICAL EYE MODEL 
Saccadic eye movements occur at a frequency of approximately 0.5Hz in the human adult 
eye and this movement will influence the aqueous flow around the silicone oil tamponade 
and thus affect the release of drugs. These saccadic movements were simulated using a 
mechanical device which allows a specific velocity profile to be defined and produces 
movements which reflect the in vivo environment.  
The percentage release in both the static experiments and those exposed to saccadic 
movements reached near saturation limit (44.4%) after 72 hours with percentage release 
reaching 43.7% in the saccadic models and 41.0% in the static models. The burst release was 
more apparent in the experiments exposed to motion with 32.6% released after 24 hours 
compared with just 24.2% in the static models. When tested with a repeated measures 
ANOVA with group (static vs saccade) as a between and time as a within-subjects factor, 
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group returned a statistically significant main effect (F (1, 5) = 11.79, p = 0.018), time also did 
(F (2, 10) = 77.87, p < 0.0001) but the time x group interaction was not statistically significant 
(F (2, 10) = 1.49, p = 0.272). Bonferroni’s post hoc test indicated that the only significant 
difference in percentage release was seen after 24 hours (p=0.016). (Figure 3-7).  
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Concentration Profiles of Ibuprofen released from Silicone Oil in Spherical Eye Model 
exposed to different Flow Rates 
Figure 3-6: Concentration profiles of ibuprofen released from silicone oil into aqueous 
phase in spherical eye model exposed to flow rates (a,b) 20µL/min, (c,d) 200µL/min, (e,f) 
400µL/min and (g) 2mL/min. Data presented as mean ± 1 SD, n=6.  
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Concentration Curve Statistics of Ibuprofen released from Silicone Oil into Aqueous 
Phase in Spherical Eye Model exposed to different Flow Rates 
Table 3-1: Concentration curve statistics for Ibuprofen released from silicone oil exposed to 
flow rates of 20µL/min, 200µL/min, 400µL/min and 2mL/min. 2mL/min only conducted 
over 8 hours therefore AUC and Cave are not comparable with other flow rates. 
 
  
Flow Rate 
Area under 
Curve 
(AUC, 
µg.hr/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
20µL/min 5183 132 8 56.5 
200µL/min 521.0 49.6 4 17.8 
400µL/min 262.7 40.41 2 11.6 
2mL/min 98.8 25.5 2 10.21 
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Concentration Profiles of Ibuprofen released from Silicone Oil in Spherical Eye Model 
exposed to Saccadic Simulation 
 
Figure 3-7: Release profiles of ibu from SiO in spherical eye model under static conditions 
(black) and saccadic simulation (green). Release presented as cumulative percentage 
release of Ibu into PBS over time. Data presented as mean ± 1 SD, n=6. * p = 0.016 (Two-
way ANOVA; Bonferroni post hoc test). 
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3.2.4.5 STATIC VS SACCADIC SIMULATION R RELEASE OF IBUPROFEN IN EYE-ON-A-CHIP MODEL 
The same movement patterns used on the spherical eye model were also investigated in the 
eye-on-a-chip (EOC) device. The EOC held different volume ratios in comparison to the 
spherical eye models with 600µL of ibu-SiO in the central chamber and 100µL of PBS in the 
channels. This put the saturation limit in the PBS at 41.6% release. Alongside the studies into 
saccadic motion effects, the release under non-saturation conditions were also investigated 
with the PBS phase replenished every 24 hrs. For both studies, the percentage release failed 
to reach saturation limit by 72 hours and so the studies were extended to look at the release 
over 7 days (168 hours). 
In the experiments where only the sample volume was replaced every 24 hours, a repeated 
measures ANOVA was conducted using group (static vs saccade) as a between and time as a 
within-subjects factor. Group returned a statistically significant main effect (F (1, 5) = 58.44, 
p = 0.0006), time also did (F (3, 15) =120.6, p < 0.0001) but the group x temperature 
interaction was not statistically significant (F (3, 15) = 1.56, p = 0.240). Release at both 
temperatures reached near saturation after 72 hours, 41% and 42.5% for RT and 37⁰C 
respectively and Bonferroni’s post hoc test indicated there was a significant difference in the 
release percentage at each time point excluding over the first 24 hours (48 hrs, p = 0.0097. 
72 hrs, p = 0.0016. 168 hrs, p = 0.0004). This is the opposite trend to that seen in the spherical 
eye model in the previous section. At 24 hours, percentage release reached in the saccadic 
models was 12.0% compared with 7.1% in the static models. After 168 hours, the static 
models had still failed to reach the saturation limit of 41.6% with only 28.8% released, 
whereas the chips exposed to saccadic motion had reached a mean cumulative percentage 
release of 40.5% (Figure 3-8). 
A repeated measures ANOVA was conducted using group (static vs saccade) as a between 
and time as a within-subjects factor for chips which had the PBS replenished every 24 hours. 
Group returned a statistically significant main effect (F (1, 5) = 12.79, p = 0.0186), time also 
did (F (2, 10) =78.90, p < 0.0001) but the group x temperature interaction was not statistically 
significant (F (2, 10) = 1.478, p = 0.274). Bonferroni’s post hoc test revealed a statistically 
significant difference (p=0.0129) in release after 24 hours with 12.7% ibuprofen released 
following saccadic simulation in comparison to just 8.3% release in the static  models. 
However, for each time point after 24 hours, the release of ibuprofen under both conditions 
showed the same pattern with a slight decrease in cumulative percentage release in the 
  Chapter 3 
186 
 
static models and no statistically significant difference between the two(48 hrs, p = 0.846. 72 
hrs, p = 0.648. 168 hrs, p = 0.269) . Given that the PBS was replenished daily, the saturation 
limit was not reached. Interestingly, even after 168 hours neither condition reached 100% 
release of ibuprofen, the cumulative percentage release only reached 57.7 and 51.7% for 
static and saccadic conditions respectively (Figure 3-9).  
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Concentration Profiles of Ibuprofen released from Silicone Oil in Eye-on-a-Chip Model 
exposed to Saccadic Simulation 
Figure 3-8: Release profiles of ibu from SiO in eye-on-a-chip model under static conditions 
(black) and saccadic simulation (green). Release presented as cumulative percentage 
release of Ibu into non-replenished PBS over time. Data presented as mean ± 1 SD, n=9. * 
p < 0.01, **p < 0.001 (Repeated measures Two-way ANOVA; Bonferroni post hoc test). 
Figure 3-9: Release profiles of ibu from SiO in eye-on-a-chip model under static conditions 
(black) and saccadic simulation (green). Release presented as cumulative percentage 
release of Ibu into PBS replenished every 24 hrs over time. Data presented as mean ± 1 SD, 
n=9. *p < 0.01 (Repeated measures Two-way ANOVA; Bonferroni post hoc test).  
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3.3 COMPUTATIONAL MODEL OF AQUEOUS OUTFLOW 
As in chapter 2, all of the computational analysis in this study was conducted using COMSOL 
Multiphysics software. The data from the in vitro models above were used to validate the 
computer simulations described in this section, however, modelling of the simulated 
saccadic motions was not investigated to due limitations of time, therefore only the static 
release in the spherical model and EOC was studied as well as the laminar flow studies in the 
spherical model. Future work would be needed to investigate the implementation of the 
saccadic velocity profile into the COMSOL Multiphysics simulations. Again, by building a 
computational model using experimentally derived data and boundary conditions it is 
possible to predict and optimise the conditions of the drug release studies. These computer 
models could be valuable tools for a more time and cost effective method for developing this 
drug delivery method. 
3.3.1 METHODS 
3.3.1.1 PHYSICAL AND MATHEMATICAL DESCRIPTION OF THE AQUEOUS OUTFLOW MODELS 
Spherical Eye Model 
The model built was based on a two-dimensional (2D) projection of the spherical eye model 
using COMSOL Multiphysics finite element analysis software. Using the schematic diagrams, 
the input geometry was built within the software (Figure 3-10). The models were composed 
of two physics elements: (1) a laminar flow interface, to compute the velocity flow and 
pressure fields of the fluid flow that occurs across the spherical chamber, and (2) a diluted 
species interface, which is able to calculate the concentration field of a dilute solute in a 
solvent i.e. the ibuprofen release from the silicone oil into PBS. These simulations required 
the use of the laminar flow moving mesh physics interface to track the movement of the 
interface between the silicone oil phase and the aqueous PBS phase within the spherical 
chamber, this physics interface was previously discussed in section 2.3.1.5. 
The transport of diluted species physics used in these models follows the same principles as 
described in 2.3.1.5. The simulation solves for the diffusion and convection in the two 
different fluids. An additional expression for the partition coefficient is included in the mass 
transport between the two phases. To satisfy the convective terms of the mass balance 
equation, the solution for the laminar flow, moving mesh physics node was used to describe 
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the velocity field in the model in order to solve for the concentration filed of the ibuprofen 
across the model. 
Eye-on-a-Chip Model 
Only the static studies were conducted for the eye-on-a-chip (EOC) model in the 
computational simulations. This made the physics of the model less complex as no laminar 
flow interface was required. The solution for the EOC model was, therefore, purely based on 
the transport of diluted species physics interface. Also, given the complex geometry of the 
model, it was not able to be built within the software so the geometry was imported into 
COMSOL from the CAD file originally used for laser engraving the chips (Figure 3-11).  
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COMSOL Geometry for the Spherical Eye Model and Eye-on-a-Chip Model 
Figure 3-10: Input geometry for spherical eye model. 
 
Figure 3-11: Input geometry for eye-on-a-chip model. 
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3.3.1.2 INPUT PARAMETERS FOR IBUPROFEN RELEASE EXPERIMENTS 
The input parameters were either defined experimentally or calculated. The values for the 
partition coefficient of Ibuprofen and the interfacial tension of 1000 c.st silicone oil and PBS 
were taken from the literature. All the input parameters used for both the spherical eye 
model and eye-on-a-chip model were identical to those used in the ibuprofen release 
simulations in the Kirkstall QV600 model from chapter 2. This is because all of the 
components and physics systems of each of the models were identical, it was just the 
geometries which were different. Therefore the input parameters for spherical model and 
EOC can be found in chapter 2, Table 2-22. 
3.3.1.3 BOUNDARY CONDITIONS USED FOR IBUPROFEN RELEASE EXPERIMENTS 
The boundary conditions used in the spherical eye model were the same as were applied in 
the Kirkstall QV600 geometry (2.3.1.8). No slip conditions were applied to the exterior 
boundary walls and those walls in contact with the fluid-fluid interface were assigned a 
Navier slip condition. This condition allows the fluid-fluid interface to move along the wall.  
The inlet was assigned to the left hand port and outlet to the right and the conditions were 
as previously describes and the same flow rates were investigated as with the Kirkstall 
QV600: 20µL/min, 200µL/min, 400µL/min and 2mL/min. A volume force was also 
implemented across the entire geometry to account for gravity in the system. 
Both the spherical eye model and EOC used two transport of diluted species nodes to 
investigate the release of ibuprofen from the silicone oil: one for the oil phase and one for 
the aqueous phase. As in the previous model, a no flux condition was applied on the exterior 
boundary walls of the geometry. An outflow condition was applied to the right hand wall of 
the outlet port of the chamber to allow the removal of ibuprofen via the fluid flow field. The 
appropriate diffusion coefficients as described in Table 2-22 were applied to each fluid 
domain and a pointwise constraint equal to that previously described was applied at the 
fluid-fluid interface. This pointwise constraint takes into account the concentration at the 
interfaces and solves for the mass flux across that boundary using a function of the 
concentration gradient and the partition coefficient. 
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3.3.1.4 MESH USED FOR SPHERICAL EYE MODEL AND EYE-ON-A-CHIP MODEL 
For the spherical eye model release studies, the mesh was made up of 17510 free triangular 
elements (Figure 3-12). A grid independence test was carried out to ensure the mesh was 
refined enough to produce accurate results. The velocity at two points within the well was 
compared across a range of increasingly finer meshes to evaluate the accuracy of the results 
compared with the finest mesh. A percentage error of 5% or less compared with the finest 
mesh was deemed sufficiently accurate. This was achieved at 17510 elements and this mesh 
was used for all spherical eye model simulations. 
Again, for the EOC a grid independence test was carried out. The concentration at two points 
within the centre of the chamber were compared across a range of mesh element numbers 
from an extremely coarse mesh of 944 elements to an extremely fine mesh of 14383 
elements. The percentage different in concentration at the two points compared with the 
most refined mesh was used to evaluate the accuracy of the results. A percentage error of 
5% or less was deemed accurate enough. This was reached at 4345 elements and this mesh 
was used for all the following simulations (Figure 3-13). 
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Meshes generated for Spherical Eye Model and Eye-on-a-Chip Model 
Figure 3-12: Mesh generated for spherical eye model used in ibuprofen release simulations. 
Mesh consists of 17510 free triangular elements. 
 
Figure 3-13: Mesh generated for eye-on-a-chip model used in ibuprofen release 
simulations. Mesh consists of 4345 free triangular elements.  
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3.3.2 RESULTS 
3.3.2.1 GRID INDEPENDENCE TESTS 
Analysing the effects of altering the density of the meshes allows for a suitable mesh to be 
built that minimises the number of elements to save on computational power, and therefore 
time needed to produce a solution, without compromising on the accuracy of the results.  
The simulations were run at decreasing mesh densities and the value of the velocities 
(spherical eye model) or concentrations (EOC model) at two points within the model were 
compared to the finest mesh and the density at which the error between the solutions and 
the solutions of the finest mesh reached ≤5% were determined to have reached an 
acceptable solution. 
As with the Kirkstall QV600 model, the percentage difference in solution decreases with 
increasing number of elements in the mesh. For the spherical eye model, the least dense 
mesh consisted of 506 elements and the densest mesh consisted of 17510 elements. None 
of the less refined meshes produced velocity results within the accuracy limit in comparison 
with the finest mess, therefore the mesh which was used consisted of 17510 elements 
(Figure 3-14). 
With the eye-on-a-chip model, all of the less dense meshes produced concentration results 
within 5% of the finest mesh for a point within the oil domain of the model, however, it was 
only when the mesh was refined to 4345 elements that the results for a point in the aqueous 
phase of the model fell below the error limit. This mesh was used for the remaining 
simulations (Figure 3-15). 
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Grid Independence Tests for Ibuprofen Release Studies in Spherical Eye Model and EOC 
 
Figure 3-14: Percentage difference in velocity at two points in the centre of the spherical 
eye model compared with the finest mesh (17510 elements). A <5% error was deemed to 
be acceptable mesh density. 
Figure 3-15: Percentage difference in velocity at two points in the centre of the eye-on-a-
chip compared with the finest mesh (14383 elements). A <5% error was deemed to be 
acceptable mesh density. 
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3.3.2.2 STATIC RELEASE PROFILES IN SPHERICAL EYE MODEL 
The concentration profile of ibuprofen was plotted graphically to determine the points of 
highest concentration and the percentage release of ibuprofen was compared to the in vitro 
results for validation. 
Ibuprofen distribution in the oil domain showed release from the periphery of the silicone 
oil bubble with the concentration decreasing to the centre of the bubble over time, excluding 
the portion of the bubble that was in contact with the wall of the sphere, which maintains 
the highest concentration of ibuprofen within the oil domain at each time point. In the 
aqueous phase, the distribution of ibuprofen was concentrated in the ‘corners’ of the model 
in the region of the geometry with the smallest surface area. Over time, the distribution 
moves down towards the bottom of the aqueous phase as well as spreading further down 
the ports of the geometry (Figure 3-16A).  
Comparing the release profiles of the in vitro and simulated results, the difference in 
percentage release was 3.6%, 0.9% and 0.6% for 24hr, 48hr and 72hr respectively. Both 
conditions neared the saturation limit (44.6%) after 72 hours, 41.0% for the in vitro data and 
41.6% in the simulation. The simulated data also suggested a sharp release of ibuprofen over 
the first 5 hours (Figure 3-16B). Further in vitro experiments need to be done to investigate 
the release profile over these shorter time periods. 
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Simulation vs Experimental Release Profile of Ibuprofen Release in Static Spherical Eye 
Model  
Figure 3-16: (a) Concentration field solution for ibuprofen concentration across the 
spherical eye model at 0, 24, 48 and 72 hr. Colour scale bar indicates concentration in 
mol/m3. (b) Experimental (black) vs simulated (blue) release profiles of ibuprofen in 
aqueous phase of static spherical eye model. Experimental data presented as mean 
cumulative release ± 1 SD, n = 6.  
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3.3.2.3 DEVELOPMENT OF VELOCITY PROFILES IN SPHERICAL EYE MODEL 
Inlet flow rates of 20µL/min, 200µL/min, 400µL/min and 2mL/min were investigated in the 
simulations to coincide with the in vitro experiments. For each flow rate, the streamlines 
showed the flow field forming a steady stream from inlet to outlet in the aqueous phase 
around the silicone oil bubble. With increasing inlet flow rate, the peak velocities within the 
geometry increased but the stream beneath the silicone oil bubble is maintained. At the 
‘corners’ between the aqueous and oil phase there were small regions of recirculating 
aqueous which became more influenced by the main stream of flow as the flow rate 
increased. At the highest flow rate, 2mL/min, secondary flows started to form at the exit 
point of the inlet port and the force of the fluid flow out of the inlet port pushed the silicone 
bubble towards the outlet (Figure 3-17).  
Within the silicone oil domain, there appeared to be a very low velocity circulation. At 
20µL/min this circulation is split across the oil domain. As the inlet flow rate increased, the 
center of the circulation shifts further towards the outlet whilst maintaining its uniformity 
through the domain. The circulation velocity is much lower in comparison to the main stream 
of flow through the system. 
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Velocity Fields of Different Flow Rates in the Spherical Eye model 
 
 
Figure 3-17: Velocity fields for different inlet flow rates used in the spherical eye model 
geometry for ibuprofen release studies. Inlet flow rates: (a) 20µL/min, (b) 200µL/min, (c) 
400µL/min and (d) 2mL/min. Colour scale bar indicates velocity (m/s). Streamlines show 
velocity field. 
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3.3.2.4 CONCENTRATION PROFILES OF IBUPROFEN IN SPHERICAL EYE MODEL EXPOSED TO VARYING FLOW 
RATES 
The concentration in the aqueous phase of the spherical model showed similar profile 
patterns as observed in the Kirkstall QV600 chamber at the respective inlet flow rates. The 
simulations were run over 72hrs, but in each case, the defining features of the concentration 
profiles were observed over the first 24 hours. Each flow rate showed the concentration of 
ibuprofen within the silicone oil domain decreasing over time with the diffusion occurring 
from a central point which appeared to be defined by the centre of the flow circulation within 
the oil domain shown in section 3.3.2.3 (Figure 3-17).  
At 20µL/min, in the ‘corner’ areas, the ibuprofen concentration becomes trapped in the 
recirculating flow and is not cleared via the main stream of flow. The diffusion within the oil 
domain is focussed around two concentration centres which match the centres of the 
circulating flow within the oil. Over time, ibuprofen is released from the oil domain and 
cleared from the system in the main stream of flow via the outlet port, however, the 
concentration in the main flow stream is extremely low in comparison with other regions of 
the system (Figure 3-18A). The concentration data from within the aqueous phase shows the 
same profile pattern as the in vitro data. There is a rise in ibuprofen concentration in the PBS 
up to 13 hours, after which the elimination phase begins and the drug is cleared from the 
system. The simulated peak concentration reached 128µg/mL, a 3% decrease in comparison 
to the in vitro data (Figure 3-18B). 
For 200µL, 400µL and 2mL/min, there was a spike in concentration, reached after 5hr, 3hr 
and 2hr respectively. Following the spike, the elimination phase began. For each flow rate, 
the simulated data produced Cmax results within 20% of the in vitro values and the Tmax data 
was within one hour.  
The concentration fields showed similar patterns to the 20µL/min fields. The region at the 
‘corners’ had increased concentration where ibuprofen had become trapped in the 
secondary recirculating flow. The diffusion of ibuprofen from the silicone oil was targeted 
around the point where the centre of the circulating flow within the oil was positioned. As 
the flow was increased, this centre shifted further towards the outlet (Figure 3-19, Figure 
3-20 and Figure 3-21). Only at 2mL/min after 72hrs does the ibuprofen appear to be 
completely cleared from the silicone oil bubble (Figure 3-21). 
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Concentration Fields and Receptor Domain Profile of Ibuprofen in the Spherical Eye 
Model at 20µL/min 
 
Figure 3-18: (a) Concentration field solution for ibuprofen concentration across the 
spherical eye model at 0, 24, 48 and 72 hr. Colour scale bar indicates concentration in 
mol/m3. (b) Experimental vs simulated concentration profiles of ibuprofen in aqueous 
phase of spherical eye model. Flow rate = 20µL/min. Experimental data presented as mean 
concentration ± 1 SD, n = 6.  
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Concentration Fields and Receptor Domain Profile of Ibuprofen in the Spherical Eye 
Model at 200µL/min 
 
Figure 3-19: (a) Concentration field solution for ibuprofen concentration across the 
spherical eye model at 0, 24, 48 and 72 hr. Colour scale bar indicates concentration in 
mol/m3. (b) Experimental vs simulated concentration profiles of ibuprofen in aqueous 
phase of spherical eye model. Flow rate = 200µL/min. Experimental data presented as 
mean concentration ± 1 SD, n = 6. 
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Concentration Fields and Receptor Domain Profile of Ibuprofen in the Spherical Eye 
Model at 400µL/min 
 
Figure 3-20: (a) Concentration field solution for ibuprofen concentration across the 
spherical eye model at 0, 24, 48 and 72 hr. Colour scale bar indicates concentration in 
mol/m3. (b) Experimental vs simulated concentration profiles of ibuprofen in aqueous 
phase of spherical eye model. Flow rate = 400µL/min. Experimental data presented as 
mean concentration ± 1 SD, n = 6. 
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Concentration Fields and Receptor Domain Profile of Ibuprofen in the Spherical Eye 
Model at 2mL/min 
 
 
Figure 3-21: (a) Concentration field solution for ibuprofen concentration across the 
spherical eye model at 0, 24, 48 and 72 hr. Colour scale bar indicates concentration in 
mol/m3. (b) Experimental vs simulated concentration profiles of ibuprofen in aqueous 
phase of spherical eye model. Flow rate = 2mL/min. Experimental data presented as mean 
concentration ± 1 SD, n = 6. 
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Concentration Curve Statistics for Simulated vs Experimental Dextran Transport 
Studies across Seeded Membranes at 200µL/min 
Table 3-2: Concentration curve statistics for ibuprofen release from silicone oil in spherical 
eye model exposed to a flow rate of 20µL/min. 
Table 3-3: Concentration curve statistics for ibuprofen release from silicone oil in spherical 
eye model exposed to a flow rate of 200µL/min. 
Table 3-4: Concentration curve statistics for ibuprofen release from silicone oil in spherical 
eye model exposed to a flow rate of 400µL/min. 
Table 3-5: Concentration curve statistics for ibuprofen release from silicone oil in spherical 
eye model exposed to a flow rate of 2mL/min. 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 5103 132 8 56.5 
Simulation 4439 128 13 59.9 
 
Area under 
Curve 
(AUC, 
µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 521 50.0 4 17.8 
Simulation 545 55.9 5 7.5 
 
Area under 
Curve 
(AUC, µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 262 40.4 2 11.6 
Simulation 257 48.1 3 3.5 
 
Area under 
Curve 
(AUC, µg.h/mL) 
Peak 
Concentration 
(Cmax, µg/mL) 
Time of Peak 
Concentration 
(tmax, hr) 
Average 
Concentration 
(Cave, µg/mL) 
Experimental 98.8 25.5 2 10.2 
Simulation 177.1 31.1 2 2.4 
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3.3.2.5 STATIC RELEASE PROFILES IN EYE-ON-A-CHIP MODEL 
The static release of ibuprofen was also evaluated in the EOC model. As in the static results 
for the spherical eye model, the ibuprofen diffuses out from the centre of the silicone oil 
bubble. The concentration initially decreases at the periphery and the highest concentration 
is maintained at the centre of the oil domain, over time the region of high concentration 
decreases in size as the ibuprofen moves into the aqueous phase. The concentration in the 
aqueous phase increases over time but appears to be constant across that phase of the 
model. After simulating 7 days of diffusion, the percentage release appears to plateau 
however the plateau is reached well before the 41% saturation limit. The release profile 
shows a greater burst release than that observed from the in vitro data which has an almost 
linear release pattern in comparison. The differences in percent release were 236%, 110%, 
67% and 12% for 24, 48, 72 and 168hr respectively ( 
Figure 3-22). 
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Concentration Fields across EOC Model over 7 days 
 
Figure 3-22: (a) Concentration field solution for ibuprofen concentration across the eye-on-
a-chip model at 0, 24, 48, 72 and 168 hr. Colour scale bar indicates concentration in mol/m3. 
(b) Experimental vs simulated concentration profiles of ibuprofen in aqueous phase of EOC 
model. Experimental data presented as mean concentration ± 1 SD, n = 9. 
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3.4 DISCUSSION 
Following a vitrectomy and the replacement of the vitreous humour with a silicone oil 
tamponade, any remaining void within the vitreous cavity is replaced with aqueous humour 
which migrates from the anterior segment of the eye. The interaction between these two 
liquid phases, the silicone oil tamponade and aqueous humour, could have implications for 
the release of any drugs solubilised within the oil phase.  
Utilising the silicone oil tamponade as a drug reservoir, it is expected that once any drug is 
released from the oil it will undergo the same clearance mechanisms as drugs injected 
intravitreally, i.e. anteriorly via aqueous outflow or posteriorly through the blood retina 
barrier. Bulk flow of aqueous humour within both segments of the eye and its subsequent 
drainage has been shown to act as a major drug elimination route following intravitreal 
injections [229]. Dynamic factors such as this produce some of the greatest barriers to drug 
delivery in the posterior segment and are often overlooked in in vitro models. The spherical 
eye model used in these studies was initially designed to investigate contact angles and 
interfacial tensions of substances used for tamponades in retinal detachment surgery [222]. 
The spherical geometry and presence of inlet and outlets ports made an appropriate model 
for evaluating aqueous flow around the ibuprofen-silicone oil tamponade and ultimately the 
clearance of ibuprofen away from the oil.  
Dye studies were conducted to illustrate the flow profile within the model with a range of 
flow rates from 20µL/min to 20mL/min. These studies showed that at lower flow rates 
(20µL/min to 2mL/min), the aqueous fluid, in this case PBS, flowed circumferentially around 
the silicone oil from the inlet port to the outlet port, with the dye ultimately diffusing 
throughout the entire aqueous phase. The pattern of fluid flow was comparable for each of 
the lower flow rates however the velocities within the model were obviously greater as flow 
rate increased, indicated by the dye reaching the outlet of the model in less time. The flow 
profiles broadly mimic the mass transfer within the model and show the path that any 
ibuprofen released from the silicone oil would be expected to take through the model. The 
consistency of the flow profiles at lower flow rates could be an important factor to consider 
when comparing the model with the in vivo environment. Secretion of aqueous from the 
ciliary body into the vitreous in vivo is reported to occur at a rate of 2-3µL/min [96, 230, 231], 
the lowest flow rate investigated in these studies was 20µL/min. One of the limitations of 
using a syringe pump to generate the flow is that they are displacement controlled devices 
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which use micro-stepping motors and therefore producing a consistently precise flow field is 
difficult, particularly at very low flow rates. Similar problems are observed with peristaltic 
pumps, therefore flow rates from 20µL/min to 2mL/min were selected to provide consistent 
smooth flow which could be generated with both pump types to allow comparison across 
the models. Using the systematic data collected across these flow rates it could be possible 
to extrapolate the data to gain an understanding of the flow profiles at lower flow rates such 
as 2µL/min. The highest flow rate investigated, 20mL/min, produced a fluid flow force which 
caused the silicone oil bubble to be removed from the system. This unrealistically high flow 
rate was not used in any drug release studies but was used to illustrate the destruction of 
the system.  
The flow profiles produced in the in vitro models were able to be reproduced by the 
computational simulations. Qualitatively, the simulated flow profiles showed the same 
circumferential flow around the tamponade from inlet to outlet but one of the advantages 
of the computational models is they are able to provide more information about the profile 
which is unable to be seen in the in vitro experiments. Technologies such as PIV discussed in 
chapter 2 are available to visualise flow fields, however this was outside of the scope of the 
project. From the streamlines present in the simulated data, stagnant areas of recirculating 
aqueous can be observed between the main stream of flow and the point at which the 
silicone oil is in contact with the walls of the sphere, excluding the aqueous from the top 
region of the geometry. These secondary flows appear to have no interaction with the 
primary stream of flow, this is important in terms of clearance of ibuprofen from these 
regions. From the corresponding concentration projections it can be seen, particularly at 
20µL/min, that where the flow is recirculating in the velocity profile, the concentration of 
ibuprofen is very high. This suggests, that once released from the silicone oil tamponade, the 
ibuprofen becomes trapped and accumulates in these areas. As the flow rate increases, this 
accumulation is dissipated and the concentration of ibuprofen is completely removed from 
the aqueous phase of the system. Given that the flow rates of aqueous in the eye are very 
low, should any stagnant areas of aqueous flow present themselves, there is a risk that drug 
accumulation could occur within these regions which could ultimately lead to toxicity in the 
adjacent tissues.  
Within the EOC device, these regions of accumulation did not present in the computer 
simulations. This is surprising, particularly at the point at which the oil meets the wall of the 
device which produces a ‘corner’ region where one would expect a build up to occur. In 
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addition, the percentage error between the simulated and in vitro results for release of 
ibuprofen were very high in this model.  Although the simulated percentage release achieved 
at the final time point was within 12% of the in vitro results, the profile of release up to that 
point was not comparable. It is possible that this could be attributed to the method of input 
geometry for this particular device. For the model simulations of the Kirkstall QV600 and the 
spherical eye model, the geometry was built within the COMSOL Multiphysics software 
based on dimensions from schematic diagrams. The geometry for the EOC model was 
imported from a CAD file used to manufacture the chips. Following the import of the 
geometry, it appears resolution is lost between the micro-channels of the chip which in vitro 
have a width of 100µm. In the simulation geometry it is clear that these micro-channels have 
a much greater width which therefore increases the interfacial contact area of the SiO and 
aqueous phase which we have previously shown increases the rate of diffusion in the model 
as seen by the results for release within the well plates. One limitation of the software is that 
it is difficult to create very complex and intricate geometries within the software itself and it 
is therefore useful that CAD files are able to be imported. However in this instance, resolution 
of small scale features was lost. In the future it would be necessary to create the intricate 
EOC geometry within the COMSOL software to ensure accuracy in its assembly and produce 
results within a smaller error of the experimental data.  
With the spherical eye model, which is a much simpler geometry, the simulation was able to 
produce results within 5% of the in vitro data for static experiments and 20% for the flow 
conditions. For most of the experimental conditions, the simulation overestimated the Cmax 
in each case, with the exception of the 20µL/min conditions which predicted a Cmax 3% lower. 
Similar observations occur in work presented by Kavousanakis et al., and Jooybar et al. who 
model the distribution of drugs within the posterior segment of eye following intravitreal 
injection or sub-scleral implantation [131, 132]. Although the technologies are different, 
similar physics methods are used to solve the computational models and both report an 
overestimation in Cmax for the drugs used in comparison with experimental data of 
fluorescein kinetics in the vitreous, provided by Palastine and Brubaker [135]. For use as a 
predictive tool in the development of this drug delivery technology, which hopefully can 
minimise the use of animal models in any future work, it seems more beneficial for the model 
to produce an over prediction within the accepted range in error as opposed to an 
underestimation as administering a potential toxic dose would have greater consequences 
than a potential sub-therepeutic dose. 
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The flow mechanics of the vitreous chamber have been studied before both theoretically 
and experimentally using chambers similar to the spherical eye model used in this study. The 
majority of these studies investigate the effects of saccadic movements on the fluid dynamics 
of the vitreous cavity. Saccades are quick movements of the eye that abruptly change the 
point of fixation and as such are thought to have the most important role in inducing motion 
in the vitreous chamber [220]. The following have been identified as the characteristic 
features of a saccadic eye movement: (1) very high angular acceleration, (2) less severe 
deceleration but effective halting of the movement, (3) a peak angular velocity between 400-
600˚s-1 [232].  David et al. conducted a theoretical investigation into the effects of small 
oscillatory movements of the eyeball on movement of the vitreous. They found that for low 
frequencies of rotation, the vitreous would act as a solid body under motion, as the 
frequency increases the centre of the sphere would remain stationary with increasing motion 
as you move out radially from the centre [233]. The results of this study were used by Repetto 
et al. as a comparison for the observations in flow profiles within their spherical, poly(methyl 
methacrylate) model of the vitreous chamber under simulated saccadic eye movements 
[234]. After reaching satisfactory agreement between the theoretical and experimental data, 
they proceeded to conduct further theoretical studies in to the effect of these movements 
on other potential vitreous fluids such as silicone oil. The result of this study suggested that 
using low viscosity silicone oils as tamponade agents reduced the shear stress effects on the 
wall of their model caused by saccadic motion and would minimise stress on the retina 
following tamponade placement [234]. Similarly, Chen et al. have used a poly(methyl 
methacrylate) spherical eye chamber in studies which investigate the flow of heavy SiO and 
emulsification of different viscosity SiO during simulated saccadic eye movements [227, 235]. 
The chambers used in these studies were spherical in design as with the model used in this 
study. In reality the vitreous chamber is not perfectly spherical and a major geometrical 
feature is the indentation caused by the position of the lens within the eye. Stocchino et al. 
used an experimental set up based on the work of Repetto et al. [234] but modified their eye 
chamber to exhibit this indentation feature. They found that inclusion of the indent caused 
an additional circulation stream to form within the vitreous cavity fluid, at the back of the 
indentation [236]. This additional flow feature could result in an altered distribution of ibu 
within the SiO and so in future it would be interesting to study these effects in a more 
geometrically accurate eye model. One other model, known as the PK-Eye model, was 
designed by Awaad et al. and included both an anterior and posterior chamber in an attempt 
to investigate ocular drug clearance via the anterior aqueous outflow pathway. This model 
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had a posterior cavity and anterior cavity separated by dialysis membrane and they 
conducted dye studies to show the flow regime after either injection into the posterior 
region or anterior region and clearance through the anterior segment. This model did not 
account for lens indentation but did show that dye would not penetrate into the anterior 
chamber unless flow was present to clear it away [114]..  
The saccadic movement profile used in our study was based on the one described by Chan 
et al. used to investigate emulsification effects on silicone oils [226]. The profile is described 
in section 3.2.3.4, and the comparison with typical saccades observed in healthy human 
adults is shown in Table 3-3.This movement pattern was used to observe differences in the 
percentage release of ibu from SiO when exposed to saccadic movements in comparison to 
static controls. In the spherical eye model there was an increase in percentage release of the 
drug over each 24 hour time point when exposed to saccadic simulation, however the only 
statistically significant difference was seen at 24 hours with 8.4% more released in the 
moving samples compared with the static models. It was expected that the saccadic 
movements would increase the rate at which ibu was released as the mechanical action of 
the motion moves the aqueous more around the silicone oil bolus and therefore transports 
ibu already released into the aqueous away from the source of the concentration, i.e. the 
SiO, into the bulk of the aqueous phase and maintains a greater concentration gradient at 
the interface of the two phases. The effects of the saccadic motion were more obvious in the 
results observed in the EOC model where there was a statistically significant increase in 
percentage release of ibu at 48, 72 and 168 hours. Given the dimensions of the micro-
channels within the chip device, it is possible that the physical movement of the aqueous 
phase which the saccadic simulation provides, clears these micro-channels of ibu which could 
accumulate within them, and moves it into the outer perfusion channel. A limitation of this 
system, is that natural human saccadic motion is not periodical and the amplitude of the 
movement can vary from very small, such as when we reading, to very large, looking around 
a room. However it does allow us to investigate the effects of the motion in a controlled and 
reproducible manner. Further studies into the effects of changing the profile of this motion 
on the drug release profile could be interesting to investigate. 
There have been theoretical studies investigating saccadic motion on vitreous movement 
and its implications in drug delivery in the posterior segment. These studies model the 
transport of drug injected into the vitreous humour of humans and the subsequent diffusion 
of the drugs out into other tissues. They predict that dispersion of drugs through the vitreous 
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is much more efficient when exposed to saccadic motion compared to purely diffusion alone 
in a static system [237, 238]. Kathawate et al. actually describe a mathematical model of drug 
diffusion through vitreous substitutes, including silicone oil, but do not include flow induced 
by saccadic motion in their model design. They also model intravitreal injection of the drugs 
into the silicone oil as opposed to simulating the oil as drug reservoir. Their results show that 
diffusion, not convection, is the overriding physics of the system when higher viscosity fluids 
such as SiO are used, however minimal convective terms are used in the model [239]. 
Unfortunately, time restrictions prevented the inclusion of saccadic motion boundary 
conditions into the model generated in this study and so there is no simulated data to 
compare to the experimental work, but in the future I think having a validated predicted 
simulation of ibu distribution within SiO based on the influence of saccadic motion could 
prove a cost and time effective tool to use in the development of this drug delivery system.  
Although the majority of the results presented in this study are within the tolerated 15% 
error between simulated and experimental results, I believe that the consistency could be 
improved and the error reduced by expanding the complexity of the model in to three 
dimensions (3D), which would be the next step in developing the computer models in to 
predictive tools. However this work has been able to produce a computational model of a 
spherical eye model, used in vitro in the development of this novel silicone oil tamponade 
drug delivery device, and validated this model using comparison with relevant experimental 
data. It has also shown that saccadic motion has a role to play in ibuprofen release from 
silicone oil which could be an important consideration taking this technology forward. 
 Human Device 
Amplitudes (˚) 5-15 10 
Max. angular velocity 
(˚/s) 
300-400 390 
Duration (ms) 50 50 
Table 3-3: Characteristics of human saccades vs device simulated saccades. Human values 
from [240, 241]. 
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4.1 DISCUSSION 
The retinal pigmented epithelium (RPE) is a highly specialised monolayer of cells located at 
the back of the retina which plays a vital role in homeostasis and maintenance of the retinal 
tissue. Along with the Bruch’s membrane and choroidal endothelium, it makes up the outer 
blood retinal barrier (OBRB) which is the structure that separates the neural retinal layer 
from the choroidal vasculature and regulates the passage of molecules and waste products 
in and out of the outer retina. Damage to the RPE cell layer can cause a breakdown in the 
barrier function of the OBRB and ultimately lead to sight threatening complications. Retinal 
detachment (RD) is one such condition, whereby the inner neuroretina becomes detached 
from the underlying RPE layer. RD is classified as an ophthalmic emergency and requires 
urgent treatment to avoid further complications and prevent loss of vision. Complications 
can include conditions such as proliferative vitreoretinopathy (PVR), a fibrotic disease in 
which aqueous penetrates the sub-retinal space allowing cytokines and inflammatory factors 
into the wound site which can cause migration of the RPE into the vitreous cavity. In 
complicated or severe cases of RD, the most common treatment method is a vitrectomy 
followed by the insertion of a tamponade to fill the vitreous cavity. The surgery involves 
removing the natural vitreous and replacing it with either a gas or silicone oil tamponade. 
The purpose of the tamponade is to maintain contact with the damaged area of the retina 
and exclude any aqueous from the wound site which could cause an inflammatory response. 
It seems that there is an opportunity for this tamponade system to gain a supplementary 
function as a drug delivery device which could further prevent the likelihood of complications 
developing.  
Silicone oil is currently the only tamponade agent available for long term administration as 
it does not dissipate over time like a gas tamponade does. Utilising the silicone oil tamponade 
as a drug reservoir to provide sustained drug delivery in the posterior segment has been 
studied in the past with varying success. One limitation of this technology is that many of the 
drugs used in the treatment of proliferative diseases are water soluble and therefore poorly 
soluble in SiO. The success of such a drug delivery device is dependent on the compatibility 
of drugs that it can be used with, and whether the device can deliver a therapeutic dose over 
a reasonable period of the necessary treatment time, in the case of PVR this would be 6-8 
weeks [242]. Previous studies have investigated the use of lipophilic drugs such as 5- 
fluoruracil, retinoic acid and α-tocopherol [71, 91, 209, 243]. Ibuprofen is a non-steroidal 
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anti-inflammatory drug (NSAID) which is lipophilic in nature and therefore readily soluble in 
SiO. Solubilising ibuprofen within the SiO could produce a drug delivery reservoir with anti-
inflammatory capabilities. One previous study has investigated the release of ibuprofen from 
a silicone oil tamponade and there is scope to for the study of this technology to be taken 
further [209]. 
One method of analysing the vast range of potential parameters of a system, such as a new 
drug delivery device, in a time and cost effective manner is to implement computational 
simulations.  Finite element analysis (FEM) is a numerical method that has applications in 
solving mathematical physics and engineering problems such as fluid flow and mass 
transport. This method provides analytical solutions for complex systems which are 
described by partial differential equations by dividing the larger system into discrete smaller 
parts, elements. The solutions from the simple equations which describe each element are 
then assembled in to a larger set of equations which are used to provide a solution for the 
entire problem. COMSOL Multiphysics is a finite element analysis simulation software which 
has had widespread use in solving scientific and engineering research problems. One of the 
benefits of this software is its ability to model multiple physics interfaces simultaneously, 
making it ideal to study drug transport under the influence of fluid flow.  
The aim of this study was to design computational simulations based on complementary in 
vitro systems which could accurately predict the in vitro behaviour of a novel tamponade 
drug delivery system. This drug delivery system was designed around 1000c.st silicone oil, a 
material that is currently used in vitreoretinal surgery, with solubilised ibuprofen, an anti-
inflammatory drug commonly used in pain relief. The hypothesis was that computer models 
built using experimentally derived parameters from simple in vitro experiments would be 
able to accurately predict the release behaviour of ibuprofen from silicone oil in more 
complex in vitro experiments across a number of model designs. The rationale behind this 
hypothesis is that numerically based computer simulations have been used for many years 
to analyse complex physical behaviours, including drug transport and delivery, and their 
success is ultimately determined by the accuracy of the input parameters and boundary 
conditions. Therefore obtaining experimentally validated computational simulations of the 
release behaviour of ibu from SiO in a number of in vitro models will allow us to analyse a 
vast range of input parameters in a more time and cost effective fashion and eventually use 
these simulations as predictive tools to further develop this technology in the hope of 
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ultimately contributing to the rapid and cost-effective development of a new drug delivery 
device that is appropriate for clinical use. 
In the present study I was able to create a computer model which showed good agreement 
between simulated and experimental results for the passage of different molecular weight 
dextrans across a model of the outer blood retinal barrier which consisted of a human RPE 
cell line, ARPE-19, and a synthetic Bruch’s membrane replacement, NH3 treated ePTFE. In 
addition to this I was able to show that ARPE-19 cells withstand culture in the presence of 
media flow and, when subjected to flow rates up to 200µL/min, barrier functionality is 
increased compared with static cultures. The results showed however, that there was a 
threshold limit as to the speed of flow which they can withstand. At 400µL/min, there was a 
loss of barrier function and a breakdown in the tight junction network. This breakdown in 
the monolayer barrier obviously had implications for the permeability of dextran across it 
and therefore agreement of the computer simulated and experimental results was 
decreased under these conditions as one of the limitations of the computer model is it does 
not take into account biological changes within the barrier and so assumes a constant 
permeability across each time point. These findings appear to corroborate a previous study 
which cultured ARPE-19 cells under flow. Yeste et al. showed reduced permeability of 
dextran in ARPE-19 cells cultured in a microfluidic chip device with a flow rate of 100µL/min 
[111]. On the contrary, Chen at al. showed no statistically significant difference in dextran 
permeability in ARPE-19 cells cultured under media flowing at a rate of 0.8µL/min in their 
microfluidic device, however the flow rate within this device is so low that it is likely the cells 
are exposed to very little force from the flow [112].  
Using the knowledge gained from modelling the transport of dextran, I was then able to build 
a computer model which could predict the release of ibuprofen from a silicone oil reservoir 
under the same flow rates in two different in vitro models. Within these two models, the 
computer simulated results showed strong agreement with the in vitro data. Similarly, the 
computer model was able to accurately predict the release within static conditions in well 
plates and a spherical eye model. The time scale of study (72 hours) was based on work by 
Cauldbeck et al. who showed that 100% of ibuprofen freely solubilised in silicone oil was 
released after 3 days within a 24-well plate [209]. This study has shown that the time-
dependent percentage release of ibu from SiO varies dependent on the interfacial contact 
area of the silicone oil and aqueous phase, however the computer model can be used to 
predict this release behaviour and can therefore be used as a predictive tool to narrow the 
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range of experimental study required. It is important to consider the geometrical 
requirements of such a drug delivery device which is why three different in vitro models were 
used in this study.  
Each of the in vitro models used in this study have their own advantages and disadvantages 
and utilising all three gives a greater understanding of how the mechanisms of different 
model designs affect ibuprofen release from SiO.  The Kirkstall QV600 chamber provided the 
means of being able to design an OBRB model with RPE cells incorporated to investigate 
permeability of this barrier and transport across it. Although not investigated here, it would 
also allow the same OBRB model to be used to assess the release of ibu from SiO across the 
cell/synthetic BM barrier using the basolateral media flow as an analogy to choroidal blood 
flow. Therefore this system has benefits in modelling the posterior clearance mechanism 
which intravitreal drugs are exposed to in vivo. The disadvantages of this model are that it is 
geometrically inaccurate and currently only explores the permeability limitation provided by 
the RPE and not the choroidal endothelium. The spherical eye model provides a more 
geometrically accurate model of the eye, however it is not designed to accommodate cell 
culture. It could be possible to grow cells within the model in the future, however work would 
need to be done on optimising the attachment of the cells to the walls of the model and 
maintaining sterility could prove difficult. This spherical chamber with the two ports is more 
suitable in modelling the aqueous outflow pathway that intravitreal drugs could follow in 
vivo.  
The computer models of two of these models showed comparable results, however within 
the third model, the eye-on-a-chip device, the results were not as agreeable. The EOC device 
was initial developed to investigate the emulsification of different silicone oils [226]. This 
device provides both a better geometrical representation of the eye and the ability to sustain 
cell culture but in a 2D chip configuration. There seems to be much debate recently regarding 
the suitability of microfluidic chip devices as models but they do have advantages in terms 
of reproducibility and high-throughput nature.  The percentage release at the final time point 
was equal between the simulated and experimental results, however the release profile up 
to that final time point was not equivalent. This could be because the input geometry within 
the computer model did not accurately match the in vitro specification. This further 
highlights the point made previously that the computer model is only as good as the 
information that is applied to it. Previous studies have looked to simulate the release 
mechanics of drugs injected intravitreally within the posterior segment of the eye. The 
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majority of these study the transport of drugs within the natural vitreous of the eye. One 
paper has investigated drug movement in silicone oil within the eye but again only following 
intravitreal injection. These computer models are theoretical and although they employ a 
more geometrically representative model of the eye, the data cannot be experimentally 
validated due to the nature of the study and the requirement to investigate human eyes in 
vivo. Most of these papers base their input parameters on work conducted by Palestine and 
Brubaker who investigated fluorescein kinetics in the vitreous [135] and in order to prove 
the accuracy and reliability of computer models, more experimental data needs to made 
available for comparison. The difficulty in validated computer models of the human eye 
comes from the inability to run in vivo tests for obvious ethical reasons. In vivo tests would 
be able to determine the true permeability of all of the ocular tissues as well as the in situ 
flow dynamics that occur within the eye, though this would not be achievable without 
invasive measurement techniques. One benefit of computer models is that they are able to 
provide us information which we are unable to see or collect under experimental conditions, 
however it is important that there is some way of validating the simulated results in order to 
produce models which can be believed. 
For this study I aimed to produce computer models that could be experimentally validated, 
so the computer models were designed around in vitro models which were accessible and 
would be used in the early stages of the development of the ibu-SiO device. Using the 
validated models built in this study, it is now possible to explore more variables such as 
different drugs, alternative tamponade materials and more complex drug release 
mechanisms quickly and at reduced cost compared with experimental investigation. 
Ultimately any alterations in the design of the device would need to be tested 
experimentally, however the computer models should be able to be used as predictive tools 
to identify and narrow the range of experimental conditions which need to be studied, saving 
time and cost. 
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4.2 CONCLUSIONS 
- ARPE-19 cells are able to survive when exposed to basolateral media flow in the 
Kirkstall QV600 culture chamber depending on the flow rate applied. 
 
- High flow rates affect TEER and cell phenotype, reducing the barrier functionality of 
ARPE-19 cells cultured on NH3 treated ePTFE membranes. 
 
- The concentration of dextran on the basolateral side of the ARPE-19/transwell 
membrane displays a different profile depending on the flow rate of the media used 
to clear it away from the barrier. 
 
- Results from computer models of the flow within the QV600, designed using data 
from static dextran transport assays, showed agreement with experimental data 
from equivalent flow experiments. 
 
- Computer model does not consider biological changes within the cell layer, therefore 
there is a decrease in agreement in cellular models in comparison with the acellular 
models. 
 
- Saccadic eye movements increase the rate at which ibuprofen is released from the 
silicone oil. 
 
- Release rate of ibuprofen varies with interfacial contact area between the silicone 
oil phase and aqueous phase. 
 
- Computer models of the QV600 and a spherical eye model are able to predict the 
release profiles of ibuprofen from silicone oil under flow used to simulate drug 
clearance. 
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4.3 FUTURE STUDIES 
- Develop a more complex model of the outer blood retinal barrier, including choroidal 
endothelial cells and primary human cells, to make it more physiologically relevant. 
This would provide a more realistic view of the transport of molecules across the 
barrier. 
 
- Investigate the release and transport of ibuprofen from silicone oil across the cellular 
model. This would require finding alternative measurement techniques for detecting 
the concentration of ibuprofen, however it would lead to a greater understanding of 
the clearance of the drug away from the RPE layer. 
 
- Further develop the computer models used in this study to incorporate 
mathematical descriptions of the biological changes which occur within the cell 
layer. This would create time dependent changes in key parameters, such as 
permeability, which could reduce the error observed between the simulated and 
experimental results. 
 
- Investigate the suitability of ibuprofen as a treatment for fibrotic retinal pathologies 
to determine whether this drug is appropriate for use in this delivery system. 
 
 
- Expand the simulations into 3 dimensions (3D), again to reduce errors in agreement, 
and ultimately apply the knowledge gained from the in vitro and simulated data to a 
3D model of the human eye. 
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